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ABSTRACT 
Streptococcus pneumoniae is an important human pathogen in all age groups worldwide 
that causes a variety of diseases, ranging from life threatening septicaemia and 
meningitis to less severe sinusitis and otitis media. The factors that determine the 
virulence of S. pneumoniae are very complex but a key aspect of the organism's disease 
causing potential is the ability of the bacteria to regulate virulence factor expression and 
activity. In this study two main approaches were taken to investigate virulence gene 
expression in S. pneumoniae. Firstly, the feasibility of Recombinase based In vivo 
Expression Technology, RIVET, for use in S. pneumoniae to study gene expression in 
vitro, and then in vivo was assessed. However, the system was found to be unsuitable 
for use in this study. Secondly, the requirement for and the role of virulence gene 
regulators identified by Signature Tagged Mutagenesis were investigated. The 
requirement for different virulence gene regulators varied according to the murine 
model of infection used. Two of the regulators, MgrA and R1rA, were essential for 
nasopharyngeal carriage and production of pneumonia in mice by serotype 4 S. 
Pneumoniae. Both were shown to control the transcription of genes of a newly 
described pathogenicity islet, PPI2, encoding R1rA and proteins predicted to act at the 
bacterial cell surface. The PPI2 genes rlrA and rrgA were shown to be required for 
adhesion of serotype 4 S. pneumoniae to human epithelial cells and PPI2 gene 
expression was affected by the gaseous composition of the growth environment in an 
MgrA dependent manner. The distribution of MgrA, R1rA and PPI2 varied between 
clinical S. pneumoniae isolates emphasizing the likelihood of a different repertoire of 
virulence genes and regulators amongst different serotypes and strains of this important 
human pathogen. 
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ST sequence type 
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CHAPTER I INTRODUCTION 
1.1 STREPTOCOCCUS PNEUMONIAE 
Streptococcus pneumoniae is a Gram-positive coccus that characteristically grows in 
pairs or chains in liquid medium. It was originally isolated in 1880 by Louis Pasteur and 
G. M. Sternberg though was not assigned a name, Diplococcus pneumoniae, until the 
1920s, This name (probably due to its characteristic pairing seen in sputum of patients 
with pneumonia) was changed to S. pneumoniae in 1974 (Watson et al., 1993; Winslow 
et al., 1920). A brief review of the history of S. pneumoniae highlights the 
interrelationship between the study of this organism and the developments in 
microbiology and infectious disease including the discovery of transformation, 
antibiotic use and vaccine development to name a few. Yet after more than a century 
since its initial isolation S. pneumoniae remains a major cause of morbidity and 
mortality worldwide. 
1.1.1 Carriage, disease and epidemiology 
Although an important human pathogen, S. pneumoniae usually resides as a component 
of the normal microflora of the nasopharynx. This asymptomatic colonization occurs 
shortly after birth (Austrian, 1986) and continues intermittently throughout life. It is a 
highly dynamic process; acquisition is followed by carriage for a period of weeks or 
months and then loss and recolonisation with other strains (Gray et al., 1980). Younger 
children carry single strains for months whereas older toddlers and adults have a more 
rapid flora turnover in matter of weeks. At any one time and with appropriate culture 
methods, the organism can be detected in 20-30% of healthy adults and up to 40% of 
healthy children (Ghaffar et al., 1999; Leino et al., 2001). Actual pneumococcal disease 
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is considered to occur subsequent to nasopharyngeal carriage (Gray et al., 1980; Obaro 
and Aaberge, 2002) but is a relatively rare event with only a small number of those 
colonized proceeding to symptomatic disease. This can vary in severity from mild otitis 
media and sinusitis, to pneumonia and lethal septicaemia and meningitis. For all forms 
of pneumococcal disease those at highest risk are children less than 5 years old, the 
elderly and people with chronic underlying medical conditions, including HIV. S. 
pneumoniae is the commonest cause of community-acquired bacterial pneumonia in 
adults and children, with an incidence ranging from 1.7 per 1000 person-years to as 
great as 19.0 in those with risk factors (Mangtani et al., 2003; Simberkoff et al., 1986). 
There is a significant mortality associated with invasive disease, highest in developing 
countries but still of major importance in developed countries. Studies over the last 10 
years vary in absolute figures from 10-20 cases of invasive disease per 100,000 
individuals (Sleeman et al., 2001) across Europe and USA. This difference most likely 
reflects differences in reporting and clinical practice between countries. However, even 
the milder disease manifestations place a large burden on medical services. S. 
pneumoniae has been reported to account for 30-50% of otitis media episodes in the 
USA, resulting in 7 million otitis media-related visits per year to paediatricians (1997). 
One US-based study determined that 62% of children have an episode of acute otitis 
media by one year of age, with most cases occurring between the ages of 6 to 12 months 
(Teele et al., 1989). 
1.1.2 S. pneumoniae serotypes and vaccines 
It is clear that not all strains of S. pneumoniae are created equal with respect to their 
ability to cause invasive disease. There are 90 serotypes of S. pneumoniae defined by 
variations in the immunochemistry of their polysaccharide capsule. Geographical, age- 
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related differences and differences in disease manifestations with certain serogroups 
have led to the suggestion that each strain be considered as a separate pathogen from an 
epidemiological standpoint (Hausdorff et al., 2000a; Hausdorff et al., 2000b). 
The polysaccharide capsule is arguably the organism's most important virulence -factor. 
Isolates lacking a capsule rarely cause invasive disease in humans and are greatly 
attenuated in virulence in animal models of infection (Malley et al., 2001). Antibodies 
against capsule are highly protective against invasive disease. For these reasons initial 
pneumococcal vaccine efforts were directed against capsular polysaccharide and the 
capsule still remains the target of anti-pneumococcal vaccines in present day use. The 
capsule varies in chemical composition between serotypes (Kamerling, 2000) and its 
actual composition and structure is considered important in the disease-causing 
potential of the organism. There is an apparent serotype-specific difference in invasive 
potential. A recent epidemiological study compared 501 mixed carriage and invasive 
strains of S. pneumoniae. The carriage isolates had been obtained from nasopharyngeal 
aspirates from healthy young children and the invasive strains were clinical isolates 
recovered from normally sterile sites in children with proven pneumococcal disease. 
Serotypes 4 and I were found to be overrepresented among isolates from invasive 
disease. At the other extreme one serotype 3 clone appeared to have a low invasive 
potential being almost invariably recovered from carriage (Brueggemann et al., 2003). 
In fact more than 80% of serious illness is caused by only 15 serotypes (Hausdorff et 
al., 2000a; Hausdorff et al., 2000b; Scott et al., 1996). Some serotypes are particularly 
associated with disease in particular populations such as children or are associated with 
habouring antibiotic resistance (McGee et al., 2001; Scott et al., 1996). 
21 
The rank order of serotypes recovered from invasive disease in developed countries has 
been used as a guide to the development of both the 23-valent polysaccharide vaccine 
and the newer conjugate vaccines. An original 14-valent polysaccharide was licensed in 
1977 covering the 14 serotypes causing 75% of invasive disease (Austrian, 1977). This 
was extended to the 23-valent version in 1983 which encompasses the 23 pneumococcal 
serotypes that account for 90% of isolates recovered from sterile sites (1997). This 
vaccine is widely used today and is recommended for use in people over the age of 60 
and in high-risk individuals aged more than 5 years. However the polysaccharide 
antigens are poorly immunogenic in children less than 2 years of age, where a large 
burden of disease lies. Following on from the success of the conjugate HIB vaccine in 
this age group protein-polysaccharide conjugate pneumococcal vaccines have been 
developed for use in children less than 5 years of age. A 7-valent vaccine, licensed for 
use in USA in 2000, now constitutes part of the routine vaccination schedule in that 
country. The conjugate vaccine in use, Prevnar, covers the 7 serotypes; 4,6B, 9V, 14, 
18C, 19F and 23F, which constitute 75% of those causing invasive disease in either 
USA or UK and Europe but only 45-60% of invasive serotypes in Latin America, 
Africa and parts of Asia (Hausdorff et al., 2000b; Sleeman et al., 2001). Inclusion of a 
further 4 serotypes in an 11-valent vaccine increases coverage to greater than 75% in all 
areas worldwide but this has serious cost implications (Hausdorff et al., 2000b). The 7- 
valent vaccine is already considered too expensive by most developing countries to 
enable mass vaccination. 
Although it is still early since the introduction of the newer pneumococcal conjugate 
vaccines studies have already shown that they provide some protection against S. 
pneumoniae disease in the targeted age group in certain populations. Two studies from 
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the USA reported a clear benefit in bacteraemic disease with a 93.9% (95% CI 79.6- 
98.5) and 78.6% (95% CI 9.4-95.1) efficacy in preventing bacteraemia (Black et al., 
2000; O'Brien et at., 2003). The results for preventing pneumonia and otitis media are 
Jess impressive (Klugman, 2001 a). Finnish trials showed only a 56% (95% CI 44-66) or 
57% (95% CI 44-67) efficacy for prevention of acute otitis media (AOM) (Eskola et al., 
2001; Kilpi et al., 2003). However it must be recognized that even a small reduction in 
incidence of disease can equate to a huge impact in terms reduction of actual numbers 
of cases. There are equally interesting data coming from studies examining the efficacy 
of these vaccines and their effect on non-vaccine-serotype strains and nasopharyngeal 
carriage. There is a reduction in carriage of vaccine serotype strains but also seemingly 
an increase in carriage of non-vaccine serotypes (Klugman, 2001b; Mbelle et al., 1999; 
Obaro et al., 1996). This has long-term implications for the efficacy of the vaccines. In 
one Finnish study the increase in carriage was also reflected in an increase of 33% in 
AOM by non-vaccine serotypes (Eskola et al., 2001). Replacement of carried 
pneumococci by non-vaccine serotype strains could occur by many different 
mechanisms. The most likely explanation is that children who are immunized are at 
increased risk of colonization with non-vaccine serotypes. If they are exposed to both 
non-vaccine and vaccine serotypes but are immune to the acquisition of latter, 
secondary to immunization, they will be preferentially colonized by the former. 
Alternatively it may be that replacement colonization represents the unmasking of sub- 
dominant serotypes, previously carried in low numbers. A final possibility is that the 
host-immune response selects for clones that have undergone in vivo recombination of 
the capsule genes and thus switched capsule serotype. As discussed later, this capsular 
switching does occur in vivo but is considered to be a very rare event. Whatever the 
mechanism there is evidence that the widespread introduction of conjugate vaccines 
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will, with time, affect carriage serotype distribution and this may have a knock-on effect 
in those serotypes causing invasive disease. 
1.1.3 Upsurgence of antibiotic resistance 
Hand in hand with the apparent success and concerns over longterm failure of new 
pneumococcal vaccines in disease prevention, disease treatment is also providing new 
challenges. Penicillin has historically been the antibiotic of choice for treatment of 
pneumococcal disease. Yet as early as 1941, only 12 years after the discovery of 
penicillin, resistance to the drug could be detected in clinical isolates (Abraham et al., 
1941) and since the 1960s there has been a dramatic worldwide increase in resistance to 
penicillin and other antibiotics, including macrolides, chloramphenicol and tetracyclines 
in clinical isolates (Doern et al., 2001; Huebner et al., 2000; Whitney et al., 2000). The 
mechanisms by which strains become ß-lactam resistant have been well studied. 
Penicillin and other ß-lactam drugs bind to and inhibit penicillin-binding proteins 
(PBPs), which normally catalyse important steps in the assembly of peptidoglycan in 
the bacterial cell wall. Resistance is due to alterations in these PBPs, leading to a 
decreased binding affinity both for drug and normal substrate (Hakenheck et al., 1999). 
S. pneumoniae contains six PBPs. All can occur as low affinity variants (Hakenbeck et 
al., 2000). Interestingly these low affinity forms of PBPs are recognized as the products 
of DNA transformation and recombination events. They are encoded by mosaic genes 
that contain sequence blocks highly divergent from those of sensitive strains and as 
such appear to be a result of gene transfer not only among pneumococcal strains but 
also from other streptococcal species. Low affinity forms of PBP 2b and 2x confer low- 
level resistance and are prerequisites for high-level ß-lactam resistance. 
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Penicillin-resistant strains compensate for the changes in affinity for the cell wall 
building blocks by activation of genes murrt and murN which produce branched chain 
cell wall peptides rather than the typical linear structures. The capacity to produce these 
branched chain cell wall precursors is a prerequisite for expression of PBPs with 
lowered affinity for penicillin as interruption of murMN leads to complete inhibition of 
expression of penicillin resistance (Filipe et al., 2001,2002). The murMN genes or their 
products could be new drug targets for penicillin-resistant S. pneumoniae (PRSP). 
It was realized in the 1990s that PRSP were more likely to be resistant to other 
antibiotic groups such as macrolides, teracyclines, chloramphenicol and most recently 
quinolones. As currently two thirds of clinical isolates in the USA have intermediate or 
high level resistance to penicillin, 40-60% of these are also resistant to at least one other 
antibiotic and this mirrors the trend worldwide. Pneumococcal disease management 
therefore remains an ever increasing challenge (Garau, 2002). 
1.2 EVOLUTION OF S. PNEUMONIAE 
1.2.1 Transformation and competence and in S. pneumoniae 
Experiments performed by Griffith in the 1920s showed that intraperitoneal injection of 
live unencapsulated serotype 2 S. pneumoniae mutants together with heat-killed 
serotype 1 encapsulated S. pneumoniae led to the emergence of viable type l 
encapsulated bacteria resulting in death of the mice (Griffith, 1928). Griffith termed this 
process `transformation'. These initial findings were not fully explained until the 1940s 
when Avery and colleagues demonstrated that deoxyribonucleic acid (DNA) was the 
transforming agent and contained the genetic material encoding the capsular phenotype 
(Avery et al., 1944). With the use of antibiotic resistance markers it was possible to 
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demonstrate the transfer of genetic material from one bacterium to another by freshly 
released DNA (Hotchkiss, 1951) and later demonstrate that such cell to cell 
transformations occurred both in infected animals and between bacteria grown in lab 
medium (Ottolenghi and Hotchkiss, 1962; Ottolenghi and MacLeod, 1963; Ottolenghi- 
Nightingale, 1969). 
It is now appreciated that this uptake of exogenous native DNA and subsequent 
homology-dependent integration into the recipient chromosome (transformation) is one 
of the simplest modes of exchange of genetic material. S. pneumoniae is naturally 
transformable. During the transformation process itself exogenous double-stranded 
DNA binds to the cell membrane and is subjected to single-stranded nicks (Lacks and 
Greenberg, 1976). One strand is then transported across the cell membrane and if 
sufficiently similar in nucleotide sequence to a chromosomal counterpart is incorporated 
into the recipient's genome by homologous recombination (Fox and Allen, 1964; 
Prudhomme et al., 2002). Competence, a physiological state in which exogenous DNA 
can be internalized, is a prerequisite for transformation in S. pneumoniae. It arises in 
exponentially growing cultures at a critical cell density and is dependent on a quorum 
sensing system. The cell-to-cell signal is called competence stimulating peptide, CSP. It 
is a small peptide processed from a precursor (ComC) (Havarstein et al., 1995), and 
secreted by the ABC transporter ComAB (Hui et al., 1995). CSP is sensed by a receptor 
histidine protein kinase, located in the cell membrane (Comb), which is linked to a 
response regulator (ComE). Binding of CSP activates a phosphorelay resulting in the 
phosphorylation of response regulator ComE. This phosphorylated form of ComE is a 
transcriptional activator and induces the transcription of numerous genes. It binds 
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specifically to a target site consisting of two 9 bp imperfect direct repeats separated by a 
stretch of 12 nucleotides in the promoter region of its target genes (Ween et al., 1999). 
These include the comCDE operon and a large number of genes, encoding factors with 
functions in binding, uptake, processing and integration of exogenous DNA (Campbell 
et al., 1998; Mortier-Barriere et al., 1998; Pestova and Morrison, 1998). Regulation 
also depends on a novel sigma factor (ComX) itself controlled by the autostimulatory 
CSP sensing system (Morrison and Lee, 2000). Initial microarray studies had shown 
that the whole competence regulon is made of two classes of genes, early (e. g. 
comCDE) and late (Peterson et al., 2000; Rimini et al., 2000). The early genes rely on 
ComE for expression whereas the late genes depend on ComX (Lee and Morrison, 
1999; Luo and Morrison, 2003). More recent comprehensive microarray studies have 
expanded the identification of competence induced genes to over 100 genes including a 
further pool of genes with a delayed expression profile and a group of genes that are 
repressed during the CSP response (Dagkessamanskaia et al., 2004; Peterson et al., 
2004). 
1.2.2 Transformation and Recombination and implications for evolution and 
population structure in S. pneumoniae 
It is clear that the process of transformation allows the exchange of genetic material 
within a single species and potentially between species. The cellular machinery 
necessary for transformation has been found to be present in most S. pneumoniae 
isolates (Ramirez et at., 1997). Recent molecular typing tools such as multilocus 
sequence typing (MLST) and statistical methods have allowed a quantitative estimation 
of the impact of recombination versus mutation on population structure (Enright and 
Spratt, 1998; Feil et al., 2000). For S. pneumoniae it is estimated that individual 
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housekeeping genes are -10 times more likely and individual nucleotides are -50 times 
more likely to evolve by recombination than mutation and hence it has been suggested 
that specific clones of S. pneumoniae evolved predominantly by recombination (Feil et 
al., 2000). This has been questioned specifically for serotype 6 strains (Ashley 
Robinson et al., 2002) where the authors report that both recombination and mutation 
have played important roles in the evolution of serotype 6A clones whereas 
recombination alone was the dominant mechanism for evolution of serotype 6B. This 
study used MLST to identify major clones amongst 212 carriage and invasive strains. 
Serotype 6A isolates were more frequently isolated from the carriage state and 6B 
isolates from invasive disease. The original MLST work in S. pneumoniae referred to 
above was performed on 274 invasive strains only. It is possible that evolutionary 
pressures on S. pneumoniae differ between carriage and invasive strains resulting in 
bias towards different systems predominating in each. 
A single pneumococcal serotype typically comprises a number of genetically divergent 
clones as assessed by MLST (Brueggemann et al., 2003; Takala et al., 1996) (Enright 
and Spratt, 1998). At least some of this may be as a consequence of the horizontal 
transfer of the capsular biosynthetic genes into new lineages. In all but one serotype 
(serotype 37) the capsule biosynthetic loci are located in the same position of the S. 
pneumoniae chromosome, between dexB and aliA genes and are organized into 
cassettes (Garcia et al., 2000). Most capsule cassettes also share a common 
arrangement. The first four genes (capABCD) share some degree of similarity and the 
remaining genes, predicted to be involved in capsule biosynthesis are serotype-specific. 
The regions flanking the cassette are also similar between serotypes. This arrangement 
is ideal for facilitating the transfer of the entire capsule locus between pneumococcal 
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strains resulting in serotype switching, which has serious implications for capsule-based 
vaccines. Evidence that S. pneumoniae strains can indeed change their serotype in vivo 
was first obtained from the analysis of populations of antibiotic resistant strains. Isolates 
were identified that differed in serotype but that were indistinguishable by multilocus 
enzyme electrophoresis, and restriction endonuclease cleavage electrophoretic profiling 
of penicillin-binding protein (PBP) genes, demonstrating them to be members of a 
single clone (Coffey et al., 1991). Subsequent reports of serotype variants of antibiotic 
resistant clones including molecular studies have shown that indeed serotype changes 
occur by recombinational events replacing the capsular cassette of a recipient with that 
of the donor (Coffey et al., 1998; Coffey et al., 1999). A recent carriage study sampling 
children in the Oxford region showed that 68 out of 100 children carried multiple 
serotypes during the first two years of life (Meats et al., 2003). In all cases isolates from 
the same children that varied in serotype also varied in clonal type indicating the 
acquisition of a different pneumococcal strain rather than a change specifically in 
capsular type secondary to a recombinational event. This indicates that serotype 
replacement by the afore mentioned type of recombinational event is not so common 
that it can be detected in cohorts over relatively short periods of time. 
1.2.3 Pathogenicity Islands and S. pneumoniae 
Microarray technology has allowed the investigation of variation within the entire 
chromosome between strains of S. pneumoniae. One study comparing 20 different S. 
pneumoniae isolates (representing 10 different serotypes) by hybridization of 
chromosomal DNA to an oligonucleotide array representing the serotype 4 genome 
showed that only 75% of the loci were conserved in all isolates (Hakenbeck et al., 
2001). A total of 470 genes showed variation in at least one of the strains and between 
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8-11 % of genes varied in each strain. It appears therefore that the genes contained by 
one particular strain represent only a limited snapshot of the genetic information 
contained within the pneumococcal species as a whole. There is a stable pool of DNA, 
which is common to all strains, and a separate pool of variable DNA, which contains 
amongst other things the capsule biosynthetic loci. 
With the availability of genome sequences of numerous bacterial species it has become 
apparent that many genomes take this form and consist of a core sequence, which 
encodes housekeeping functions, and additional variable sequences. Yet even before the 
advent of genome sequence availability specific sequences had been discovered in 
numerous species that differ from the rest of the genome in their G+C content and 
codon usage and that appear to have been acquired by horizontal transfer. These so 
called islands encode diverse functions ranging from biosynthetic pathways, antibiotic 
resistance and properties involved in microbial fitness. A subset of genomic islands 
contain genes involved in bacterial virulence and are called pathogenicity islands 
(PAIs). The first PAI was described in uropathogenic E. coli (Hacker et al., 1983) but 
many species have DNA segments that share typical features of a PAI (Hacker et al., 
1997; Hacker and Kaper, 2000). A PAI is defined as a region of the genome, which is 
absent or sporadically distributed in non-pathogenic close relatives, that carries one or 
more virulence factor. The overall nucleotide composition of the island often differs 
from the core genome in G+C content and codon usage, reflecting the generation of 
PAIs by horizontal gene transfer. This G+C difference may not be observed if the 
DNAs of the donors and the recipients have a similar G+C content. PAls are often 
flanked by sequences defining the edges such as direct repeats that could arise from 
integration of a transposon or bacteriophage, but often they do not represent 
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homogenous pieces of DNA but rather are made up of mosaic-like structures which 
have been generated by a multi-step process and thus boundaries can become obscured 
and harder to delineate with time. 
S. pneumoniae appears to possess PAIs though only two islands have formally been 
described (Brown et al., 2004; Hava et al., 2003a). Both are present in serotype 4 
(TIGR4 strain). Amongst the variable genes identified by comparative genomics were 
10 gene clusters where the hybridization signal was uniformly low, encompassing 130 
loci. Seven of these contain one or more genes encoding transposases and one 
resembles a prophage suggestive of mobile elements (Hakenbeck et al., 2001). The 
sequences and exact positions of these clusters were not reported in this study. A second 
characterization of inter-strain genomic difference by microarray identified 9 TIGR4 
gene clusters that did not hybridize with D39 or R6 genomic DNA, 6 of these had 
atypical nucleotide composition. Not surprisingly the capsule locus was common to 
both studies, so was an area with an IgA protease paralog (SP0071) and a gene 
encoding a choline binding protein (SP0061) (Tettelin et al., 2001). 
Which components of the S. pneumoniae genome are important for determining 
virulence? Are these components common to all strains or do they show inter-strain 
variability? How many virulence determinants are encoded for by PAIs? These 
questions are hard to answer with our present knowledge. Historically researchers have 
focused on capsule type to define disease-inducing potential and it is true that there is 
an apparent serotype-specific difference in invasive potential, but serotype is by no 
means the only contributing factor. Experiments examining the colonizing and disease 
forming potential of serotype 2,3 and chimeric pneumococcal mutants with capsular 
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switching demonstrated that this was the case. For example, wild-type serotype 3 strain 
and a capsule switched mutant (genetically serotype 2 in all but capsule locus) behaved 
similarly with respect to nasopharyngeal colonization but the wild-type serotype 3 strain 
survived less well than the capsule switched mutant in the lung (Kadioglu et al., 2002) 
showing that there must be other genomic differences outside the capsular locus 
contributing to survival. What we can say from these and other experiments is that a 
combination of capsule and genetic background determines virulence and these 
virulence-determining factors do not appear to be common to all strains. Factors that are 
required for virulence in one strain may not be needed in another and presently only a 
few of the known virulence factors have actually been shown to be on PAIs. 
1.3 VIRULENCE FACTORS IN S. PNEUMONIAE 
Analysis of virulence factors used by pathogens is essential for our understanding of the 
molecular mechanisms underlying the pathogenesis of disease. Identification and 
functional analysis of virulence genes and their protein products not only furthers our 
general understanding of mechanisms but can also provide us with specific knowledge 
that can be used in the development of antimicrobials or vaccines. 
What is a virulence factor? A simple definition would be any microbe-specific factor 
that contributes to the ability of that microbe to cause disease. In reality it is more 
complex than this. From the perspective of the pathogen a successful infection is 
defined by multiplication within a host and ultimately transmission. This cycle may or 
may not involve a negative outcome for the host. In general terms there are several steps 
in the cycle: 1) attachment to host tissue, 2) growth or invasion at the site of attachment, 
3) avoidance and/or resistance to host immune defenses, 4) acquisition of nutrients, 5) 
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multiplication and finally 6) transmission (Lipsitch and Moxon, 1997). The definition 
of a virulence factor could be widened to include any microbial-specific factor that 
contributes to these events. Some factors will be important for microbial cell nutrient 
acquisition and cell viability 'in and outside the host. These are essential for the 
organism's ability survive but may not be specific to the disease process or provoking a 
host response. There are also factors that are essential for a successful host-pathogen 
interaction, such as adhesins, which may not themselves be detrimental to the host. One 
can therefore divide virulence factors into those that are required for microbial cell 
viability and those which are solely required for disease production. 
S. pneumoniae is rarely found outside the human host and requires the host for survival. 
One might therefore argue that a successful S. pneumoniae strain would not benefit 
from host death but would be better placed living in harmony with its host. A bacterium 
needs only to have a suitable route for transmission to a second host to ensure 
continuing survival of the species. Asymptomatic nasopharyngeal carriage by the 
human therefore could be seen as an ideal. Nasopharyngeal colonization is also a pre- 
requisite for invasive disease (Bogart et al., 2004). When considering virulence factors 
in this organism one may wish to include all factors that are important for successful 
nasopharyngeal carriage as well as those required for disease such as pneumonia or 
septicaemia. 
Information about the mechanisms by which bacteria interact with their host and cause 
disease has increased dramatically in the post-genomic age. The release of the S. 
pneumoniae genome sequence by TIGR in 1997 was a watershed for pneumococcal 
pathogenesis research. The organism has a relatively small genome of -2.1 MB 
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containing 2236 predicted coding regions. Many virulence factors were known of 
before the availability of the sequence including the capsule, pneumolysin (Ply), IgA 
protease, neuraminidase, hyaluronidase, pneumococcal surface adhesin A (PsaA) and a 
few choline binding proteins (LytA, CbpA and PspA) (AlonsoDeVelasco et al., 1995; 
McCullers and Tuomanen, 2001b; Mitchell, 2000). A detailed and comprehensive 
description of all that is known about S. pneumoniae virulence factors and disease 
pathogenesis is beyond the realms of this introduction but some relevant aspects are 
highlighted in the sections below. Factors involved solely in nutrient acquisition and 
bacterial viability have been excluded. As discussed later the availability of the genome 
sequence and genetic screens has accelerated the discovery of additional virulence 
factors. 
1.3.1 Surface associated factors: Role in attachment to host surfaces and 
internalisation of bacteria 
S. pneumoniae attaches to host surfaces in both a carriage state and in disease and 
attachment is crucial for disease and colonisation. The molecular basis for adhesion to 
various host surfaces in this organism is complex and has not been fully defined. It has 
been suggested that adherence and invasion may involve, at very least, a two step 
process. Initial binding to the host cells leads to cytokine activation. This results in 
expression of novel receptors on the surface of activated host cells and increased 
pneumococcal adherence (Jedrzejas, 2001). There is evidence that the receptors and/or 
structures involved in adherence are different for nasopharyngeal and lung epithelial 
cells. Several surface structures including proteins have been identified as playing a role 
in adherence to the upper and/or lower respiratory tract epithelial cells in vitro and 
nasopharyngeal colonisation in animal models. 
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The cell wall lying below the polysaccharide capsule consists of polysaccharides and 
teichoic acid and serves as an anchor for cell wall associated surface proteins. Some of 
these proteins are involved in adhesion to host mucosal surfaces by interactions with 
specific receptors but in addition they contribute to the hydrophobic and electrostatic 
surface characteristics of the bacteria, thus facilitating adherence through non-specific 
physiochemical interactions (Swiatlo et al., 2002). The cell wall also contains 
phosphorycholine (ChoP) on teichoic acid, which facilitates bacterial interaction with 
the receptor for platelet-activating factor (rPAF), on human endothelial cells. This 
interaction with rPAF increases adherence to and invasion of host cells (Cundell et al., 
1995b) (Ring et al., 1998) and has been suggested to have a major role in the lung 
(Rijneveld et al., 2003). The natural ligand for rPAF contains ChoP (Cundell et al., 
1995b). The quantity of the surface expressed receptor on host cells is up-regulated by 
cytokine activation resulting in increased bacterial adherence and internalisation. As 
well as binding to rPAF, ChoP acts as a docking site for a class of proteins known as 
choline-binding proteins (CBPs). The major choline-binding protein A (CbpA) has been 
shown to be an adhesin. CbpA- deficient pneumococci have impaired ability to interact 
with cytokine-activated human epithelial cells, immobilised sialic acid and lacto-N- 
neotetraose (Rosenow et al., 1997). CbpA has also been demonstrated to interact with 
polymeric Ig receptor (pIgR) and this interaction has been proposed to be important for 
the migration of S. pneumoniae across the upper respiratory tract mucosal barrier (Lu et 
al., 2003; Zhang et al., 2000). 
Another class of surface-associated proteins are covalently attached to the cell wall via 
an LPXTG motif, the majority being anchored. by the sortase A enzyme. In the R6 
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genome there are 23 proteins containing the LPXTG motif and only one gene, srtA, 
encoding a sortase. Inactivation of srtA decreases adherence of S. pneumoniae to human 
pharyngeal cells in vitro suggesting that some of the sortase-target proteins are involved 
in adherence to and colonization of the nasopharyngeal cells (Kharat and Tomasz, 
2003). Work presented in this thesis demonstrates the importance of sortase-anchored 
cell surface proteins in serotype 4 S. pneumoniae in adhesion to host cells. IgA protease 
has a characteristic LPXTG motif consistent with its covalent attachment to the cell 
wall by a sortase enzyme. One function of the enzyme in adhesion has been elucidated 
by Weiser et al (Weiser et al., 2003). They showed increased adherence of S. 
pneumoniae to lung epithelial cells in the presence of human IgA. The effect required 
functional IgA protease and is thought to be brought about by cleavage of opsonising 
IgA by the protease, resulting in a change in surface charge and increased physical 
proximity of the pneumococcal cell-wall ChoP to rPAF. 
Another sortase-anchored enzyme in S. pneumoniae, neuraminidase or NanA, acts at the 
bacterial/host cell interface and facilitates S. pneumoniae adherence and colonization. 
The enzyme cleaves sialic-acid from host cell glycolipids, glycoproteins and 
oligosaccharides and is thus thought to expose N-acetyl-glycosamine and possibly other 
receptors for bacterial adherence (Camara et al., 1994; Krivan et al., 1988). Both 
Neisseria meningitidis and Haemophilus influenzae are capable of mimicking host 
structures by decorating their lipopolysaccharides with sialic acid and may use this as a 
protective mechanism against host defenses. These organisms are thought to compete 
with S. pneumoniae for nasopharyngeal colonisation. NanA expressed by S. 
pneumoniae has been shown to desialylate the cell surfaces of both these species in 
vitro (Shakhnovich et al., 2002). Interfering with the biology of these potential 
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competitors in this way may be a mechanism by which S. pneumoniae can gain a 
selective advantage for colonization of the host upper respiratory tract. 
Many Gram-positive bacteria utilize extracellular matrix (ECM) molecules to mediate 
attachment to host surfaces (Chhatwal, 2002). There are many examples of surface 
exposed proteins that facilitate interactions with matrix molecules such as fibronectin, 
collagen and fibrinogen in Staphylococcus, Enterococcus and other streptococcal 
species (Foster and Hook, 1998; Joh et al., 1999; Patti et al., 1994; Rozdzinski et al., 
2001) but S. pneumoniae has been notably absent in these reports. S. pneumoniae was 
shown to bind to immobilized fibronectin in a dose dependent manner and this binding 
is reduced by trypsin treatment of bacteria suggesting a surface exposed protein- 
dependent mechanism (van der Flier et al., 1995). In these studies the level of binding 
varied in different clinical isolates and strains of different serotypes. Isolates of types 
7F, 14,18C and 19F bound most efficiently whereas isolates of serotype 2 and 4 bound 
poorly suggesting that either capsule composition effects fibrinogen interactions or that 
fibrinogen binding is not a universal mechanism of attachment for S. pneumoniae and 
not all strains habour fibrinogen-binding proteins. However a more recent study 
characterised a surface associated pneumococcal protein, PavA, which binds fibronectin 
and is associated with virulence. The pavA gene has sequence similarity to Fbp54, a 
fibronectin binding protein in S. pyogenes, and was found to be present in 64 
independent isolates tested representing different serotypes including serotypes 2 and 4. 
The capsule was shown to have an inhibitory role in attachment to fibronectin in this 
study. 
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PsaA was originally reported as a surface adhesin in S. pneumoniae based on sequence 
similarity to other streptococcal adhesins (Sampson et al., 1994). psaA- mutants are 
virtually avirulent in animal models of disease and show reduced ability to adhere to 
type II pneumocytes in vitro (Berry and Paton, 1996). The psaA gene is part of an 
operon consisting of three genes which encode a manganese transport system (Dintilhac 
et al., 1997). It is not clear whether the PsaA protein is itself the adhesin or whether the 
decrease in adhesion seen in psaA-mutants is a reflection of the requirement for 
manganese as a regulator of adhesin expression. 
Regulation of expression of these various surface factors and bacterial adherence to 
mucosal surfaces is not fully understood though one mechanism has been demonstrated. 
Phase variation has been shown to affect the cell wall composition, surface protein and 
capsule polysaccharide expression. This phenotypic variation is also associated with 
differences in colonization and invasion capacities in strains (Weiser et al., 1996). 
Transparent phase variants, which have less capsular polysaccharide, more teichoic acid 
and more CbpA, than their opaque counterparts, show greater adherence than opaque 
variants (Kim and Weiser, 1998; Weiser and Kapoor, 1999). 
1.3.2 Factors involved in the avoidance and/or modulation of host immune 
defenses 
S. pneumoniae must evade host immune responses during colonization and invasive 
disease to survive. Some of the factors involved and mechanisms by which the bacteria 
achieves this have been elucidated. Often these factors have additional roles involved in 
virulence in other ways. 
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The polysaccharide capsule has long been recognized as playing a major role in 
virulence and is arguably the most important virulence factor in S. pneumoniae by 
preventing bacterial phagocytosis (McCullers and Tuomanen, 2001a). Acapsular 
isolates rarely cause invasive disease in humans and are greatly attenuated in virulence 
in animal models of infection (Malley et al., 2001). Reduced capsular expression results 
in greater access of antibodies and complement to the bacterial surface and hence 
increased clearance by the host immune system (Magee and Yother, 2001). Capsular 
polysaccharides are highly immunogenic and antibodies against them protect against 
invasive disease with the homologous serotype by induction of opsonophagocytosis. 
The CBP, pneumococcal surface protein A or PspA, is common to every S. pneumoniae 
strain studied and is required for virulence (Crain et al., 1990; McDaniel et al., 1987). It 
has been shown to inhibit complement binding and activation. thus being important in 
reducing complement mediated clearance and phagocytosis of bacteria (Briles et al., 
1997; Tu et al., 1999) (Ren et al., 2004). It is also a lactoferrin-binding protein and as 
such may have an additional role in nutrient acquisition during infection 
(Hammerschmidt et al., 1999). 
Pneumolysin, a thiol-activated, multifunctional cytolysin released by S. pneumoniae, is 
another well-characterized pneumococcal virulence factor. It is a cytoplasmic protein 
which is released on bacterial cell autolysis and also during bacterial growth 
(Balachandran et al., 2001). The role of the toxin in virulence is complex but it is 
important both in early and later stages of disease. It appears to have many independent 
functions that contribute to the pathogenesis of S. pneumoniae disease, including affects 
on host response, tissue inflammation and even enhancement of bacteria adhesion to 
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host cells. It interacts with cholesterol and inserts into host cell membranes resulting in 
pore formation and cell lysis. It is also capable of a variety of detrimental modulatory 
effects on the host immune system including directly activating the classical 
complement pathway in the absence of antibody resulting in a reduction in serum 
opsonic activity (Mitchell et al., 1991; Paton et al., 1984). The enzyme can directly 
inhibit human neutrophil and monocyte respiratory bursts, chemotaxis, bacteriocidal 
activity and production of lymphokines and immunoglobulins (Paton and Ferrante, 
1983; Rubins and Janoff, 1998). The use of cDNA microarrays has enabled the 
identification of 142 genes in THP-1 human monocyte cells, which are responsive to S. 
pneumoniae in a pneumolysin-dependent manner and some of which may be involved 
in mediating these affects (Rogers et al., 2003). Infection of mice with pneumolysin- 
deficient mutants results in chronic bacteraemia rather than the rapidly progressive 
sepsis observed with isogenic wild-type strains. This is consistent with the hypothesis 
that the presence of pneumolysin impairs host resistance to overwhelming infection and 
ability to prevent exponential bacterial growth (Benton et al., 1995; Benton et al., 
1998). 
1.3.3 Virulence factors involved in damage to host tissue and bacterial spread 
Development of inflammation, damage and destruction to host tissues is central to the 
pathophysiology of disease. The induction of inflammation also increases bacterial 
invasion into respiratory epithelium and vascular endothelium, at least in part, by up- 
regulation of receptors on host cells and exposure of other host components required for 
bacterial adherence. The primary inflammatory stimulant is the S. pneumoniae cell wall. 
(Tuomanen et al., 1985). Binding of the peptidoglycan to CD 14, a host cell surface 
receptor, and toll-like receptor 2 initiates a cytokine cascade. Other cell wall 
40 
components can also trigger cytokine release by CD 14 independent pathways (Cauwels 
et al., 1997). The result is the induction of NF-K B, TNFa and various interleukins 
(Bergeron et al., 1998; Spellerberg et al., 1996). 
Pneumolysin is also an important inflammatory stimulant. Pneumolysin-deficient S. 
pneumoniae strains exhibit reduced virulence in mice with delayed development of the 
cellular inflammatory response (Kadioglu et al., 2000). The toxin's cytotoxic activity 
results in host cell lysis and tissue destruction. Pneumolysin's other activities include 
inhibition of ciliary beating on the human respiratory epithelium, which could result in 
impaired bacterial clearance from the respiratory tract (Feldman et al., 1990; Feldman et 
al., 1991) and separation of epithelial cell tight junctions (Rayner et al., 1995), that may 
expose host receptors for binding of S. pneumoniae and enhance bacterial invasion and 
spread. 
Hyaluronate lyase (Hyl), which degrades hyluronic acid, a component of connective 
tissue, has also been implicated in destruction of tissue integrity and allowing S. 
pneumoniae greater access to deeper tissues and the bloodstream (Berry and Paton, 
2000; Mitchell, 2000). Lastly, two surface exposed plasminogen-binding proteins, a- 
Enolase (Eno), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) have been 
described in S. pneumoniae and are proposed to have a role in promoting penetration of 
bacteria through the basement membranes (Bergmann et al., 2001; Bergmann et al., 
2004). Plasminogen is a monomeric proenzyme of the serine protease plasmin and plays 
a crucial role in fibrinolysis and the degradation of ECM (Vassalli et al., 1991). Many 
pathogens capture plasmin(ogen), potentially allowing the bacteria to acquire surface 
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associated proteolytic activity. This activity has been shown to facilitate their invasion 
and dissemination in the infected host (Lottenberg et al., 1994; Lottenberg, 1997). 
1.4 CONTEMPORARY STRATEGIES FOR IDENTIFICATION OF 
VIRULENCE GENES AND IN VIVO EXPRESSED GENES AND THEIR 
APPPLICATION TO S. PNEUMONIAE 
More classical approaches to virulence gene identification in general and in S. 
pneumoniae that led to the discovery of many of the factors described above will not be 
discussed here but have been detailed elsewhere (Camilli et al., 2001). 1 will focus here 
on more contemporary strategies relating to the thesis and specifically those used to 
identify in vivo expressed genes. 
1.4.1 Sequence scanning and genomic analysis 
At the beginning of 2004 there were over 100 complete genome sequences open to 
public access via the TIGR or other institutional websites or available on a more limited 
basis. Coupled with the availability of computer resources including numerous 
algorithms this has allowed the comparison of whole proteins, selected protein motifs, 
genes or nucleotide sequences across species and genera enabling the identification of 
new candidate virulence genes or vaccine targets. In this way orthologues of proteins 
known to be important for virulence in one organism can be identified in another and 
assigned a putative function. Regions within genomes that have a different G+C content 
can be highlighted. These often indicate segments of DNA that have been acquired from 
another species by horizontal transfer and often contain virulence genes. This type of 
work now forms a basis for identifying new virulence factors and providing some 
knowledge of possible function prior to further in-depth molecular studies. 
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1.4.2 Functional genomics in S. pneumoniae 
Access to the complete pneumococcal genome sequence has allowed systematic and 
comprehensive searches for virulence factors in particular categories and has aided the 
identification of hundreds of potential new vaccine candidates. For example, S. 
pneumoniae produce a family of surface proteins that attach to the cell wall teichoic 
acid or the membrane-associated lipoteichoic acid via a choline-binding repeat domain 
consisting of 2-10 sequence repeats (Garcia et al., 1998). CbpA, the largest and the 
most abundant of the choline-binding proteins, functions as a surface adhesin and plays 
an important role in nasopharyngeal colonization (Rosenow et al., 1997). By 
performing genome-wide searches with the C-terminal choline binding region of CbpA 
12 further genes encoding choline-binding motifs were identified (Gosink et al., 2000). 
Construction of mutants was then used to demonstrate that several of these choline- 
binding proteins are involved in adherence to epithelial cells, nasopharyngeal 
colonization and/or sepsis (Gosink et al., 2000). Another group identified surface- 
exposed proteins as potential vaccine candidates by examining the genome sequence for 
open reading frames (ORFs) with motifs associated with transport, cell-wall anchorage, 
or choline-binding as well as ORFs with similarity to known virulence factors in other 
bacteria (Wizemann et at., 2001). They discovered that genes encoding putative surface 
exposed proteins represent 4% of the S. pneumoniae genome. They expressed 
approximately 100 of these in E. coli enabling protein purification for testing as 
immunogens in mice. Five proteins were shown to be protective immunogens in a 
mouse sepsis model involving infra-peritoneal inoculation of bacteria (Wizemann et al., 
2001). 
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The ability of S. pneumoniae to sense and adapt to changing host environments is likely 
to be important for bacterial survival and the pathogenic process. This adaptation is 
often mediated in bacteria by two-component signal transduction systems (TCSTs) 
comprising a sensor histidine kinase and a cognate response regulator (Stock et al., 
2000). The use of similar genomic scanning in two independent surveys has identified 
13 two-component signal transduction systems (TCSTs) in the S. pneumoniae genome. 
Mutations were constructed in genes encoding either both or one of the components of 
the TCSTs (Lange et al., 1999; Throup et al., 2000). The majority of these systems are 
required for virulence in a murine model of pneumonia, though as discussed in more 
detail later there was disconcordance in the findings in the two studies. 
1.4.3 Genetic Screens: Signature tagged mutagenesis 
Since the mid 1990s, at the same time as the first genome sequences were becoming 
available, there have been numerous publications on genetic screens to identify new 
virulence factors. All methods have drawbacks and ideally one would use more than 
one approach to complement findings. Signature Tagged Mutagenesis (STM) screens 
aim to identify factors that are essential for infection by negative selection (Hensel et 
al., 1995) and have now been applied to a myriad of pathogens (reviewed in (Chiang et 
al., 1999; Mecsas, 2002)). In most cases STM utilizes transposon mutagenesis to 
generate insertion mutants, though other methods of mutagenesis have been used. A 
select number of differentially marked (signature tagged) transposons are employed, 
such that each can be identified in a larger pool. These signature tags consist of a 
randomized sequence of around 40 bp, that is unique to each specific tag, flanked by 
sequence arms common to all tags. The common arm sequence allows recognition of 
any tag by a set of universal primers and the variable region allows identification of 
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each specific tag. Individual mutants with different tags are grown separately, pooled 
and inoculated into an animal host or cell culture system. This is termed the input pool. 
After a period of time bacteria are isolated from the animal (output pool) and the 
presence or absence of mutants within the output pool is detected by PCR amplification 
of the tags and hybridization to a dot-blot containing all of the unique tag sequences. 
Loss of a mutant from input to output is predicted to be due to disruption of a gene 
required for bacterial survival and/or multiplication in vivo. The disrupted site can be 
determined by analysis of the mutant. STM screens have allowed the simultaneous 
identification of multiple factors in a single infection and as such has been an incredibly 
powerful tool for mass identification of virulence factors. It is not however without 
limitations. Firstly, since the input contains a mixed population theoretically there could 
be trans- complementation of a mutation in one bacteria by a product from a second 
bacteria, eg. toxin production. This would lead to failure of selection of that mutation as 
disrupting a virulence gene. Secondly, mutants must be viable in vitro, genes that are 
essential for growth during the selection process will not be obtained, although this may 
not necessarily be seen as a disadvantage. Thirdly, the use of transposon insertion as the 
method of mutagenesis can lead to the generation of polar effects on neighbouring 
genes, which can complicate the interpretation of the output data. Lastly STM as with 
most other genetic screens will not identify virulence factors that are functionally 
redundant with other bacterial proteins, as a single mutation can be functionally 
complemented. 
1.4.4 STM and S. pneumoniae 
There have now been three published STM screens in S. pneumoniae, each in a different 
serotype strain; 3 (Lau et al., 2001), 4 (Hava and Camilli, 2002) and 19F (Polissi et al., 
C-, 
45 
1998). Each screen used the murine model of pneumonia to identify genes that are 
essential for bacterial survival. All three screens then also included further analysis of 
mutants in either a bacteraemia model or a model of nasopharyngeal carriage. Between 
the three screens over 200 new virulence genes were identified. All screens identified 
some of the already known virulence genes, and genes whose products were predicted 
to be involved in cell adhesion, metabolism, transportation across the cell membrane 
and regulation to name a few. The largest group in each screen were hypothetical genes 
with unknown function. Interestingly there is remarkably little overlap in the genes 
identified by each screen, giving some insight into the virulence properties of different 
serotypes. However it is difficult to make meaningful comparisons when the screens did 
not approach saturating levels and when publications did not reveal the identity of all 
the genes hit. 
A difference in the results from these STM screens, and those reported in other gram- 
positive pathogens is the percentage of mutagenised strains identified as attenuated in 
vivo. Screens in S. pneumoniae have found that up to 20% of the mutated strains 
screened are decreased in virulence as compared to a figure of nearer 7% noted in STM 
screens performed in other pathogens (Autret et al., 2001; Jones et al., 2000; Mei et al., 
1997). The finding that such a high proportion of mutants are attenuated may not be all 
that surprising given that S. pneumoniae has a relatively small genome and no reservoir 
outside the human host. One would expect that, to avoid redundancy, a large percentage 
of its genes would be essential for colonization and survival in the human host. Many of 
these genes required for successful interaction with the mucosal surface of the 
nasopharynx leading to colonisation may also be involved in more detrimental 
interactions with the upper and lower respiratory tract such as pneumonia. 
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1.4.5 Genetic Screens: in vivo expression technology 
In vivo expression technology (IVET) was originally conceived upon the premise that 
most virulence factors are transcriptionally induced at some stage during infection 
(Mahan et al., 1993). Although certain environmental parameters can be mimicked in 
vitro often the signals required for virulence gene induction cannot be guessed at and 
reproduced in vitro and a subset of genes will only be expressed in vivo. An advantage 
of IVET is that the live host and infection are used identify in vivo induced (ivi) genes. 
There are several variations of IVET but all rely on the generation of transcriptional 
fusions of genomic sequences to a reporter gene encoding enzymatic activity 
(Angelichio and Camilli, 2002). The variation lies in the actual type of reporter gene 
used. The original IVET took advantage of the fact that a purine auxotroph (ApurA) of 
Salmonella enterica serovar typhimurium is rapidly eliminated from the mouse unless it 
is complemented in trans (Mahan et al., 1993). Ivi genes were identified by ligating 
random genomic fragments upstream of a promoterless purA-lacZY synthetic operon 
present on a suicide vector. This library was transferred into S. typhimurium and the 
resultant mutants were used to infect mice. Growth in the mouse provided positive 
selection for genes that expressed an ivi gene driving the expression of purA-lacZY as 
these strains became prototrophic and survived. Other variations of IVET employ 
antibiotic resistance genes as selectable markers, pore-forming listeriolysin or a 
recombination based system (RIVET discussed later) (Camilli et al., 1994; Gahan and 
Hill, 2000; Mahan et al., 1995). These IVET systems have now been used to identify 
ivi genes in numerous pathogens (Angelichio and Camilli, 2002). But like STM, IVET 
is not without disadvantages. The screen will select for any ivi genes. The genes 
identified may not necessarily be required for virulence and, indeed, not truly encode 
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virulence factors. This is illustrated in the original IVET screen. In taking bacteria from 
growth in rich medium in vitro to the more restricted nutritional environment of the 
mouse peritoneum one would predict induction of expression of numerous nutrient 
acquisition, metabolic and catabolic genes, which was what the initial IVET detected. 
Another drawback with IVET is that selection in vitro for the input pool may require the 
transcriptional fusion to be silent. Thus genes that are transcribed in vitro will be 
excluded from the input even if are further induced in vivo and play a pivotal role in 
infection. 
1.4.6 In vivo gene expression in S. pneumoniae 
Classical IVET has not as yet been reported as being used in S. pneumoniae but other 
techniques have been employed to examine gene induction in vivo. 
Differential fluorescence induction technology (DFI) has been used to identify 
promoters of S. pneumoniae that are induced under various in vitro and in vivo 
conditions. The technology relies on a green fluorescent protein (GFP) reporter gene to 
indicate expression from a given promoter under test conditions (Valdivia and Falkow, 
1997). Random small fragments of chromosomal DNA from S. pneumoniae were 
ligated upstream of a promoterless gfp gene on a shuttle plasmid. The resulting library 
was transformed into S. pneumoniae and subjected to in vitro conditions such as high 
osmolarity, temperature shift and change in CO2 concentration and also in vivo 
screening in models of otitis media, pneumonia and growth in an intraperitoneal 
chamber implant (Marra et al., 2002a; Marra et al., 2002b). After a period of growth in 
vitro or time in the animal model, fluorescent-activated cell sorting (FACS) was used to 
sort harvested bacteria based on their fluorescent levels. The roles in virulence of genes 
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identified as being induced in vitro or in vivo were ascertained by construction of 
deletion mutants and subsequent testing in vivo. Several genes were found to be induced 
twofold or greater in the selected in vitro or in vivo conditions. Of these 25 were 
mutated and 14 of these were attenuated in one or more of the animal models (Marra et 
al., 2002a). What exact roles they play is yet to be elucidated. 
Two other studies have looked specifically for evidence of differential virulence gene 
expression in vitro and in vivo. The first compared mRNA levels for specific virulence 
factors in total RNA harvested from serotype 3 S. pneumoniae grown in dialysis bag 
implanted into the peritoneal cavity of mice to those from control in vitro cultures 
(Orihuela et al., 2000). However the environment encountered by bacteria in a 
peritoneal dialysis bag cannot simulate that which occurs in a natural infection. Levels 
of mRNA for 4 genes (ply, encoding pneumolysin, capA3, encoding a gene involved in 
capsule biosynthesis, pspA, encoding a surface antigen involved in iron acquisition and 
lytA, the major autolysin) were examined by northern blotting. Only ply and capA3 
showed changes in expression in vivo. Both were up-regulated 2-3 fold as compared to 
levels in in vitro grown bacteria. There was no difference in expression of lytA and pspA 
in vivo compared to in vitro. The second study compared the relative abundance of 
mRNA transcripts of five genes in serotype 2 S. pneumoniae harvested from the blood 
of mice at 12 and 24 hours following infra-peritoneal infection to mRNA levels present 
in organisms grown in serum broth (Ogunniyi et al., 2002). The group exmained ply, 
pspA, psaA, encoding pneumococcal surface antigen, cbpA, encoding choline-binding 
protein A, and the capsule biosynthetic gene cps2A. The expression of all but cbpA were 
found to be up-regulated during infection. These types of studies provide some direct 
molecular evidence that known virulence-associated genes of S. pneumoniae are 
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differentially expressed in vivo, but we are a long way from being able to pinpoint the 
timing of and identify the signals for their expression. 
1.4.7 DNA microarrays and comparative genomics 
The main advantage of microarrays over other systems is they have provided us with 
the ability to measure simultaneously the presence of tens of thousands of different 
nucleic acid sequences, thus allowing the analysis of gene expression and ability to 
perform comparative genomics on a genome-wide scale. The method takes advantage of 
the fact that, due to the specificity and affinity of complementary base pairing, a DNA 
copy of a gene can provide an ideal reagent for specific and quantitative detection of 
that sequence in a mixture of others. The array is essentially a microscopic 
chequerboard representing thousands of different such DNA sequences. 
There are several methods of producing these microarrays. Commercially produced 
arrays are usually high-density oligonucleotide arrays constructed by synthesizing short 
(-25-mer) oligonucleotides in situ on glass wafers. The technology required for 
production makes these types of arrays too expensive for `in house' production, which 
tend to be generated by spotting/printing single or double stranded DNA onto glass 
slides. Here the DNA used is either cloned, synthesised or polymerase chain reaction- 
amplified products. The relative abundance of each or any of these gene sequences in 
two DNA or RNA samples can be measured. The two samples are differentially labeled 
using fluorescent dyes. They are then mixed and hybridised with the arrayed DNA 
spots. However if RNA samples are to be assessed the initial step before labeling and 
hybridization is cDNA synthesis using RNA as the template. This cDNA is taken 
forward to subsequent steps. After hybridization, measurements are taken for each 
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fluorescent dye separately for each spot. These are used to determine the ratio, and in 
turn the relative abundance, of the sequence of each specific gene in the two original 
samples. 
As well as providing data on quantitative differences between samples enabling relative 
abundance of mRNAs to be determined, arrays can be used to determine absolute 
differences between strains allowing comparative genomics. It has become increasingly 
apparent that within many single bacterial species there is enormous variability between 
genomes of different strains. Microarray analysis has become a well-established tool for 
exploring the distribution of genes among collections of isolates from the same species 
and identifying virulence determinants. For example comparative genomics on 15 
clinical H. pylori clinical isolates identified a set of 1,281 core genes (out of 1,643) 
common to all strains (Salama et al., 2000). Amongst those variable genes was a strain 
specific pathogenicity island that encodes a type IV secretion system and an additional 
set of genes that appeared to be co-inherited with this island that encoded new putative 
virulence factors. One important aspect of comparative genomics is that the information 
obtained is based on the microarray used. If the tester strain has additional unique 
sequences these will not be detected. 
As previously mentioned it is clear from epidemiological, molecular and animal studies 
that all strains of S. pneumoniae are not equally efficient at colonizing a host or causing 
disease. These differences are probably due to a combination of things; capsular make- 
up, specific surface protein expression and as yet other uncharacterized genetic 
differences. Comparison of the completed or partially completed genome sequences of 
4 different serotypes clearly reveals the substantial genetic diversity between serotypes 
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(Hoskins et al., 2001; Tettelin et al., 2001). The extent of diversity also varies with 
specific populations. The genetic diversity as assessed by MLST of the invasive 
pneumococcal population irrespective of the serotype is significantly less than the 
carriage population (Brueggemann et al., 2003). Microarrays have been used 
successfully to perform comparative genomics and determine genetic differences 
between strains of S. pneumoniae and their use in more extensive comparative studies 
between clinical invasive and carriage isolates will no doubt play a significant part in 
adding to our understanding of which factors contribute to virulence. 
1.4.8 Global expression studies 
A central requirement for all pathogenic organisms is to possess the ability to adapt to 
changing environmental conditions. This adaptation must involve regulating gene 
expression in response to environmental signals. There has been a natural assumption 
that there is up-regulation of expression of genes that are needed in a particular 
environment and down-regulation of those that are not needed under the same 
conditions. Similarly one might expect the same principle to apply to virulence genes, 
ensuring their expression in the appropriate host environment in which they are required 
and this hypothesis has been the basis of array studies attempting to further identify 
virulence factors. This simple assumption, though, may not hold true. Two studies in 
Saccharomyces cerevisiae showed little overlap between genes identified as having a 
change in mRNA expression in specific conditions, as determined by microarray 
profiling, and genes necessary for survival in the same conditions. The conditions 
looked at included exposure to DNA-damaging agents, change in carbon source or 
challenge with an anti-fungal compound (Birrell et al., 2002; Giaever et al., 2002). This 
indicates that a significant proportion of genes identified by expression profiling may 
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not be absolutely required for an adaptive response, making microarray studies without 
further experimental work unhelpful. Some form of genetic analysis is necessary to 
identify the subset of genes which are required for adaptation to the condition in 
question. 
Bearing this caveat in mind bacterial expression patterns under different in vitro 
conditions that mimic particular host conditions have been examined with the use of 
microarrays (Merrell et al., 2003; Tao et al., 1999) with the aim of identifying specific 
genes that are up-regulated in specific conditions. Changes in gene expression 
compared to wild-type have also been determined for bacterial mutants lacking putative 
virulence gene regulators in attempts to identify their targets (Kato-Maeda et al., 2001; 
Schoolnik, 2002a, b). In this way multiple new virulence factors have been identified 
and the conditions required for their expression elucidated. Finally eucaryotic 
microarrays have also been used to study the host response to pathogen interactions 
(Boldrick et al., 2002). 
Microarrays have been used successfully to examine gene expression on a genome-wide 
basis in S. pneumoniae. To date there have been over a dozen studies published that 
utilize microarray technology to examine S. pneumoniae gene expression profiles with 
the aim of determining proteins that are co-expressed in specific growth conditions or in 
mutant backgrounds. These have primarily revolved around further characterizing genes 
involved in competence or identifying regulons of TCSTS. They will be discussed in 
the section on regulatory networks in S. pneumoniae. 
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As with all the methods that have been mentioned microarray analysis too has its 
limitations. There has been a lag between the initial publication of microarray studies 
and production of standards in both experimental and statistical methodology allowing 
meaningful interpretation of data and comparison of studies. There are concerns about 
the relative stability of different mRNA species when wishing to assess global 
expression changes (Bernstein et al., 2002). The choice of in vitro growth conditions 
will always affect the expression patterns that are obtained and is unlikely to match the 
exact conditions experienced in vivo. Ideally one would like to obtain nucleic acid from 
bacteria from host infected tissue but a major technical hurdle to date has been to 
harvest and purify adequate quantities of bacterial RNA to confidently monitor bacterial 
gene expression at different stages of and in different types of infection. Recently the 
gene expression patterns of Vibrio cholerae, recovered from the stool of human patients 
has been examined (Merrell et al., 2002) and expression studies have been performed 
on RNA from bacteria obtained from blood in septicaemic murine infections. Despite 
drawbacks microarray technology has and will continue to provide a wealth of data on 
virulence genes and their expression. 
1.5 VIRULENCE GENE REGULATION AND REGULATORY NETWORKS 
IN S. PNEUMONIAE 
During the process of survival and multiplication in the host S. pneumoniae will 
experience different microenvironments. Bacteria need to be able to adapt to the 
changing environment and focus their cellular processes to efficient functioning in new 
environments. For example, transition from a state of colonization to invasive disease 
involves adapting from survival at a mucosal surface to survival within host tissue and 
the bloodstream. This inevitably involves the control of expression of various factors 
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involved in housekeeping and metabolic processes but also virulence factors. Research 
focusing on regulation of gene expression in S. pneumoniae and more specifically 
elucidation of regulatory networks within the organism can be grossly divided into two; 
(1) Work detailing the complex networks involved in development of competence and 
transformation and (2) Studies investigating other regulatory networks, primarily 
focusing on elements of virulence. It is interesting that, historically, studies into 
competence have dominated research on gene regulation in S. pneumoniae. At the time 
of starting this thesis project in January 2000 virtually nothing was published on 
virulence gene regulation in S. pneumoniae. It has only been relatively recently, perhaps 
sparked by the identification of genes with regulatory function as well as access to the 
genome sequence, that there has been much interest specifically in virulence gene 
regulation in this organism. Most of that discussed below has come to light during the 
time of my project. The regulatory cascade involved in development of competence has 
been touched on early in this work and reviewed elsewhere (Morrison and Lee, 2000). 
Since competence is not the primary focus of this thesis it will not be discussed in 
further detail except to comment on its links into other regulatory systems and 
virulence. 
1.5.1 Transcriptional regulators 
The three STM screens not only identified many new virulence genes but also indicated 
that tissue-specific virulence factors might exist. The presence of tissue specificity in 
virulence factor requirement may also indicate the presence of mechanisms to regulate 
their expression and/or function in different host tissues. In one STM study the mutant 
pools were assessed simultaneously for survival in models of lung infection and 
septicaemia (Lau et al., 2001). A third of the mutants were found to be essential for 
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both types of infection, a third each were essential for either pneumonia or septicaemia. 
In another STM study the phenotypes of a subset of the total 387 attenuated mutants 
were examined in two other murine models, namely bacteraemia and nasopharyngeal 
carriage. This identified four classes of mutants defective in infection models of the: 
lung, lung and blood, lung and nasopharynx, and all three tissues (Hava and Camilli, 
2002). These findings indicate that some factors function in multiple environments 
whereas others only in specific environments though what external triggers are 
responsible for altering their expression and activity is not clear. 
In total 20 different putative or known transcriptional regulators (excluding the TCSTS) 
were identified by the three STM screens. Some have now been assigned direct or 
indirect regulatory roles (Hava et al., 2003b). Possible regulatory roles have been 
predicted for the majority of the remaining factors (Table 1.1). 
Transcriptional regulators other than those identified in the STM screens have been 
investigated for their role in virulence gene regulation. A screen to isolate mutants that 
affected expression of the competence related genes comCDE lead to the identification 
of the transcriptional repressor CstR (Chastanet et al,, 2001). The repressor. was shown 
to also repress expression of Clp ATP-dependant proteases, one of which had already 
been identified as a virulence factor by STM. RegR, a Lacl/Ga1R family regulator, 
modulates virulence and competence in S. pneumoniae (Chapuy-Regaud et al., 2003). It 
represses expression of hyaluronidase, a cell wall anchored virulence factor (Berry et 
al., 1994; Berry and Paton, 2000; Paton et al., 1993) in vitro and also acts upstream of 
the CiaRH TCSTS to activate competence. Its activity is sensitive to alterations in pH. 
RegM, a homologue of the staphylococcal catabolite repressor protein, CcpA, is 
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required for virulence in a murine model of septicaemia. It does not appear to be 
involved in regulation of expression of virulence factors CbpA, PspA, PsaA and Ply but 
was involved in regulating expression of the capsular polysaccharide biosynthesis locus 
(cps) (Giammarinaro and Paton, 2002) and as such is the first gene implicated in the 
transcriptional regulation of capsule genes. The function of neither RegM or RegR is 
likely to be solely the control of virulence gene expression as both have similarity to 
regulators that control metabolic pathways in other organisms. 
Some of these regulators may be involved in defining the tissue specific expression of 
the virulence genes identified in the STM screens. Finding their targets however is 
simpler than determining the signals to which they respond but without this knowledge 
we cannot begin to dissect the regulatory networks that are important in a switch of 
phenotype from a relatively benign one seen in carriage to an aggressive one seen in 
invasive disease. What is becoming clear though is that there are complex regulatory 
networks that link the expression of virulence genes to other cellular pathways 
including competence. 
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Table 1.1 Transcriutional regulators identified by STM 
TIGR4 
locus' 
Gene Serotypeb Regulatory role` Reference 
SP0141 4 Unknown (Hava and Camilli, 
2002) 
SP0246 4 Unknown, DeoR family (Hava and Camilli, 
2002) 
SP0247 4 Unknown (Hava and Camilli, 
2002) 
SP0306 smrD 3,4 Putative cellobiose (Hava and Camilli, 
metabolism 2002; Lau et al., 2001) 
SP0461 rlrA 4 Regulation of rlrA islet (Hava et al., 2003a) 
genes 
SP0807 4 Regulation of septation (Hava and Camilli, 
ring formation 2002) 
SP0927 smrC 3,4 Regulator of cbpE operon (Hava and Camilli, 
(putative) 2002; Lau et al., 2001) 
SP0975 smrF 3 mRNA stabilization (Lau et al., 2001) 
(putative) 
SP1115 4 MutR regulator (putative) (Hava and Camilli, 
2002) 
SP1278 pyrR 4 Pyrimidine metabolism (Hava and Camilli, 
2002) 
SP1433 4 Unknown, AraC family (Hava and Camilli, 
2002) 
SP1638 smrB 3 Iron dependant regulator (Lau et al., 2001) 
(Putative) 
SP1800 mgrA 4 Virulence gene regulator This work 
(Putative), mga-like 
SP1830 4 Regulation of phosphate (Hava and Camilli, 
transport (putative) 2002) 
SP1854 galR 4 Galactose operon (Hava and Camilli, 
repressor 2002) 
SP1856 4 Unknown, MerR family (Hava and Camilli, 
2002) 
SP2131 4 Pentitol metabolism (Hava and Camilli, 
(putative) 2002) 
SP2142 4 Unknown, ROK family (Nava and Camilli, 
2002) 
SP2195 cstR 3 Regulator of Clp (Chastanet et al., 2001; 
proteases Lau et al., 2001) 
Unclear' 19F Sugar metabolism (Polissi et al., 1998) 
(putative) 
'The TIGR4 annotated gene name. °The serotype in which each regulator was 
identified by STM. `Putative regulatory targets based on sequence similarity and 
information or previous studies. No sequence information or locus details 
available. 
58 
1.5.2 Two component signal transduction systems (TCSTS) 
TCSTS are found in a wide range of bacteria where they have been shown to regulate 
diverse processes, including chemotaxis, nutrient utilization, surface adhesion, the 
switch between aerobic and anaerobic metabolism and virulence gene expression (Stock 
et al., 2000). TCSTSs consist of a sensor kinase that autophosphorylates in response to 
an environmental stimulus and a cognate response regulator (RR) to which an active 
phosphate is transferred. Phosphorylation of the RR results in a downstream response. 
The phosphorylated RR often acts as a DNA-binding protein, binding to promoter 
regions resulting in changes in gene expression. There are genes encoding 13 TCSTSs 
in the S. pneumoniae genome, many of which were also identified in the STM screens 
as being required for disease. The role of each in virulence has been assessed but the 
specific function of only 6 of them have been addressed in any detail (Table 1.2). 
Table 1.2 The roles of TCSTS in S. pneumoniae 
Gene names Known or putative regulatory role Reference 
CiaRH Regulation of competence, induction of htrA (Sebert et al., 2002) 
Com DE Quorum sensing, regulation of competence (Peterson et al., 
and virulence genes 2000) 
B1pHR Production of bacteriocin-like proteins (de Saizieu et al., 
2000) 
MicAB Competence repression, oxygen/redox (Echenique and 
potential sensing Trombe, 2001 a; 
Kadioglu et al., 
2003) 
VncRS Induction of vex123 transcription. Possible (Novak et al., 1999b; 
role in vancomycin tolerance Robertson et al., 
2002) 
PnpRS Regulation of psaA, psaB, psaC and (McCluskey et al., 
resistance to oxidative stress 2004; Novak et al., 
1999a) 
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Three published studies examine the involvement of TCSTS in disease in murine 
models of infection. Lange and colleagues created knockout, mutations in genes 
encoding components of eleven TCSTS of serotype 3 and serotype 22 S. pneumoniae 
strains and found no difference in virulence between the mutants and wild-type strains 
in a murine septicaemia model (Lange et al., 1999). In contrast deletions in the genes 
encoding components of eight of the same TCSTS in serotype 3 S. pneumoniae resulted 
in attenuation of strains in a murine model of pneumonia (Throup et al., 2000). The 
route of inoculation, therefore, appears to be crucial for the role of the TCSTS. 
Intraperitoneal inoculation circumvents any requirement for adaptation at the mucosal 
surface of the respiratory tract and this may explain why TCSTS mutants show different 
phenotypes with respect to ability to cause disease in a septicaemia versus a pneumonia 
model. These two studies were complimented by examination of the role of the 8 
TCSTS, in which mutants were attenuated for pneumonia, in persistence in 
nasopharyngeal colonization (Sebert et al., 2002). It was found that only the CiaRH 
TCSTS was required for efficient nasopharyngeal carriage in a murine model. 
Microarray analysis comparing expression profiles of a CiaRH deficient mutant to wild- 
type bacteria identified 46 genes that were differentially expressed in the two strains and 
were thus potentially regulated by the system. The authors hypothesized that the defect 
in the colonizing ability of the ttciaRH strain may have been at least in part mediated by 
a reduction in the product of htrA, a serine protease. This gene was down-regulated 37 
fold in the AciaRH strain, and was shown to be required for colonization (Sebert et al., 
2002). The CiaRH system is also a strong repressor of competence development 
(Echenique et al., 2000; Guenzi et al., 1994). 
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There are at least two quorum-sensing systems in S. pneumoniae each containing a 
TCSTS. Both have been implicated in virulence (Lau et al., 2001; Throup et al., 2000) 
which is highly suggestive that cross-talk between bacteria plays a role in S. 
pneumoniae pathogenesis. The well characterised com system is involved in induction 
of competence and transformation and the hip system is involved in expression of 
putative bacteriocins. During initial studies investigating the mechanisms of 
competence it was not evident that competence and virulence were linked although it 
had always been tempting to believe that they were. There is now a lot of evidence 
indicating that the two are intertwined. Components of the com system have been 
identified by STM as being required for bacterial survival in murine models (Hava and 
Camilli, 2002; Lau et al., 2001). The lytA gene, encoding autolysin a known virulence 
factor in S. pneumoniae, has been shown to be part of the cinA-recA operon which is 
induced during competence (Mortier-Barriere et al., 1998). Two microarray studies 
investigating the transcriptional kinetics during competence development and 
identifying genes whose expression was dependent on the presence of the signaling 
peptide (Peterson et al., 2000; Rimini et al., 2000) both identified a subset of genes not 
previously known to be associated with competence but with possible roles in virulence 
such as choline-binding proteins. Other TCSTS, such as CiaRH and MicAB are 
involved in regulation of competence and have a role in virulence. 
The blpHR system was one of the TCTSTs shown to have a role in virulence in a 
pneumonia model (Throup et al., 2000). Closer inspection of the neighbouring region in 
the genome identified a short ORF, blpC, encoding a peptide similar to ComC, and two 
genes, blpA and blpB, highly related to the ABC transporter ComAB all suggestive of 
the presence of a second quorum sensing system in S. pneumoniae. Microarray-based 
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expression profiling led to the identification of 16 genes whose expression was highly 
expressed in a B1pC dependent manner. Their actual function and which are directly 
involved in virulence is yet to be fully determined. Most encode for relatively small 
peptides. Seven blp ORFs, distributed over three operons, contain a Gly-Gly motif 
characteristic of peptides that are secreted and processed by ComA/B-like proteins and 
sequence similarity searches give putative bacteriocin-like function to many of these (de 
Saizieu et al., 2000). Bacteriocins are compounds that are produced by bacteria that 
selectively inhibit or kill closely related bacteria or species. One can see a role for these 
bacteriocins is aiding strain colonization of the nasopharynx where there is competition 
with other pneumococcal strains and other bacterial species but as the lung parenchyma 
is usually sterile what role they play in lung infection is not apparent. The authors also 
found strain-dependent sequence variation in the Blp genes and demonstrated that there 
was no blp regulon cross-induction between strains possessing different blp pherotypes. 
Bacteriocin diversity has been proposed to be the outcome of intense microbial 
competition and emergence of resistance in target organisms. The related Com system 
also displays sequence variation within the signal peptide, ComC, and in its proposed 
target, the N-terminal of the histidine kinase, ComD (Havarstein et al., 1997). Such 
strain-specific peptide pheromones may allow S. pneumoniae clones to co-ordinate their 
responses to external stimuli even in the presence of other S. pneumoniae strains or 
other related streptococcal species. 
The MicAB two-component system provides another example of this link between 
competence and virulence. Oxygen limitation in a microaerobic atmosphere abolishes 
development of competence. Studies of oxygen-independent mutant strains 
demonstrated the involvement of the CiaRH and ComDE TCSTS in this regulation but 
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the oxygen-sensing mechanism was not apparent (Echenique et al., 2000). PAS 
domains perceive cell energetic status by sensing oxygen, redox potential, ligands, 
proton motive force and light (Taylor and Zhulin, 1999). Redox sensing and signal 
transduction via TCSTS carrying PAS domains is one strategy used by bacteria for 
adaptation to variations in oxygen concentrations. Genome analysis found the histidine 
kinase MicB to be the only PAS domain containing protein in S. pneumoniae (TIGR4 
genome) (Echenique and Trombe, 2001a). Mutation of the PAS domain in MicB 
abolishes the kinase activity and allows expression of competence under 
microaerophilic conditions indicating that at least one function of the MicAB system is 
the perception of signals produced in response to oxygen deprivation and their 
transduction, culminating in the repression of competence. Whether this repression of 
the comCDE operon is via control of CiaRH regulation or a complementary pathway 
has yet to be established. The response regulator MicA has been shown to be essential 
for bacterial growth as insertion mutations into the micA gene could not be obtained in 
any genetic background (Lange et al., 1999; Throup et al., 2000). The MicAB system 
more recently been shown to be involved in virulence in a murine model of pneumonia 
and it has been proposed that it is involved in the adaptive response of the bacteria to 
changes in oxygen levels during the course of infection (Kadioglu et al., 2003). 
The functions of the PnpRS and VncRS TCSTS are less clear but have been 
investigated. Based on similarity to B. subtilis PhoP/R and the fact that the genes 
encoding it are upstream of genes encoding a phosphate specific transporter (pstABC), 
the PnpRS system was initially thought to be regulated by/or linked to phosphate 
uptake. However the fact that the expression of the pst genes did not require an intact 
PnpRS system and mutations in pnpRS did not result in a phenotype similar to the pst 
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mutants suggests that there is no functional relationship between the two loci (Novak et 
al., 1999a). The finding that pnpRS expression was not responsive to phosphate levels 
also supports this hypothesis (Orihuela et al., 2001). A more recent study demonstrates 
that, at least in serotype 4, this TCSTS has a role in virulence, regulation of the genes 
psaA, psaB and psaC and resistance to oxidative stress. There was no evidence in this 
study, however, that the PnpRS was involved in virulence or regulated the same set of 
genes in two other serotypes (2 and 3) (McCluskey et al., 2004). 
The VncRS story is more complicated. This TCSTS was originally believed to be part 
of a third quorum sensing-like system that included an upstream gene encoding the 
effector signal peptide, Pep27, and three genes upstream to this ORF encoding a 
putative ABC transporter (VexABC). The whole system was proposed to be associated 
with vancomycin tolerance and programmed bacterial cell death (Novak et al., 1999a; 
Novak et al., 2000). A more recent study though, disputes these findings. The authors of 
this study failed to demonstrate tolerance to vancomycin in either vncS or pep27 
mutants. They also demonstrated by microarray transcriptional analysis that inactivation 
of vncS or vncR failed to alter expression of genes known to contribute to autolysis that 
had been implicated in earlier work. A role for VncRS in transcriptional regulation of 
the vex gene cluster was found though the function of the products encoded by the vex 
genes has yet to be confirmed (Robertson et al., 2002). 
1.5.3 Phase variation 
Phase variation is another mechanism of gene regulation employed by S. pneumoniae. It 
is a strategy used by many bacterial species that can provide a large repertoire of 
phenotypes from within a clonal population and potentially provides adaptation to 
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changing environmental conditions (Synder et al., 2001). The molecular mechanisms 
behind phase variation have been best worked out in Neisseria spp. and are associated 
with reversible changes within simple DNA repeats, composed of repeated sequence 
motifs of less than 10 nucleotides. These repeats are located either within open reading 
frames (ORFs) or within promoters. Alterations in the number of repeats located within 
ORFs alter the relative translational reading frame of the sequence 5' and 3' of the repeat 
(Stern et al., 1986; Stibitz et al., 1989). Changes in the length of repeats located within 
promoters alter the relative position of promoter components and thereby influence 
transcription (Sarkari et al., 1994; van der Ende et al., 1995). 
A total of 397 (18%) of genes in the TIGR4 genome have short sequence repeats 
(Tettelin et al., 2001) and are potential candidates for undergoing phase variation in a 
similar way. Of these 25 are directly related to virulence. The two best described phase 
variants in S. pneumoniae are characterised by differences in colony opacity 
appearance. Transparent variants have less polysaccharide capsule, more cell wall 
teichoic acid, more choline-binding protein A (CbpA) and less pneumococcal surface 
protein A (pspA) than their opaque counterparts (Kim and Weiser, 1998; Weiser and 
Kapoor, 1999). The genes from the teichoic acid and capsule pathways that are 
associated with colony opacity variation are amongst those identified in the. TIGR4 
genome to iterative DNA motifs. These phenotypic variants are also associated with 
differences in virulence. Only the opaque variant of several strains was able to cause 
sepsis in a bacteraemia model (Kim and Weiser, 1998) whereas transparent variants 
were more efficient at adhering to human endothelial and epithelial cell lines and 
colonising the nasopharynx in animal models (Cundell et al., 1995c; Weiser et al., 
1996). Transparent variants are selected for during carriage in an infant rat model 
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(Weiser et al., 1994) compared to a selection for opaque variants during otitis media 
and in septicaemia (Tong et al., 2001). Despite knowing that S. pneumoniae undergoes 
phase variation the actual genetic mechanisms that contribute to it in S. pneumoniae 
have not been demonstrated. 
1.5.4 Inter strain variation in virulence gene regulation 
Hand in hand with the increase in our knowledge of virulence gene regulation and 
regulatory networks in S. pneumoniae over the last three years has been the growing 
realization that virulence determinants and even regulatory pathways can differ from 
strain to strain. Pneumococcal pathogenesis work to date has utilized a variety of 
different strain backgrounds, e. g 2,3,4,6,19F and 22. There has been little consistency 
in gene naming or annotation. Even since the availability of the TIGR4 genome there 
has been a lack in attempt to annotate genes according to TIGR4 locus names. This 
produces some difficulty with cross-referencing work performed in different strain 
backgrounds. Yet despite these hurdles it is becoming apparent that inter-serotype/strain 
differences do occur for isolated virulence gene distribution and resultant product 
function. Some virulence factors are not conserved across serotype. There are at least 10 
genes identified as important for virulence of serotype 4 in a murine model of 
pneumonia that are not present in D39 or R6 (Hava. and Camilli, 2002; Tettelin et al., 
2001), e. g. the rlrA locus and pia locus (this work and (Brown et al., 2001)). There are 
an increasing number of examples of factors that are involved in disease production in 
one genetic background but not others. These include regulatory components, which 
may also imply that there are different targets for these regulators in different strains. 
Inactivation of MicB resulted in an attenuated phenotype with respect to causing 
pneumonia in a serotype 6B or 2 background (Kadioglu et al., 2003) but had a wild- 
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type phenotype in a serotype 3 background (Throup et al., 2000). Similarly mutations in 
the response regulator SP0661 resulted in different phenotypes with respect to ability to 
cause disease in different murine models in four serotypes, 2,3,4 and 22 (this work) 
(Blue and Mitchell, 2003; Lange et al., 1999). Inactivation of regR resulted in an 
attenuated phenotype in a 6B background but not in D39 (Chapuy-Regaud et al., 2003) 
despite the fact that at least one of its targets, hyl, is present in both strains. This data 
and the finding that there is diversity in signaling pheromones in S. pneumoniae 
suggests that each S. pneumoniae clone is potentially unique in its exact quota of 
virulence determinants and co-ordination of their expression. 
AIMS OF THE PROJECT 
At the time this project was initiated there was very little published about regulation of 
virulence gene expression in S. pneumoniae and nothing was known about virulence 
gene regulation in vivo. My ultimate goal was to investigate the regulation and 
expression of one or more pneumococcal virulence genes in vitro and in vivo. Despite 
the apparent lack of data on virulence gene regulation at the time, there were several 
simultaneous advances in the field in general that aided development of this project. 
The S. pneumoniae genome sequence had just been completed (Tettelin et al., 2001). 
One STM screen had been published (Polissi et al., 1998), another followed shortly 
afterwards (Lau et al., 2001) and a third was completed by a colleague whilst I was 
working in the Camilli laboratory (Hava and Camilli, 2002). There was an increasing 
amount being elucidated on the quorum sensing and regulatory system controlling 
induction of competence and transformation in S. pneumoniae, that gave insights into 
some regulatory mechanisms employed by this pathogen. Finally there had been some 
exciting applications of new in vivo techniques (RIVET) and microarray technology 
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that allowed investigation of the temporal expression of virulence determinants in vivo 
in other pathogens (Lee et al., 1999; Lee et al., 2001) and identification of one regulon 
within S. pneumoniae (de Saizieu et al., 2000). 
The main aim of the project was to investigate virulence gene regulation in S. 
pneumoniae. To achieve this the following objectives were set: 
1. To assess the feasibility of RIVET for use in S. pneumoniae to study the 
expression of virulence factors, initially in vitro, and then in vivo. Pneumolysin 
was chosen as the first virulence factor to study. 
2. To use different models of infection to determine the requirement of virulence 
gene regulators identified by STM. 
3. To identify genes under the control of the regulators of interest. 
4. To perform functional analysis of the virulence genes controlled by the subset of 
regulators analysed in (2) and (3). 
5. To examine the distribution of regulators and the genes which they control in 
clinical isolates. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Bacterial strains and plasmids 
Strains, plasmids, and primers used in this study are listed in Tables 2.1,2.2,2.3 and 
2.4. The parental S. pneumoniae strains used in genetic manipulations in this study are 
either derivatives of TIGR4, a serotype 4 clinical isolate, of AC365, a serotype 9V S. 
pneumoniae clinical isolate or of D39. AC1365 was a gift from Dr J Weiser, University 
of Pennsylvania Medical School, Philadelphia, Pennsylvania, USA. D39, serotype 2 S. 
pneumoniae strain, was a gift from Dr J Brown, University College Hospital, London, 
UK. The collection of clinical strains for detection of the rlrA islet was a gift from Dr 
A. Brueggemann, University of Oxford, Oxford, UK. 
2.1.2 Media and culture conditions 
E. coli strains were grown in Luria-Bertani (LB) broth or on LB agar at 37°C. S. 
pneumoniae strains were grown at 37°C and 5-6% CO2 on Columbia agar supplemented 
with 5% horse blood or in Todd-Hewitt broth plus 5% yeast extract (THY), and 
supplemented with Oxyrase (5 µg ml') for serotype 4 S. pneumoniae and 0.8% maltose 
when indicated. Where indicated lacZ reporter S. pneumoniae strains were grown in 
THY broth without Oxyrase in a) ambient air (20% oxygen, 0.03% carbon dioxide), b) 
10% carbon dioxide, 10% hydrogen and 80% nitrogen (generated by an anaerobic 
chamber), c) 5% carbon dioxide, 20% oxygen or d) 10% carbon dioxide, 20% oxygen 
(generated in a micro-processor controlled incubator). Unless otherwise stated, 
antibiotic concentrations used in this study were as follows: 
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A) Agar plates: chloramphenicol (Cm) 4 jig ml', streptomycin (Sm) 100 ug ml', 
and spectinomycin (Spc) 200 jug m1-' 
for S. pneumoniae; Amp 50-100 jcg ml-' , 
Cm 10 pg m1-' and Spc 100 pg ml-' for E. coli. 
B) Liquid cultures: chloramphenicol (Cm) 2 pg ml', streptomycin (Sm) 50 jig ml-', 
and spectinomycin (Spc) 100 jig m1'' for S. pneumoniae; Amp 50 pg ml-' , Cm 5 
pg m1-` and Spc 50 pg ml-' for E. coli. 
2.1.3 Reagents and antibodies 
Unless otherwise stated, chemicals were purchased from Sigma and enzymes from 
Gibco-BRL or New England Biolabs and were used with buffers according to the 
manufacturers instructions. 
Rabbit anti-resolvase antibody was a gift from Dr A Camilli (Tufts University, Boston, 
USA) and was used at dilutions 1: 5000. Rhodamine-conjugated phalloidin (Molecular 
probes) was used at a dilution of 1: 50. Cyanine 2 (Cy2)-conjugated donkey anti-rabbit 
antibodies (Jackson Immunoresearch Laboratories) were used at a dilution of 1: 200. 
Anti-capsule serotype 2 and 4 were used at dilutions of 1: 500 - 1: 2000. 
2.1.4 Eucaryotic cells and culture conditions 
A549 cells, a human lung epithelial cell line were grown according to ATCC guidelines 
in Dulbecco's modified Eagle medium (DMEM; Gibco-BRL) supplemented with 10% 
foetal bovine serum (FBS) and 2mM glutamine at 37°C and 5% CO2. These were 
seeded into 24-well tissue culture plates and allowed to adhere for 48h prior to the 
binding assay. 
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2.2 IN VIVO STUDIES 
2.2.1 Mouse infections and competition experiments 
In all animal infections 6 to 10 week old female Swiss Webster (USA) or CD l (UK) 
mice were used (Taconic or Charles River Laboratories in either USA or UK 
respectively). Prior to competition experiments magellan2 insertion mutations or other 
mutations were backcrossed into AC353 as described (Hava and Camilli, 2002). 
Bacteria were prepared for inoculation as follows. Mutant or wild-type strains were 
grown during the day in THY broth supplemented with the appropriate antibiotic until 
an ODD was reached. Cultures were then adjusted to an appropriate concentration, split 
into aliquots, immediately frozen and stored with 20% glycerol at -80°C. The number of 
colony forming units per millilitre (cfu/ml) was confirmed by serial dilution. Further 
adjustment to an appropriate input dose was made at the time of inoculation of the mice. 
In all experiments mice were lightly anaesthetized with methoxyflurane or halothane 
prior to inoculation and were sacrificed by CO2 asphyxiation at the end of the infection. 
For lung infection 40 µl of the bacterial suspension was, inoculated intranasally 
(approximately 1x107 CFU). The infection was allowed to proceed for 44 hours, at 
which time mice were euthanased, lungs aseptically removed, mechanically 
homogenized and serial dilutions plated on blood agar plates. Approximately 5- x 105 
bacteria were inoculated for i. p. infections and bacteria were recovered from the 
bloodstream by cardiac puncture after 20 hours. To assess nasopharyngeal carriage 10 
µl of a bacterial suspension was inoculated intra-nasally (approximately lx 108 CFU) 
and bacteria were recovered at 7 days by washing the nasopharynx with 400 pl of sterile 
phosphate-buffered saline. 
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For single infections the input dose was calculated by serial dilution of the inoculum 
and the absolute output number, measured as CFU/gram of tissue, was calculated from 
serial dilutions of the homogenate and knowledge of the weight of tissue dissected. For 
resolution assays the percentage of Spcs CFU was determined in the input inoculum and 
output homogenate by plating recovered bacteria on blood agar plates supplemented 
with Sm and subsequently replica plating colonies to either Sm or Sm Spc blood agar 
plates. For competition experiments mutant and wild-type bacteria were mixed in a 1: 1 
ratio and inoculated at doses described. The input ratio of mutant: wild-type bacteria 
inoculated into the mice was determined as described below. In parallel to all 
infections, the same. mutant: wild-type mixture was inoculated into l0mis of THY 
supplemented with appropriate antibiotic and Oxyrase (5 µg ml-') and grown to mid/late 
exponential phase to assess in vitro growth. 
For each mouse competition experiment and in vitro competition growth 
experiments, the ratio of mutant to wild-type bacteria recovered was determined by 
plating recovered bacteria on blood agar plates supplemented with Sm and subsequently 
replica plating colonies to either Sm and Sm Cm, or Sm and Sm Spc blood agar plates. 
In vivo competition indices (CI) were calculated as the ratio of mutant to wild-type 
bacteria recovered from each animal adjusted by the input ratio. 
2.3 MANIPULATION OF DNA AND RNA 
DNA was electrophoresed through 0.6-1.6% Tris-acetate EDTA buffer (TAE; 40mM 
tris-acetate, 1 mM EDTA, pH 8.0) gels. Gels were stained with ethidium bromide and 
DNA was visualized in a UV transilluminator. DNA fragment size and concentration 
was determined by comparison with Hyperladder (Bioline). Isolation of DNA 
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fragments, ligation into plasmid vectors, bacterial transformation and isolation of 
recombinant clones were carried out according to standard protocols (Sambrook et al., 
1998). 
2.3.1 Preparation of genomic and plasmid DNA 
Genomic DNA was prepared from bacteria grown overnight on blood agar plates using 
the DNAEasy Tissue kit (Qiagen) according to the manufacturers tissue preparation 
protocol. Plasmid DNA was prepared using the QlAprep Spin Miniprep kit and 
QlAfilter Plasmid Midi kit (Qiagen) according to the manufacturers instructions. 
2.3.2 Polymerase chain reaction (PCR) 
Primers used in this study are listed in Tables 2.1 and 2.2. Unless otherwise noted, all 
PCR reactions were performed in reaction buffer containing lx Taq reaction buffer 
(Promega), 250#M dNTPs, 114M of each primer, and a 10: 1 mix of Taq and Pfu DNA 
polymerases. Reaction conditions consisted of 25 cycles of 95°C - 30s, 50 to 52°C - 
30s, and 72°C - 30s/kb of DNA, followed by a 10 min post-dwell amplification at 
72°C. 
2.3.3 Nucleotide sequencing and sequence analysis 
Nucleotide sequencing was carried out by the Physiology Department, Tufts University, 
Boston, USA or by MGW-Biotech (Eberrberg, Germany). Nucleotide sequences were 
analyzed and translated using DNA Strider. Nucleotide and amino acid sequence 
alignments and database searches were performed using the BLAST server at the 
National Center for Biotechnology Information (http: //www. ncbi. nim. nih. gov/blast/). 
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2.3.4 In vitro transposon mutagenesis 
In vitro magellan2 transposition reactions were carried out with purified MarC9 
transposase, 500 ng of target AC353 genomic DNA and 1 pg of each of pEMcat or 
pEMspc derivative separately, essentially as described (Lampe et al., 1996). Reactions 
were ethanol precipitated and resuspended in gap repair buffer [50mM Tris (pH 7.8), 
10mM MgC121 1mM DTT, l00nM dNTPs, and 50 ng of BSA]. Repair of transposition 
product gaps was performed as described (Akerley et al., 1998), except that E. coli 
DNA ligase (NEB) was used in place of T4 DNA ligase. Repaired transposition 
products were transformed into naturally competent AC353 as described (Bricker and 
Camilli, 1999). 
2.3.5 Plasmid and bacterial strain construction 
(1) Construction of pCH48 and CH49, the S. pneumoniae strain harbouring the 
resl -aad9-resl cassette integrated into the chromosome 
pCH48 is a derivative of pACI000 a suicide vector for S. pneumoniae and was 
constructed by stepwise addition of the components making up the final cassette (Figure 
2.1). A BamHl-Sacl1 fragment of DNA containing orf2 (sp0SS8) was excised from 
pAC637, purified and ligated into Bglll -Sac11 digested pAC 1000 resulting in pCH3. A 
Kpnl resl-rest fragment excised from pAC865 was then ligated into an isolated Kpnl 
site within orf2 in pCH3 to make pCH2. Finally, the SpcR gene (aad9) and its promoter 
was amplified from pEMSpc with primers SPCF1 and SPCRI, containing terminal 
Xbal, sites and purified. An Xbal digested fragment was ligated into the isolated Xbal 
site between the two res] sequences of pCH2 resulting in pCH48. 
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To generate the S. pneumoniae strain containing resl-aad9-resl stably integrated into 
the chromosomal copy of orf2 (sp0558), pCH48 was linearised by digestion with Ncol 
and the gel-purified fragment was transformed into competent AC353. The double 
recombination event was selected for by plating on Spc and confirmed by PCR and 
DNA sequencing. 
r aad9 --m, 4m 1 4m 
Kpnl Xbal Xbal Kpnl 
Figure 2.1 Resl-aad9-resl antibiotic cassette in pCH48 
Stepwise addition of components resulted in the construction of the resl-aad9-resl 
antibiotic cassette in orJ2 (sp0558) in pCH48. Restriction enzyme sites are marked. S. 
pneumoniae strains were transformed with linearised plasmid resulting in insertion of 
the cassette in orj2 (sp0558) onto the chromosome by homologous recombination. 
(2) Construction of pCH46 and the S. pneumoniae reporter strains CH53 and 
CH100 
To construct a ply reporter strain CH53 the tnpRmut135 allele was introduced into the 
CH49 chromosome downstream of ply, creating a ply:: tnpRm"hi35 transcriptional fusion 
(Figures 2.2 and 3.3). CH49 already contained the resl-aad9-resl cassette elsewhere on 
the chromosome. 
DNA fragments containing the 3' end of the ply gene and the 685 bp region 
immediately downstream of the ply stop codon were PCR amplified from AC353 with 
primer pairs 3PLYF1/3PLYR1 and DPLYFI/DPLYRI. The cat gene, conferring Cm 
resistance (Cm') on both E. coli and S. pneumoniae, was PCR amplified from pAC 1000 
with the primer pairs PCATFI/PCATRI. The tnpRini1/3S gene was PCR amplified from 
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pAC676 with primer pairs TNPRF2/TNPRRI. Each of these fragments was subcloned 
separately into pCR-Script Amp SK (+)(Stratagene) and subsequently inserted into 
pAC 1000 to give pCH46. This construct contained the ply sequence and the 5' 
downstream region to ply flanking the coding sequence of tnpR'""r135 and the cat gene. 
To generate CH53 pCH46 was linearised by digestion with Xhol and the gel-purified 
fragment was transformed into competent CH49. The double recombination event was 
selected for by plating on Cm and confirmed by PCR and DNA sequencing. 
--Ali 
10 
1 B 
ply tnpl? 
Figure 2.2 ply:: tnpR transcriptional fusion 
The S. pneumoniae strain CH53 was constructed by placing tnpR adjacent to ply on the 
chromosome. 
(A) The plasmid pCH46 contained the last 700 bp of the ply sequence and the 689 bp 
region immediately downstream of the ply stop codon (light blue rectangle) flanking the 
coding sequence of tnpR and the cat gene. 
(B) To generate CH53 pCH46 was linearised and the gel-purified fragment was 
transformed into competent CH49. 
To generate CH100, a S. pneumoniae strain with the tnpR allele with the rpoB-like 
RBS. Competant CH49 cells were transformed with linearised plasmid in which the 
fpRmut135 allele had been replaced by the tnpR"p°B. TnpRP°B was constructed by PCR 
amplifying the gene from AC676 with primer pairs TNPRF3/TNPRRI and purified. 
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This time the forward primer contained the sequence for the new rpoB-like RBS. A 
purified Bgll1-Xbal digested fragment was ligated into Bgll I -Xbal digested pCH46. 
(3) Construction of the new tnpRM gene and ply:: tnpr fusion strain 
The codon usage within the S. pneumoniae genome and the tnpR gene were compared 
using the backtranslate program online at 
http: //www. entelechon. com/eng/backtranslattion. html, selecting for the S. pneumoniae 
codon bias table, in conjunction with the total proteome codon usage table from 
http: //wwww tigr org/tigr-scrips/CMR2/`codontables. spl? project=bsp. Any rare or 
infrequent codons highlighted by the backtranslate program were changed to a more 
commonly used codons, selected for by using the TIGR proteome codon usage data. 
The resultant new tnpR sequence, designated tnpRM, was broken up into seven 100 bp 
lengths with 18 bp overlaps between each fragment. Each fragment would serve as the 
sequence for an oligo (ACTM1-7) from which to reconstruct the tnpR" gene. A tail 
containing Bg111 or Xbal sites was incorporated into the first (ACTM 1) and last 
(ACTM7) oligos respectively. The native tnpR RBS was replaced by an rpoB-like RBS 
sequence in ACTMI. Further forward (ACTMF) and reverse (ACTMR) primers to 
amplify the entire fragment were also designed. The 100 bp oligos were synthesised by 
the primer and sequencing service of the Department of Physiology, Tufts University, 
Boston, USA. 
The oligos were annealed by heating the reaction mixture [lx pfu reaction buffer 
(Promega) and1pM of ACTM1-7, ACTMF and ACTMR] to 98°C and slow cooling to 
50°C. The gaps were filled in by extension at 65°C for 5 minutes after addition of 
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250ysM dNTPs and Pfu DNA polymerase. The products were purified using Qia-quick 
PCR purification Kit (QIAGEN), eluting with 0.1X elution buffer. Repair of the product 
gaps was performed as described (Akerley et al., 1998), except that a thermo-ligase, 
Taq DNA ligase (NEB), was used in place of T4 DNA ligase and ligation was 
performed for 1 hour at 65°C. After further product purification the resultant putative 
tnpRM gene was amplified with primer set ACTMF/ACTMR and cloned into 
pCRScript-SK+ vector and transformed into E. coli DH5a. Multiple clones were 
sequenced and one with the correct tnpRM, CH95, was selected. 
A Bglll -Xbal digested fragment, containing tnpRM, was excised from pCH95 and 
ligated into Bglll-Xbal digested pCH46 to create pCH103. This construct contained 
the 3'ply sequence and the 5' downstream region to ply flanking the coding sequence of 
tnpRM and the cat gene. To generate the reporter strain CH 104, an S. pneumoniae strain 
habouring the tnpRM downstream of ply, pCH 103 was linearised by digestion with Xhol 
and the gel-purified fragment was transformed into competent CH49. The double 
recombination event was selected for by plating on Cm and confirmed by PCR and 
DNA sequencing. 
(4) Construction of maltose inducible/over-expressing S. pneumoniae strains 
To construct strains that express lacZ, tnpR, mgrA, rlrA or sp0661 from an inducible 
promoter, the coding sequence of each gene was introduced into S. pneumoniae maltose 
locus downstream of malM (Acebo et al., 2000b; Puyet and Espinosa, 1993) (Figure 
2.3). DNA fragments containing the 3' end of the malM gene and the 5' end of the 
malP gene were PCR amplified from AC353 with primer pairs MALMFX/MALMRP' 
and MALPF2/MALPRP. The cat gene, was PCR amplified from pAC 1000 with the 
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primer pairs PCATFI/PCATRI. The tnpRM gene, cloned into pCR-Script Amp SK 
(+)(Stratagene), was constructed as previously described. The coding sequence of lacZ 
was amplified from pEVP3 with primer sets LACFPN/LACZRI and 
LACFRB/LACZRI. The coding sequence of mgrA, rlrA and sp0661 genes were PCR 
amplified from AC353 with the primer sets SP1800F/SP1800R, RLRAFR/RLRARX 
and 0661F/0661R. In the cases of mgrA, rlrA, sp0661 and one of the lacZ alleles the 
Shine-Dalgarno sequence of the S. pneumoniae rpoB gene was engineered into the 
forward primer sequence to allow a high level of translation efficiency of each 
respective gene at the maltose locus. Each of these fragments was sub cloned separately 
into pCR-Script Amp SK (+)(Stratagene). All DNA fragments were subsequently 
inserted into pAC1000 to give pAC1472, pCH73, pCH75, pCH101 (Table 2.4). The 
final constructs contained the 3'malM sequence and the 5' malP sequence flanking the 
coding sequence of each gene under study and the cat gene. 
To generate the S. pneumoniae strains over-expressing the chosen genes each of the 
plasmids above were linearised by digestion with Xhol and the gel-purified fragment 
was transformed into naturally competent AC353. The double recombination event was 
selected for by plating on Cm and confirmed by PCR and DNA sequencing. To 
generate the serotype 2 S. pneumoniae strain over-expressing mgrA the serotype 4 mgrA 
gene sequence was excised from pAC 1472 and replaced with an equivalent mgrA gene 
sequence amplified from D39. The resultant plasmid was linearised by digestion with 
Xhol and the gel-purified fragment was transformed into naturally competent D39. 
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Figure 2.3 Maltose inducible/over-expressing S. pneumoniae strains 
Maltose inducible S. pneumoniae strains were constructed by placing the required gene 
(marked red; IacZ, tnpRM mgrA, rlrA or sp0661) downstream of ma1M as a 
transcriptional fusion on the chromosome. Plasmids were constructed with the coding 
sequence of each gene under study flanked by DNA fragments containing the last 500 
bp of ma1M and the cat gene and the first 500 bp of ma1P. To generate the S. 
pneumoniae strains over-expressing the chosen genes each of these plasmids were 
linearised and the gel-purified fragment was transformed into naturally competent 
AC353. 
(5) Construction of sp0156 and sp0661 deletion strains 
Constructs necessary to introduce unmarked in-frame deletions in sp0156 and sp0661 
into the S. pneumoniae chromosome were generated by splice overlap extension using a 
PCR fragment corresponding to the nucleotide sequence upstream region to the coding 
sequence and a PCR fragment corresponding to the nucleotide sequence downstream of 
the stop codon. In each case, the upstream fragment was generated by PCR from 
AC353 using the primers pairs 156SF1/156SR1 or 0661SF1/0661SR1. The downstream 
PCR products were amplified using 156SF2/156SR3 or 0661 SF2/0661 SR2. Following 
amplification, each PCR product was purified using the StrataPrep PCR clean-up kit 
(Stratagene). 
Next, the upstream and downstream PCR products were fused in a second PCR 
reaction. This reaction contained 5 pl of each PCR product, F1 and R2 primers (above), 
250 nM dNTPs, and 1.5 µl of a 10: 1 mixture of Taq and Pfu DNA polymerases in 1X 
Taq buffer, and consisted of 13 cycles of 95°C - 30s, 45°C - 30s, and 72°C -1 min. 
The resulting PCR products were gel purified as described above and ligated into pCR- 
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Script Amp SK (+)(Stratagene). The cloned fragment was subsequently liberated by 
digestion with BamHl and SacII, and cloned into pAC1000, digested in a similar 
manner, to generate pCH 117 and pCH 130. The final plasmids were introduced into 
AC353 by transformation and integrated plasmids were selected by plating on Cm and 
confirmed by PCR. 
To generate strains that harboured the appropriate deletion on the chromosome, the S. 
pneumoniae strains containing the singly integrated plasmid were grown in THY in the 
absence of selective pressure for the plasmid. After growth, cultures were diluted and 
plated on blood agar plates containing Sm, and resulting colonies were replica-plated to 
blood agar plates containing Cm. Strains that failed to form colonies on Cm plates were 
identified and examined for the presence of the deletion by PCR and ultimately 
confirmed by DNA sequencing. In this manner, CH119, containing Asp0661 was 
isolated. Repeated efforts were made to obtain the OspO156 strain, however all strains 
that lost the integrated plasmid regenerated the wild-type copy of sp0156. Therefore, 
magellan2 transposon insertion strain, CH108, was used in competition assays. 
(6) Construction of mgrA deletion strains 
AC1500 was constructed by replacing 1299 bp of the coding sequence of mgrA 
(corresponding to bp 180 to stop codon) with the Spc' gene (aad9) and its promoter 
amplified from pEMSpc (Figure 2.4). DNA fragments containing the region 5' to mgrA 
gene and ending 180 bp into the coding sequence of the gene and the region 3' to the 
mgrA gene were PCR amplified from AC353 using primer pairs 180AF1/1800R8 and 
DN1800/180SRX. The aad9 gene and its promoter, conferring spectinomycin 
resistance to E. coli and S. pneumoniae, was PCR amplified from pEMSpc using primer 
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pairs SPCFN/SPCRS. Each of these fragments was subcloned separately into pCR- 
Script Amp SK(+)(Stratagene) and subsequently inserted into pAC1000 to give the 
allelic exchange vector pAC 1499. To generate AC 1500, pAC 1499 was linearised by 
digestion with Xhol and the gel-purified fragment was transformed into naturally 
competent AC353 as previously described. The double recombination event was 
selected for by plating on Spc and confirmed by PCR and DNA sequencing. 
Figure 2.4 MgrA deletion strain 
The S. pneumoniae strain AC 1500 was constructed by 1299 bp of the coding sequence 
of mgrA with aad9 (SpecR gene). Terminator is marked as a blue hoop. 
(A) The plasmid pAC 1000 contained the first 180 bp of mgrA and the region 
immediately downstream of mgrA flanking aad9 and its promoter. 
(B) To generate AC 1000 pAC 1000 was linearised and the gel-purified fragment was 
transformed into competent AC353. 
To construct serotype 2 strains with a deletion-insertion of a Spc` gene in place of mgrA 
PCR amplification of the mutated region in the serotype 4 strain, AC 1500, was 
performed using primer pairs 180AF1/180SRX and the purified amplicon transformed 
into S. pneumoniae D39 or other serotype 2 background. The double recombination 
event was selected for by plating on Spc and confirmed by PCR and DNA sequencing. 
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(7) Construction of CH209, AmgrA ArlrA double mutant 
To construct CH207, the TIGR4 strain with a deletion-insertion of a Spc' gene in place 
of mgrA and a magellan2 transposon insertion in rlrA, PCR amplification of the 
mutated mgrA region in AC1500 was performed using primer pairs 180AF1/180SRX 
and the purified amplicon transformed into competent rlrA:: magellan2 cells, AC 1213. 
The double recombination event was selected for by plating on Spc and confirmed by 
PCR and DNA sequencing. 
(8) Construction of lacZ transcriptional fusion strains 
Plasmids containing the lacZ gene transcriptionally fused to either rlrA or srtD were 
derivatives of pAC1000. The lacZ gene was PCR amplified from pEVP3 using primer 
pairs LACFRB/LACZRI, srtD and rlrA from AC353 with SRTDFI/SRTDRI and 
RLFF1/RLFRI respectively and erm, a gene conferring erythromycin resistance to S. 
pneumoniae, from pCH6 with primer pairs ERMF3/ERMR3. The primers had terminal 
restriction sites incorporated into each one to allow sequential addition of genes to the 
pAC 1000. Each purified DNA fragment was initially inserted into pCR2.1-TOPO, 
using the TA cloning kit (Invitrogen) according to the manufacturer's instructions. 
From there they were excised with appropriate restriction enzymes and ligated into the 
pAC 1000 backbone. Two final plasmid constructs were made, one with rlrA fused to 
lacZ and a second with srtD fused to lacZ upstream of the erm gene. These plasmids 
were introduced into competent AC353 by transformation to generate CH210, the S. 
pneumoniae strain with a plasmid insertion resulting a srtD:: lacZ at the chromosomal 
srtD site and CH214, the S. pneumoniae strain with a plasmid insertion resulting a 
rlrA:: lacZ at the chromosomal rlrA site. Pneumococcal strains CH211, CH212, CH213 
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and CH215 are strains with either a srtD:: lacZ fusion or rlrA:: lacZ with deletions in 
one or both mgrA and rlrA (table 2.2). These were created by PCR amplification of the 
mutated mgrA region in AC 1500 or the mutated rlrA region in AC 1213 with primer 
pairs 180AF1/180SRX and RLRN1/RLRN2 and the purified amplicon was transformed 
into competent CH210 or CH214. The double recombination event was selected for by 
plating on Spc for mgrA insertion-deletion or Cm for rlrA transposon mutation and 
confirmed by PCR. 
(9) Construction of non-serotype 4 rlrA or rrgA mutant strains 
To generate serotype 2 or 9V S. pneumoniae strains with mutations in either rlrA or 
rrgA PCR amplification of the mutated region in the mutant serotype 4 strain was 
performed using primer pairs RLRAFR/RLRARX or RRGAFI/RRGARI and the 
purified amplicon transformed into required serotype 2 or 9V background. The double 
recombination event was selected for by plating on Cm for rlrA or Spc for rrgA 
confirmed by PCR. 
(10) Construction of serotype 2 strains possessing rlrA islet 
Competent D39 cells were transformed with genomic DNA from CH155, a serotype 4 
S. pneumoniae strain with a magellan5 transposon insertion in one of the IS 1167 
elements flanking the rlrA islet. The double recombination event was selected for by 
plating on Spc and confirmed by PCR. 
2.3.6 rlrA islet detection in clinical isolates 
Clinical isolates were provided by Dr A. Brueggemann, University of Oxford, Oxford, 
UK. Chromosomal DNA was purified from each strain using the DNAEasy kit as 
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previously described. Dilutions of each sample were made and spotted onto Hybond N+ 
nitrocellulose membranes (Amersham Pharmacia) and UV crosslinked. Membranes 
were processed for hybridisation and developed using Alk Phos direct labeling and 
detection kit (Amersham Pharmacia) according to the manufacturers recommendations. 
Hybridisation was carried out at 52°C after which membranes were washed twice in 
primary buffer for 10 minutes at 52°C and twice in secondary buffer for 5 minutes at 
room temperature. Nucleotide probes were prepared by PCR from AC353 genomic 
DNA and primer sets RLRAF2/T7, SRTDF/SRTDR and RPOBPF/RPOBPR. 
2.3.7 Preparation of RNA 
Total RNA was isolated from 5 ml aliquots of S. pneumöniae grown in THY broth 
supplemented with Oxyrase (5 pl ml"') with the addition of 0.8% maltose where 
indicated. Cells were pelleted at 4 °C and immediately frozen. Bacterial pellets were 
thawed on ice and treated with 400 mg m1"' lysozyme in 100 p1 of PBS for 5 min at 
room temperature. RNA was isolated with Qiagen Rneasy kit in accordance with the 
manufacturers (Qiagen) recommendations. Samples were treated on the column with 
DNase I (Qiagen), as recommended by the manufacturer. 
2.3.8 Microarray Probe synthesis, hybridisations and data Analysis. 
Probe synthesis and Hybridisations. RNA was converted to cDNA in 20 pl reactions 
by combining I pg of RNA and 0.5 ysg of random hexamers (Amersham), heating to 
65°C for 10 minutes, and then snap cooling the reactions on ice. The following was 
then added: 2 p1 of 0.1 M dithiothreitol (DTT), 0.5 pl of 10 mM dNTPs, 4#1 of 5x RT 
buffer (Invitrogen) and 1 141 (200U) of Superscript II (Gibco BRL). This mixture was 
incubated at 42°C for 150 minutes. RNA was hydrolyzed with 1 ul of 1M NaOH at 
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65°C for 10 minutes and neutralized with 1 yl of 1M HCI. Samples were purified over 
a Qia-quick PCR column (Qiagen) according to the manufacturer's instructions and 
eluted with 40 jsl elution buffer. Amino-allyl dUTP was incorporated into the cDNA 
samples as follows. For each sample, 40 /Cl of the eluted DNA was incubated for 5 
minutes at 99°C and then for 5 minutes on ice. 5 jsl of lOx random octamer buffer 
(NEB 1550-2), 3 pl of dNTP/dUTP mix (3 mM dGTP, dATP, dCTP; 1.8 mM aa-dUTP 
(Sigma-Aldrich A-0410), 1.2 mM dTTP] and 2 J41 of Exo Klenow (NEB) were added, 
and the mixture was incubated for 150 minutes at 37°C and then stored at 4°C 
overnight. Free amines were removed with a Qia-quick PCR purification kit (Qiagen), 
and the eluted sample was dried in a speed-vac. Samples were resuspended in 4.5 p1 of 
dHZO and incubated with 114M of either Cy3 or Cy5 monofunctional reactive dye 
(Amersham) for 1h at room temperature in the dark. The time point samples were 
incubated with Cy5, and the reference samples were incubated with Cy3. Reference 
samples were prepared by reverse transcribing a pool of RNA comprised of equimolar 
aliquots of RNA isolated from wild-type (AC353) bacteria at each OD. The reactions 
were quenched with 4.5 ycl of 4M hydroxylamine for 15 minutes at room temperature, 
and then each Cy5-labeled sample was mixed with a Cy3-labeled reference. 
Unincorporated dye was removed with a Qia-quick PCR purification kit, and probes 
were eluted with 40p1 of EB and were dried in a speed-vac. To hybridize, the samples 
were resuspended in 11.3 p1 of TE, pH 7.5,1 #1 of 10 mg ml-' 1 yeast tRNA, 2.25 #1 of 
20x SSC and 0.45 pl of 10% SDS. The mixture was heated to 99°C for 2 minutes and 
immediately centrifuged for 2 minutes at maximum speed. The probe was applied to a 
microarray, which is described elsewhere 
http: //falkow. stanford. edu/whatwedo/supplementarydata/pub? /MicroarrayDesign. pdf 
and incubated for at least 24 hours at 60°C. 
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Data Analysis. Arrays were scanned using a GenePix 4000A scanner (Axon 
Instruments, Union City, CA) and images were analyzed with GenePix Pro 3.0 
software. Microarray data were stored in the Stanford Microarray Database (Gollub et 
al., 2003) and are publicly available (http: //genome-www. stanford. edu/microarray). 
The data were filtered to remove poor quality measurements (for example, spots 
affected by scratches on the array were not considered) and the red:: green ratios were 
log2 transformed. Genes for which reliable measurements were obtained for over 80% 
of the arrays in the resulting dataset were selected and organized by hierarchical 
clustering using the CLUSTER program and were viewed in TREEVIEW (Eisen et al., 
1998). Statistical analysis was performed using Significance Analysis of Microarrays 
(SAM) (Tusher et al., 2001). 
2.3.9 Ribonuclease protection assays 
Template DNA for the generation of riboprobes was PCR amplified with the primer sets 
below (Table 2.1). The resulting products were purified with a QlAquick PCR 
purification kit, subsequently cloned into pGEM-T (Promega) and confirmed by PCR 
with both a T7 or SP6 primer and a primer specific for the cloned insert. These 
plasmids were used as templates for generation of riboprobes (Merrell and Camilli, 
2000). Synthesized probes were purified on a 4% denaturing polyacrylamide gel 
containing 7M urea. Ribonuclease protection assays (RPAs) were carried out as 
described by the manufacturer with an RPA11 kit (Ambion) in triplicate with at least 3 
independently isolated RNA samples. The protected fragments were visualized by 
exposing each gel to a phosphor-imaging screen (Kodak) and analyzed with a Storm 
860 scanner and IQMac V 1.2 imaging software. The relative amount of each protected 
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fragment in each assay was normalized to the amount of rpoB protected RNA in each 
lane. 
Table 2.1 Primer pairs and plasmids used for synthesis of RPA probes 
Probe Primer set pGEM-T Plasmid 
0663 663PF/663PR pCH144 
0668 668PF/668PR pCH145 
1800 1800PF2/ 1800PR PCH55 
1803 1803PF/1803PR pCH147 
1804 1804PF/ 1804PR pCH 148 
lytA LYTAFI /LYTAR 1 pCH30 
ply PLYPFI /PLYPR 1 pCH31 
rlrA RLRAF2/ RLRAR7 pAC 1279 
rpoB RPOBF3/RPOBR2 pAC1286 
rrgA RRGAF3/RRGAR3 pAC 1280 
rrgB RRGBF2/RRGBR 1 pAC1281 
rrgC RRGCF2/RRGCR2 pAC 1282 
srtB SRTBF2/SRTBR 1 pAC1283 
srtC SRTCF2/SRTCR2 pAC 1284 
strD SRTDF2/SRTDR2 pAC1285 
2.4 BIOCHEMICAL STUDIES 
2.4.1 Resolution assays 
For in vitro assays S. pneumoniae strains were grown at 37°C and 5-6% CO2 in THY 
broth supplemented with Oxyrase (5 µg ml-`) and Cm 4 pg ml"` to maintain the presence 
of the tnpR allele. Aliquots of this culture were serially diluted and ~ 200 CFU were 
plated onto blood agar plates and incubated overnight. The resulting colonies were 
replica plated onto blood agar plus Spc 200 yg ml-' and plain blood agar to determine 
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the percentage of colonies that were Spcs. In vivo assays were performed as described 
previously. 
2.4.2 SDS-PAGE and Western blotting 
Proteins were separated by electrophoresis using BioRad Ready Gels in SDS-PAGE 
running buffer. When indicated, gels were stained with Coomassie brilliant blue and 
dried. Western blots were performed using the ECL Plus Western Blotting Analysis 
System as described by the manufacturer (Amersham Pharmacia). Proteins were 
transferred to Hybond ECL nitrocellulose membranes in transfer buffer, blocked for 1h 
in PBS-T (1X PBS, 0.1% Tween-20) plus 5% milk, and incubated overnight at 4°C with 
anti-resolvase antibody (1: 2000) in PBS-T plus 5% milk. After washing, membranes 
were incubated with horseradish peroxidase linked anti-rabbit antibody diluted 1: 2000 
in PBS-T for 1h at RT. Membranes were subsequently processed for detection as 
described in the manufacturer's instructions, 
2.4.3 ß-galactosidase assays 
S. pneumoniae cells were grown to mid-exponential growth (ODWO= 0.3 to 0.4) in THY 
broth, THY 0.8% maltose or THY sucrose supplemented with appropriate antibiotics 
then chilled to - 4°C. 1 ml of cells were collected by centrifugation and the pellets 
immediately frozen and stored at -80 °C. Thawed pellets were resuspended to one-tenth 
of the original volume in 0.1 M sodium phosphate buffer, pH 7.5. Lysis was 
accomplished by adding Triton-X100 to 0.1% and incubating for 10 minutes at 37 °C. 
ß-galactosidase activity was determined as described by Miller (Miller, 1972) in assay 
reactions containing I ml of reaction buffer [I mM MgCl2,50 mM mercaptoethanol, 0.1 
M sodium phosphate buffer, pH 7.5, and 0.8 mg m1"' ONPG] and a variable volume 
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(1/20-1/5 volume) of the sample. Enzyme activity was followed at 420 nm at room 
temperature (- 25 °C) and was calculated according to Miller and reported in Miller 
units (Miller, 1972). 
2.5 INFECTION OF CULTURED CELLS 
2.5.1 A549 adherence assays 
A549 cells were seeded into 24-well tissue culture plates 48 h prior to the binding 
assays and grown to -90-95% confluence. S. pneumoniae cells were grown to mid- 
exponential growth (OD6w= 0.3 to 0.4), washed once with PBS, adjusted to an OD6w = 
0.3 in PBS and diluted 1: 10 in Ham's F12K tissue culture medium plus 10% foetal 
bovine serum. Aliquots of 350 µl were added to the monolayers of A549 cells at an 
MOI of 10: 1. Bacteria were incubated with A549 cells for 30-40 minutes at 37°C in 
5% CO2, at which time the culture fluid was removed from each well and the 
monolayers were washed 3 times with PBS (pH 7.4) to remove non-adherent bacteria. 
For enumeration of adherent and/or internalized bacteria, epithelial cells were detached 
from the wells by treatment with 200 141 of 0.25% trypsin-1 mM EDTA and lysed by the 
addition of 800 yl of ice-cold 0.025% Triton X-100. Appropriate dilutions were plated 
on blood agar plates containing Sm to count the number of bacteria adherent to the 
eukaryotic cells. The titer of adherent bacteria for each strain was compared to the 
input titer and the percentage of adherent bacteria was determined. 
For microscopy A549 monolayers were grown on coverslips in 24-well tissue culture 
plates. Infected cell layers on coverslips were fixed and prepared as described below 
after the 30-40 minute incubation and washing with PBS. All experiments were 
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performed in quadruplicate and each experiment was replicated 3 times on different 
days. 
2.6 MICROSCOPY 
2.6.1 Sample preparation and fluorescent microscopy 
For immunofluorescence, cell monolayers on coverslips were fixed in 3% PFA in PBS, 
pH 7.4, for 15 minutes at room temperature and washed three times in PBS. The 
remaining free aldehyde groups in PFA were quenched with 10 mM NH4C12 before 
labeling. Labeling antibodies were diluted in 10% horse serum, 0.1 % saponin in PBS. 
Coverslips were washed twice in PBS containing 0.1% saponin, incubated for 30 
minutes in the dark at room temperature with primary antibodies, washed twice in PBS 
containing 0.1% saponin and then incubated for 30 minutes in the dark at room 
temperature with secondary antibodies. Finally, coverslips were washed twice with 
0.1 % saponin in PBS, once in PBS and once in HZO and mounted on Mowiol. 
Samples were analysed by epifluorescence microscopy (BX50; Olympus Optical 
Co. ). Images were captured using a cooled 12-bit high-resolution monochrome digital 
camera and analysis imaging software (Soft Imaging System). Images were processed 
and false coloured where appropriate using Adobe Photoshop software (Adobe 
Systems). 
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Table 2.2 Primers used in this stud 
Primer Name Sequence (5' to 3') 
0661F CGCGGATCCAAAGGAGAATCATCATGACCTACACAATCTTA 
ATC 
0661SF1 ATTACCATCAAGACTATCTC 
0661 SF2 CAGAGCATGTGATTAAGAAAGAGTTGGG 
0661 SR 1 TCTTAATCACATGCTCTGCTCCTTAC 
0661SR2 GCCCCAACTGGAGTTGAT 
0661R CCCTCTAGATCATCGGTCTTCTCCCTTCTT 
663PF GTCAGGTAGTGGAAGATGT 
663PR ATGAAGAGTAGGATGGACA 
668PF GGTGAAAACGAGAAATGTA 
668PR GGCTCATGGAAATCACTGT 
156SF1 CAAGTCATTGCTCAAGGC 
156SF2 GAGAAAATGGCCCAGCAGCTCTTGCTTTC 
156SR1 CTGCTGGGCCATTTTCTCCCTTTCTACT 
156SR3 ATATGTACCTCCATGATTTTATCTATAATC 
1800PF2 CATGCTATACCTATTCTTTGT 
1800PR TAATACGACTCACTATAGGTACGATAGAGCGAAGATGAAC 
1800R8 GCATGCCATGGTTAAGAAGAATGAAAAATCAAG 
180AF 1 GTTTGGATCCTTTAAAATTAAAAATATAATCTT 
180SRX GGGACTCGAGATGAAACACAAGGAATGGCA 
1803PF ATGGAATGGCTTAAACA 
1803PR ATCCAGCTGCAACTCCC 
1804PF GTAGCTCACGAAATCAAAG 
1804PR AATATAAAGCTGGAACATT 
3PLYF1 GCCAAGTCTATCTCAAGTTG 
3PLYR1 GGGCCAGATCTCTAGTCATTTTCTACCTTAT 
ACTM1 GCGTAGATGTTTACAAAGGAGAATAATTATGCGCTTATTCGG 
TTATGCACGTGTTAGTACCTCTCAACAAAGTCTTGACATCCA 
GGTCAGAGCTTTGA 
ACTM2 AGCAAATCGAGACCTTTTCGGTCACTACTAGATCCAGAAGCC 
TTATCAGTAAAAATTCGATTAGCCTTCACACCTGCATCTTTC 
AAAGCTCTGACCTGGA 
ACTM3 AAAAGGTCTCGATTTGCTACGAATGAAAGTGGAAGAAGGTG 
ATGTTATTCTAGTGAAAAAGTTGGATFCGCTTGGGTCGTGAT 
ACCGCTGATATGATCCAG 
ACTM4 TTTTACCCATTTCTCCGTCTGTACTAATTCCATCATCAATAAA 
TCTAATAGATACTCCTTGTGCATCAAATTCTTTAATAAGCTG 
GATCATATCAGCGGT 
ACTM5 ACGGAGAAATGGGTAAAATGGTTGTTACTATTTTATCTGCCG 
TTGCCCAAGCTGAAAGACAACGCATTCTTGAGCGCACTAAT 
GAGGGAAGACAGGAGGC 
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ACTM6 GCCGAGGCCTTGTTGCCACATATTCAAGACAGCGTCGCGGTC 
AATCTTTCGTTTACGACCAAAGACTACACCTTTTGCCATAGC 
CTCCTGTCTTCCCTCA 
ACTM7 TGGCAACAAGGCCTCGGCGCTTCACATATTTCAAAGACAAT 
GAACATCGCTAGATCAACAGTTTATAAAGTAATCAATGAAT 
CAAATTAATCTAGACCGC 
ACTMF GCGTAGATGTTTACAAAGGAG 
ACTMR GCGGTCTAGATTAATTTGATT 
DN1800 GGATGCATGCCAAAAATAACAAAAAAAC 
DPLYFI CCCGGCTGCAGTAGCATGCGAGAGGAGAATGCTTGCGAC 
DPLYR 1 CGCGACTCGAGTAGAAAGTTTCAGCCAAGTT 
ERMF3 TGCCTCTAGAGGGAACAGAGATTTTGAC 
ERMR3 GAGGCATGCTTATTTCCTCCCGTTAAA 
LACFPN CGCGGATCCAAAGGTGGTGAACTACTG 
LACFRB CGCGGATCCAAAGGAGAATCATATGGAAGTTACTGACGTAA 
GA 
LACZRI GGGTCTAGATTA'IT1 FIGACACCAGACCA 
LYTAFI CGCACACTCAACTGGGAATC 
LYTAR1 TGTTTGGTTGGTTATTCGTG 
MALFX CCCTCGAGTGAAAGCTATCGTGAGCAATT 
MALPF2 CCCTCTAGAGAGCATGCGACAATAATCAGGAGACAAC 
MALPRP CCGCGGCTCGAGTTCAAGAGGCCATTTTTCAAG 
MALRP CCGAGCTCAAGATCTGGATCCTTATTTCTTTAAATCTACC 
OUTPFL ACTACATCACTAACGCCATTG 
OUTXYL AATTCTAGAAGGCATACCAGT 
PCATFI CCCGGTCTAGAGTCGACGGTATCGATAAGCT 
PCATRI CCGGCGCATGCTTATAAAAGCCAGTCATTAG 
PLYPFI GGCAAATAAAGCAGTAAATG 
PLYPRI ACAAGGTCTCATCCACTACG 
RLFFI ATACCGGCGGAACAGCACTGACTTTCTTA 
RLFR1 CGCGGATCCTTATAACAAATAGTGAGCC 
RLRAF2 TTACATGCTGTMATCAATAA 
RLRAFR CGCGGATCCAAAGGAGAATCATCATGCTAAACAAATACATT 
GA 
RLRAR7 AGTAGAAAGAAGCGGAGTATT 
RLRARX CCCTCTAGATTATAACAAATAGTGAGCCTT 
RPOBF3 TGCTTATGACTTGGCAGCAG 
RPOBR3 GGCTTTCAATGCTTTCAATC 
RRGAFI AGTCTTAACAGGGAGACACAC 
RRGAF3 CACTTTTATACGCTTTTGCTA 
RRGARI GCAACATTCCGATACCACCAG 
RRGAR3 TAATACGACTCACTATAGGTGCCATCCGTATTG=TC 
RRGBF2 AAACTATCATTGAAAGGGGAG 
RRGBRI TAATACGACTCACTATAGGGGCATTGCCCTGAGAGTTTA 
RRGCF2 GGCTGCGATTATGGGTATT 
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RRGCR2 TAATACGACTCACTATAGGGGTCATCTCAAACGAAGTCT 
SP1800F CGCGGATCCAAAGGAGAATCATCATGAGAGATTTATTATCT 
AAAAAAAG 
SP1800R CCCTCTAGATTACTCATCTAATCGAATAAA 
SPCFI CCGCTCTAGAACTAGTGGATCC 
SPCR1 CCCTCTAGACAATTTTTTTATAAT'17TTTTAAFCTG 
SRTBF2 AGGACTGGGATTCTGATTTA 
SRTBRI TAATACGACTCACTATAGGATCGCCACTCACTACATTATT 
SRTCF2 GATTCTTTTATGGATTATTCG 
SRTCR2 TAATACGACTCACTATAGGGACGCCTTTCTTTITCTCTTG 
SRTDFI TTTCCGCGGGGTTTATTTGGGAGCAG 
SRTDF2 GCGGTCATCCTTCTCTTGCT 
SRTDRI CGCGGATCCTTATTTCCCTCGTAGTAAA 
SRTDR2 TAATACGACTCACTATAGGGTCGTCAGACACTTGGTAAT 
TNPRF2 GGCCCAGATCTTTGAGATACATTTVFATGC 
TNPRRI GGCCCGCATGCTCTCTAGATTAGTTGCTTTCATTTATTA 
XYL1 AGCATACTCCAACTCATAAAT 
XYL2 TCAGGAAAATCTGACTTTAACA 
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Table 2.3. Strains used in this study 
Strains Relevant Genotype or Phenotype 
Source or 
Reference 
E. coli strains 
F- D(lacZYA-argF) U169 recAl endAl hsdRl supE44 thi-1 
(Hanahan, 1983; 
Kolter et al DH5ct 
relAI gyrA96 ., 1978) 
XL-1 recAl endAl gyrA96 thi-1 hsdR17 supE44 relAl Stratagene 
Blue lac[F'proAB lacFZDM15 TWO (Tel')] 
CH48 DH5a contains pCH48 Chapter 3 
AC1287 DH5a contains pAC1287 Chapter 4 
AC 1288 DH5a, contains pAC1288 Chapter 4 
AC 1289 DH5a, contains pAC 1289 Chapter 4 
AC1290 DH5a, contains pAC1290 Chapter 4 
AC 1291 DH5a, contains pAC 1291 Chapter 4 
AC 1292 XL-1 Blue, contains pAC 1292 Chapter 4 
V. choler ae strains 
(Camilli and 
AC66 C6709-1 (El Tor) lacZ:: res-tet-res. SmR TcR Mekalanos, 
1995) 
AC311 C6709 lacZ:: res-tet-res vieS':: pIVET5. 
SmR ApR Tcs, Andrew Camilli LacZ+. Resolved strain. 
S. pneumoniae strains 
TIGR4 Wild-type Type 4 encapsulated strain 
Ingeborg 
Aaberge 
AC353 Transformed Se derivative of TIGR4 
(Bricker and 
Camilli) 
CH49 AC353 orf2:: res1-aad9-resl. SmR SpcR Chapter 3 
CH53 AC353 ply:: tnpRnwt135 orf2:: resl-aad9-resl. Sm' 
SpcR Chapter 3 CMR 
CH79 AC353 malM:: lacZ.: cat:: malP. Sm' CmR Chapter 3 
CH80 AC353 malM:: lacZZ""6s:: cat:: malP. Sm' CmR Chapter 3 
CHIOO AC353 ply:: tnpR"'P'8, orf2:: res1-aad9-resl. SmR SpCR Chapter 3 CMR 
CH 102 AC353 malM:: tnpRM:: cat:: malP. orf2:: resl -aad9-rest R Chapter 3 SmR Spc CM 
CH 104 AC353 ply. : tnpR 4, orf2:: resl -aad9-resl. SmR SpcR CmR Chapter 3 
CH 107 AC353 sp0247:: magellan2. Sm' Cm' Chapter 4 
CH 108 AC353 sp0156:: magellan2. SmR CmR Chapter 4 
CH119 AC353 Asp0661. SmR Chapter 4 
CH 155 AC353 IS1167:: magellan5. SpcR Dave Hava 
CH 184 AC 1365 rrgA:: magellan5. SpcR Chapter 6 
CH 185 AC 1365 rlrA:: magellan2. CmR Chapter 6 
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CH207 D39 AmgrA. SmR SpcR Chapter 5 
CH208 D39 AmgrA. Spe' Chapter 5 
CH209 AC353 dmgrA ErlrA. SmR CmR SpcR Chapter 5 
CH210 AC353 srtD:: lacZ. Sm' CmR EryR Chapter 5 
CH211 AC353 srtD:: lacZ AmgrA. SmR SpCR CmR EryR Chapter 5 
CH212 AC353 srtD:: lacZ ArlrA. SmR CmR Ery R Chapter 5 
CH213 AC353 srtD:: lacZ ArlrA AmgrA. SmR SpCR Cm' EryR Chapter 5 
CH214 AC353 rlrA:: lacZ. Sm' Cm' Chapter 5 
CH215 AC353 rlrA:: lacZ AmgrA. SmR CmR SpcR Chapter 5 
CH216 D39 malM:: mgrA:: cat:: malP. SmR CmR Chapter 6 
CH226 D39 rlrA islet IS1167.: magellan5. SpcR SmR Chapter 6 
CH232 D39 rlrA islet IS1167:: magellan5 rlrA:: magellan2. SpCR Chapter 6 
CmSm 
CH244 D39 rlrA islet IS] 167:: magellan5 AmgrA. SmR Cm' SpcR Chapter 6 
CH246 D39 rlrA islet rrgA:: magellan5. SpCR SmR Chapter 6 
CH254 D39 rlrA islet IS1167:: magella5 R R Chapter 6 CmR Spc malM:: mgrA:: cat:: malP. Sm 
AC 1213 AC353 rlrA:: magellan2. CmR 
(Hava 
) 
et al., 
AC1214 AC353 srtD:: magellan2. CmR Chapter 6 
AC1215 AC353 rrgA:: magellan5. Spc& Chapter 6 
AC1272 AC353 mgrA:: magellan2. SmR CmR Chapter 4 
AC1278 AC353 malM:: rlrA:: cat:: malP. SmR CmR 
(Hava et al., 
2003a) 
AC1365 P12 Type 9V serotype strain Jeff Weiser 
AC 1481 AC353 malM:: mgrA:: cat:: malP. SmR CmR Chapter 4 
AC1500 AC353 AmgrA. SmR SpcR Chapter 4 
STM90 AC353 sp0661:: magellan2. Sm' CmR 
(Hava and 
Camilli, 2002) 
STM206 AC353 mgrA 5 UTR:: magellan2. SmR CmR 
(Hava and 
Camilli, 2002) 
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Table 2.4 Plasmids used in this study 
Plasmid Relevant Genotype or Phenotype 
Source or 
Reference 
Plasmids 
pEMCat Contains magellan2. APR Cm' 1(Akerl 998) 
ey et al., 
1998) 
pEMSpc Contains magellan5. APR SpcR 
(Martin et al., 
2000) 
pGEM-T Cloning vector. APR Promega 
pCRScrip t Cloning vector. APR Stratagene 
pEVP3 lacZ transcriptional fusion suicide vector. Cm' (Claverys et al. ) 
pAC46 pACYC 184 dtet:: containing tnpR"" 1135. Cm' Andrew Camilli 
pAC637 pCRSript:: sp0558. ApR Andrew Camilli 
pAC676 pIVET5:: irgA':: tnpRmut135 ApR 
(Lee et al., 
1999) 
pAC865 pCRSript-SK+:: resl-resl. ApR Andrew Camilli 
pAC 1000 pEVP3 AlacZ; suicide vector. CmR 
(Hava et al., 
2003a) 
pAC 1279 pGEM-T rlrA RPA probe. Apr Chapter 4 
pAC 1280 pGEM-T rrgA RPA probe. Apr Chapter 4 
pAC1281 pGEM-T rrgB RPA probe. Apr Chapter 4 
pAC 1282 pGEM-T rrgC RPA probe. Apr Chapter 4 
pAC 1283 pGEM-T srtB RPA probe. Apr Chapter 4 
pAC 1284 pGEM-T srtC RPA probe. Apr Chapter 4 
pAC 1285 pGEM-T srtD RPA probe. Apr Chapter 4 
PAC 1286 pGEM-T rpoB RPA probe, APR 
(Hava et al., 
2003a) 
pAC 1472 pAC 1000 `malM-mgrA-cat-malP'. SmR Cm' Chapter 2 
PAC 1499 pAC 1000 AmgrA':: aad9'. CmR SpcR Chapter 2 
pCH2 pAC 1000 orf2:: resl -rest . CmR Chapter 2 
pCH3 pAC 1000 orJ2. CmR Chapter 2 
pCH30 pGEM-T lytA RPA probe. APR Chapter 2 
pCH31 pGEM-T ply RPA probe. ApR Chapter 2 
pCH46 pAC 1000 `ply-tnpRm"`135-cat-3'ply. CmR Chapter 3 
pCH48 pAC 1000 orf2:: resl -aad9-resl. CmR Chapter 3 
pCH57 pGEM-T tnpR RPA probe. ApR Chapter 2 
pCH73 pAC1000 `malM-lacZ-cat-malP'. SmR CmR Chapter 2 
pCH75 pAC 1000 `malM-lacZmu`Res-cat-malP'. Sm' CmR Chapter 2 
pCH84 pAC 1000 'malM:: rlrA:: cat:: malP'. Sm' CmR Chapter 4 
pCH95 pCRSript-SK+:: tnpRM Chapter 2 
pCH 101 pAC 1000 `malM-tnpRM-cat-malP' SmR Cm' Chapter 2 
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pCH103 pACI000 `ply-tnpRM=cat-3'ply. Cm' Chapter 2 
pCHI 17 pAC1000 EspO661. CmR Chapter 4 
pCH 130 pAC 1000 OspO156. CmR Chapter 4 
pCH 144 pGEM-T sp0663 RPA probe. Apr Chapter 5 
pCH145 pGEM-T sp0668 RPA probe. Apr Chapter 5 
pCH147 pGEM-T sp1803 RPA probe. Ap' Chapter 4 
pCH148 pGEM-T sp1804 RPA probe. Apr Chapter 4 
98 
CHAPTER 3 RIVET AND S. PNEUMONIAE 
3.1 INTRODUCTION 
Recombinase-based in vivo expression technology or RIVET was originally designed to 
identify genes that are specifically induced during infection (Camilli et al., 1994). The 
methodology uses a reporter gene to detect transcription and is based on the loss of an 
antibiotic resistance, eg. Spectinomycin. The reporter gene, tnpR, encodes a site-specific 
resolvase enzyme derived from Tn1000. When its substrate, resolvase recognition 
sequences flanking an antibiotic resistance gene (resl -aad9-resl ), is present in the 
genome, expression of the resolvase leads to permanent excision of this cassette (Figure 
3.1). The reaction, referred to as resolution, results in a change in the antibiotic 
resistance phenotype of the bacteria. The post-resolution antibiotic-sensitive phenotype 
is stable, inheritable and can be used as a qualitative measure of gene induction during 
infection. 
Although originally developed as a promoter trap in Vibrio cholerae, RIVET has 
been used in other organisms (Lowe et al., 1998; Wang et al., 1996). It has also been 
adapted in V. cholerae to determine the spatiotemporal pattern of transcriptional 
induction of specific virulence genes (Lee et al., 1998; Lee et al., 1999). RIVET had 
never been used in S. pneumoniae and I aimed to develop the technique for use in this 
organism to study the expression of virulence factors, initially in vitro, and then in vivo. 
Pneumolysin was chosen as the first virulence factor to study. 
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Figure 3.1 Schematic of Recombinase based in vivo expression technology 
(RIVET) 
The reporter gene, tnpR, encodes a site-specific resolvase enzyme (A) derived 
from Tn1000. When its substrate, resolvase recognition sequences flanking an 
antibiotic resistance gene (resl -aad9-resl ), is present in the genome expression 
of the resolvase leads binding to sequences within the res] sites (B) and 
permanent excision of this cassette (C). The reaction, referred to as resolution, 
results in a change in the antibiotic resistance phenotype of the bacteria. The 
post-resolution antibiotic sensitive phenotype is stable, inheritable and can be 
used as a qualitative measure of gene induction during infection. 
Pneumolysin (Ply) is a thiol-activated multifunctional toxin produced by virtually all 
clinical isolates of S. pneumoniae and is an important pneumococcal virulence factor 
(Benton et al., 1997; Boulnois et al., 1991 a; Canvin et al., 1995; Paton, 1996). It is a 
cytoplasmic protein (Johnson, 1977) that, at the time of starting this project, was 
believed to be released on S. pneumoniae autolysis, leading to mammalian cell lysis, 
activation of complement and stimulation of cytokine production (Boulnois et al., 
1991b; Mitchell and Andrew, 1997). Autolysis of bacteria by autolysin (LytA), another 
recognised virulence factor (Berry et al., 1989; Tomasz et al., 1988), was thought to be 
the likely mechanism by which Ply is released (Ronda et al., 1987). Subsequently, 
published work has demonstrated that autolysin is not an absolute requirement for Ply 
release (Balachandran et al., 2001). The toxin is released in significant amounts from 
some pneumococci during exponential phase growth before autolysis occurs and is 
equally well released from autolysin-deficient strains. 
During growth in vitro, cytoplasmic and extracellular Ply is not normally detectable 
until late log phase (Benton et al., 1997). This observation had been used as evidence 
that ply transcription or release of Ply from the bacterial cell is regulated, but formal 
published experimental evidence of regulation was lacking. Experiments in animal 
models of pneumonia suggest that Ply facilitates intrapulmonary bacterial growth and 
invasion of S. pneumoniae into the blood early in disease (Rubins et al., 1995; Rubins et 
al., 1996). The exact timing of ply expression and whether expression occurs in only a 
subset of all the bacterial cells is not known. 
I hypothesised that ply (and lytA) transcription is activated or at least up-regulated at an 
early stage of infection. The primary aim of this project was to establish the pattern of 
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ply expression in vivo in murine models of infection with the use of RIVET. Adaptation 
of the RIVET system for use in studying ply expression would provide proof-of- 
principle for the study of other virulence genes of S. pneumoniae in vivo. This chapter 
describes attempts to adapt RIVET for use in S. pneumoniae using ply as the reporter 
gene. 
3.2 RESULTS 
3.2.1 Determination of pneumolysin gene (ply) expression in vitro 
Preliminary experiments were performed to determine the baseline expression of ply 
and lytA in THY broth cultures in vitro. Wild-type serotype 4 strain, AC353, was grown 
in THY broth. To examine the hypothesis that ply transcription might be differentially 
regulated over the course of growth, RNA was harvested from cells at four separate 
time points on the growth curve. Ribonuclease protection assays (RPAs) were 
performed probing for either lytA or ply. 
The RPA is a sensitive procedure for the detection and quantification of RNA species 
(usually mRNA) in a complex sample mixture of total cellular RNA. A labeled 
radioactive RNA probe is synthesized that is complementary to part of the target RNA 
to be analyzed. The labeled probe is then mixed with the sample RNA and incubated 
under conditions that favour hybridization of complementary transcripts. After 
hybridization, the mixture is treated with ribonuclease to degrade single-stranded, un- 
hybridised probe. Labelled probe that hybridized to complementary RNA in the sample 
mixture will be protected from ribonuclease digestion and can be separated on a 
polyacrylamide gel and visualised by autoradiography. When probe is present in excess 
over the target fragment in the hybridization reaction, the intensity of the protected 
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fragment will be directly proportional to the amount of complementary RNA in the 
sample mixture. 
1YtA 
Ply 
O D6oo 0.1 0.4 0.6 0.8 
Figure 3.2 Ribonuclease protection assays of IyEA and ply transcripts 
RPAs were performed to analyse mRNA levels of the ply and IytA genes at four 
different time points during growth, corresponding to OD600 0.1,0.4,0.6 and 0.8. 
Riboprobes to ply and lytA were generated and hybridised to 5 µg of total S. 
pneumoniae RNA (AC353). 
Both the ply and lytA genes were transcriptionally active. LyIA had a constant level of 
expression over the time points tested but there was an increase in ply transcript of five 
fold during exponential growth (Figure 3.2). Although ply transcript was detectable 
even at the earliest time point, it was felt that this would not exclude the use of RIVET 
as the system could be adapted to decrease the efficiency of translation of the resolvase 
protein. This is achieved by using a tnpR mutant with an altered ribosomal binding (Lee 
et al., 1999) site in the ply.: tnpR construct. Use of a mutant allele, with reduced 
translational efficiency, results in lower levels of resolvase enzyme and hence lower 
levels of resolution for any given level of transcription. When transcription is low, such 
as early in growth, resolution is minimal. The increase in transcript levels later in 
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growth should result in increased amounts of enzyme and eventual resolution at these 
time points. Ideally the system could be tuned to abolish resolution in standard in vitro 
conditions but still allow the detection of any transcriptional induction in vivo. 
3.2.2 Construction of the ply reporter strains and assessment of in vitro resolution 
Firstly, a pneumococcal strain, CH49, with a resolvable spectinomycin cassette (resl - 
aad9-resl) stably integrated into the chromosome was constructed. The extent of 
resolution of this strain during in vitro growth in the absence of tnpR was determined. 
Cells were grown at 37°C and 5-6% CO2 in THY broth supplemented with Oxyrase (5 
µg ml-1). Aliquots of this culture were taken at time points corresponding to OD6.0.1, 
0.4,0.6 and 0.8. These were serially diluted and - 200 CFU were plated onto blood agar 
plates and incubated overnight. The percentage of colonies that were Spcs were 
determined as described in chapter two. This gave a measure of background resolution 
of the cassette in the absence of the ply:: tnpR niut3 transcriptional fusion. All colonies 
were SpcR indicating that there was no detectable resolution at any time during in vitro 
growth. 
Secondly, the resolvase gene, tnpR, was inserted immediately downstream of the intact 
ply gene in CH49 creating a transcriptional fusion (Figure 3.3). A tnpR allele with 
reduced translational efficiency, tnpRmutt35, was used (Lee et al., 1999). The extent of 
resolution in vitro in this ply:: tnpR mat13 reporter strain, CH53, was measured during in 
vitro growth, as described above, only cells were grown with the addition of Cm 4jg 
ml" to maintain the presence of the tnpRmat135 allele. There was no detectable resolution 
in this strain at any time point. 
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Figure 3.3 Construction of RIVET applied to the ply gene in S. pneumoniae 
m 
in' 403 
4-- 
(A) The Resl -aad9-resl antibiotic cassette was cloned in E. coll. S. pneumoniae strains 
were transformed with linearised plasmid resulting in insertion of the cassette in orJ2 
onto the chromosome by homologous recombination. 
to R"ý"` 
crý'ý 14 
(B) The Ply:: tnpRut135 fusion was cloned in E. coli. S. pneumoniae stains were 
transformed with linearised plasmid resulting in insertion of the fusion onto the 
chromosome by homologous recombination, giving a stably integrated single copy of 
tnpRneut135 immediately downstream of ply. 
As mentioned above, the ply reporter strain above was constructed in two stages. 
Firstly, AC353 was transformed with linearised DNA from plasmid pCH48, containing 
the resl-aad9-resl cassette. Spectinomycin resistant transformants resulting from 
double cross-over homologous recombination, were selected. The presence of the 
cassette was confirmed by PCR and DNA sequencing. Secondly, this strain, CH49, was 
transformed with linearised plasmid pCH46, which possessed the ply:: tnpR '135 fusion 
and Cm' transformants selected. The insertion of the ply:: tnpR inst135 fusion into the 
correct position of the chromosome was confirmed by PCR and sequencing. To assess 
whether the f in al strain was immediately resolved upon induction of ply:: tnpR t 135 , 
200 colonies from the second stage transformation were picked and patched onto both 
blood agar and blood agar supplemented with Spc 100 µg mlF'. All transformants were 
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SpcR indicating that none showed immediate resolution on acquiring the resolvase gene. 
One of these strains, designated CH53, was selected for further study. 
3.2.3 Assessment of resolution in vivo 
The level of gene transcription in vitro may not have been adequate to overcome the 
reduced translational efficiency on the tnpR'u'135 allele but the level of transcription in 
vivo may be. To determine if this was the case resolution of the ply reporter strain, 
CH53, in a murine model of pneumonia was assessed. Eight mice were inoculated 
intranasally with - 10' CFU of CH53. Pairs of mice were euthanased at 2,8,24 and 44 
hours. The percentage of SpcR pneumococci recovered at each time point was 
determined. There was no detectable resolution at any time point. 
3.2.4 Investigation of the lack of resolution 
There were several possibilities to explain the lack of resolution in the pneumococcal 
reporter strains including; 
1. The antibiotic cassette was unresolvable 
2. There was inadequate read-through from the ply gene to the tnpR gene 
leading to lack of tnpR transcription 
3. The RBS mutant was too severe to allow any efficient translation to 
functional resolvase enzyme 
4. The codon usage of tnpR was suboptimal for S. pneumoniae, resulting in 
failure to efficiently translate the mRNA 
5. Resolvase is non-functional in S. pneumoniae 
Each of the first four possibilities was looked at in turn. 
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(1) Cassette function 
The antibiotic cassette had been checked by DNA sequencing but it was also confirmed 
that it was resolvable in a Gram-negative bacterial background. Competent cells were 
made from CH48, the E. coli strain harbouring the complete cassette on a plasmid. 
These were transformed with pAC46, a plasmid containing tnpRnrit135 under the control 
of the pACYC 184 tet promoter, a strong constitutively active promoter. Transformants 
selected for by the presence of Cm' were replica plated to LB Spc 100 pg ml-1 to assess 
for cassette resolution. All transformants were Spcs. Cassette resolution and plasmid 
maintenance was confirmed by PCR (Figure 3.4). This showed that the plasmid was 
maintained and that the cassette had been resolved. This result confirms that the cassette 
can function normally as a substrate for tnpR in an E. coli background. 
A 
Kb 
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Figure 3.4 PCR to confirm resolution of res] cassette in E. coli 
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Figure 3.4 PCR to confirm resolution of res] cassette in E. coli 
(A) Primers ORF1 and SPECF1 were used in a colony PCR to amplify a product that 
included one resl site and the aad9 gene from 8 test colonies (lanes 1-8) and unresolved 
pCH48 (lane 9) in order to assess excision of the aad9 gene. 
(B) Primers ORFS 1 and ORFS2 were used in a colony PCR to amplify the resolved 
cassette from 8 test colonies (lanes 1-8) and the unresolved cassette in pCH48 (lane 9) 
in order to confirm plasmid presence and cassette size. 
(2) TnpRniu13s transcription in S. pneumoniae 
RPAs were performed to determine the presence of tnpRn"113S transcript in S. 
pneumoniae, CH53. RNA was harvested from cells grown to mid exponential phase. 
This was probed for the presence of tnpR, ply and rpoB transcript. RpoB was used as a 
loading control. Lack of gene transcription did not appear to be the reason for failure of 
resolution as transcript for each of the three genes were detectable at all time points 
tested (Figure 3.5). 
(3) Translational failure 
To determine if tnpR""js transcript was translated into resolvase enzyme, Western blots 
probing with anti-resolvase antibody were performed on total protein extracted from 
cells grown to mid log phase. Pure resolvase enzyme, a V. cholerae strain possessing 
the tnpR gene as a single copy integrated into the chromosome downstream of a 
constitutively active promoter (AC311), the parental V. cholerae strain habouring the 
res-tet-res cassette alone (AC66) and wild-type S. pneumoniae (AC353) were used as 
controls. The 50µg of protein was loaded in each lane. An identical SDS-PAGE gel 
was prepared and stained with coomasssie brilliant blue to assess the total protein 
loading (not shown). There was no resolvase detectable by western blot in CH53, AC66 
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Figure 3.5 RPA for tnpR"'`t sJ transcript and Western blot for Resolvase protein 
(A) RPA to determine the presence of mRNA levels for ply and tnpR"in cells 
grown to OD600 0.4 and 0.7. Riboprobes to ply, tnpR and rpoB were generated to 
hybridise to 5 pg of total S. pnuemoniae RNA (AC353). RNA was probed for either p/y 
and rpoB transcript (lanes 1 and 2) or tnpR and rpoB transcript (lanes 3 and 4). 
A rpoB probe was used as a loading control. 
(B) Western blot probing total protein extracted from cells grown to mid exponential 
phase with anti-resolvase antibody; Lane 1, purified resolvase enzyme, lane 2, (AC66) 
V. cholerae strain harbouring the res-tet-res cassette alone, lane 3, (AC31 1) V. cholerae 
strain harbouring res-tet-res and vieS':: tnpR fusion, lane 4 (AC353) wild-type S. 
pneumoniae and lane 5, (CH53), S. pneurnoniae strain harbouring orf2:: resl-aad9- 
resland ply:: tnpR""""sfusion. The 50µg of protein was loaded in each lane. An 
identical SDS-PAGE gel was prepared and stained with coomasssie brilliant blue to 
assess the total protein loading (not shown). 
or AC353, but detectable resolvase was present in AC311 (Figure 3.5). 
3.2.5 Replacement of the Shine-Dalgarno (RBS) site of tnpRmut135 
The results described above are consistent with there being a failure in translation of 
tnpR"' mRNA to functional resolvase enzyme in S. pneumoniae. Although the aim of 
using a RBS mutant in the reporter strain was to reduce translational efficiency it 
appeared the level of translation, if any, was too low to allow detection of the enzyme 
by Western or measurable resolution in vitro on in vivo. 
RIVET was initially demonstrated in a Gram negative bacterial background (Camilli et 
al., 1994; Camilli and Mekalanos, 1995). The resolvase gene was isolated from the 
prokaryotic transposable element Tn1000 (Tnyb), which is one of a family of 
transposons that are related to Tn3 (Heffron, 1983). For the system to be of use in 
studying in vivo virulence gene expression in S. pneumoniae it had to be demonstrated 
that resolvase could function in S. pneumoniae. The system could then be tuned to a 
level that could then allow use of RIVET to test certain hypotheses in S. pneumoniae in 
vivo. RIVET had been used successfully to identify in vivo induced genes in one other 
Gram positive organism, Staphylococcus aureus (Lowe et al., 1998). In this study the 
Shine-Dalgarno (RBS) site of the tnpR had to be replaced with a Gram-positive 
homologue to improve the translation of the resolvase. 
A new S. pneumoniae reporter strain, CH100, was constructed in which the tnpR'135 
RBS and sequence up to the ATG start codon was replaced that found upstream of the 
rpoB gene in this organism. In vitro resolution of this strain was assayed as described 
previously but found to be. absent. Western blots were performed on total protein 
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extracted from cells grown to mid exponential phase. There was no resolvase detectable 
by western blot in the new strain, CHI 00 (Figure 3.6). 
2345 Resolvase 
4000 Ah 
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Figure 3.6 Western blot for Resolvase protein in CH100 
Western blot probing total protein extracted from cells grown to mid exponential phase 
with anti-resolvase antibody; Lane I (AC353) wild-type S. pneumoniae, lane 2 S. 
pneumoniae strain (CH 100) harbouring orf2:: resl -aad9-resl and pl_y:: tnpff' 
BR8sfusion. 
Lane 3 purified resolvase enzyme, lane 4 V. cholerae strain (AC66) harbouring the Tes- 
tet-res cassette alone, lane 5 V. cholerae strain (AC3 11) harbouring res-tet-res and 
vieS':: tnpR fusion. 50 tg of total cellular protein was loaded in lanes 1,2,4 and 5. An 
identical SDS-PAGE gel was prepared and stained with coomasssie brilliant blue to 
assess the total protein loading (not shown). 
3.2.6 Assessment of streptococcal codon usage and tnpR" gene construction 
It appeared that the lack of translation could not be explained by inadequate ribosomal 
binding to the tnpff"135 mRNA. Another possible explanation was that the codon usage 
in tnpR"`u' 135 was not optimal for translation in S. pneurnoniae. Codon usage varies 
between genes within an organism and from organism to organism (Ikemura, 1981; 
Sakai et al., 2001). The use of individual codons within one organism can alter the 
translation rate of the mRNA (Robinson et al., 1984). In E. coli synonymous codons are 
used with varying frequencies in different mRNAs. mRNAs for ribosomal proteins and 
other highly expressed proteins use a specific subset of codons almost exclusively, so 
called common codons (Grosjean and Fiers, 1982; Post et al., 1979). The concentrations 
of tRNA in E. coli have been determined and a correlation has been found between the 
frequency of codon usage in highly expressed genes and the concentration of the 
cognate tRNAs (Ikemura, 1981). There is also a correlation between codon usage, 
tRNA concentration and translation rate (Sorensen et al., 1989). Abolishment of rare 
codons and replacement with more common codons in E. coli can significantly alter 
mRNA translation to such a degree as to abolish some post-transcriptional regulatory 
effects (Kuhar et al., 2001). 
We hypothesised that the codons present in the native tnpR gene were not optimal for 
mRNA translation in S. pneumoniae and that the presence of rare codons for S. 
pneumoniae within the gene was a reason for inadequate translation in the ply:: tnpR 
fusion strain. The codon usage within the S. pneumoniae genome and the tnpR gene 
were compared by using a combination of the online backtranslation program 
(http: //www. entelechon. com/eng/backtranslattion. html) and the total proteome codon 
usage table from the TIGR website (http: //wwww. tier. ore/tigr- 
scr ps/CMR2/codontables. spl,? project=bsp). The frequency of use of any codon for each 
amino acid in the pneumococcal genome was calculated. A frequency less than 15% 
was taken to approximate to infrequently used or rarely used codons. 20 out of the 184 
codons in tnpR fell into this category (Figure 3.7). This number could be sufficient to 
abolish mRNA translation. 
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I gcc cag atc t tta gga tac att ttt ATG CGA CTT TTT GGT TAC GCA ('G(: GTA 
28 TCA ACC AGC CAG CAA TCT CTC GAT ATT CAG GTT ('(: G GCA CTC 
70 AAA GAC GCA GG(' GTG AAA GCA AAT CGC ATC TTT ACT GAC AAG 
112 GCA 1'('G G(: (' AGT TCA AGC GAT ('(; (; AAA GGG GAC TTG 
151 AGG ATG AAG GTG GAG GAA GGT GAC GTC ATC TTG GTG AAG 
193 AAA CTT GAC CGC CTT GGG CGC GAT ACT GCT GAC ATG ATC CAG 
235 TTA AT: 1 AAA GAG TTT GAC GCC CAA GGT GTA ic( ATT ('(; (; M 
277 ATT GAT GAC GGA ATC AGT ACC GAT GGG GAG ATG GGT AAA ATG 
319 GTT GTC ACT ATT CTA TCT GCA GTG GCC CAG GCA GAA CGA CAG 
361 AGA ATA CTA GAG CGT ACC AAT GAA GGT CGC CAA GAG GCA ATG 
403 GCA AAA GGA GTT GTT TTI' GGT AGA AAA AGA AAA ATA GAT AGA 
445 GAT GCA GTA TTA AAT ATG TGG CAA CAG GGG TTA GGT GCC TCA 
487 CAT C'I'A TCA AAA ACA ATG AAT ATT GCT CGT TCA ACA GTA TAT 
529 AAA GTA A'I'A AAT GAA AGC AAC TAA 
B 
Codon Amino Acid Triplet frequency in Triplet frequency 
S. pneumoniae for 
genome (%) corresponding 
amino acid (%) 
('GG Arginine 0.2 4.98 
A(IG Arginine 0.23 5.62 
( 1( Leucine 0.91 8.96 
T('(ý Serine 0.39 6.05 
1( < Serine 0.52 7.99 
AT A Isoleucine 0.74 10.38 
GGG Glycine 0.84 13.28 
(ý(i(' Glycine 0.89 14.04 
CGT Argininc 1.75 42.87 
Figure 3.7 Codon usage in tnpR and S. pneumoniae genome 
(A) Nucleotide sequence of tnpR. Open reading frame is in upper case. Rare 
codons are highlighted. 
(B) Frequency of codon usage in S. pneumoniae. The rare codons selected from 
the tnpR gene and the commonest codon used for Arginine in the whole S. 
pneumoniae genome are reported. 
Rather than systematically replace each individual codon in turn it was decided to 
design and construct a new tnpR allele with an altered rpoB-like RBS and a S. 
pneumohiae-optimized codon usage. The new allele was constructed as described in 
chapter two. Seven 100 base oligos (ACTM1-7) that overlapped by 18 bp were 
designed and synthesized. The first primer included the rpoB RBS. Rare codons 
throughout the gene were changed to ones that were more frequently used in S. 
pneumoniae but which preserved the amino acid sequence of the final protein. The final 
gene sequence was confirmed by DNA sequencing. A new ply reporter strain, CH104, 
was constructed by replacing the tnpR"iui135 allele in pCH46 with this new allele (tnpRM). 
Transformation of CH49 with this plasmid resulted in the insertion of the tnpR"4 allele 
immediately downstream of ply on the chromosome. 
3.2.7 Development of a controllable expression system 
The work above describes attempts to use RIVET in S. pneumoniae using a ply reporter 
system. Whilst performing this work it became apparent that we also needed to develop 
a way of more directly controlling the expression of tnpR, enabling us to titrate the 
amount of expression to resolution. At the time of this project the only system that had 
been used to a similar effect in S. pneumoniae was the use of the maltose inducible 
promoter in trans or integration into the maltosaccharide utilization regulon on the 
chromosome (Acebo et al., 2000a; Nieto et al., 2000). The regulon is organized into 
three operons (Figure 3.8). Two operons, involved in maltosaccharide uptake (ma1XCD) 
and catabolism (malMP), are divergently transcribed from neighbouring promoters. The 
third operon (malAR) is located downstream and its products are involved in the 
regulation (Nieto et al., 1997). MaIR encodes a transcriptional repressor that binds to 
each promoter. Binding activity is reduced and repression relieved with increasing 
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concentrations of maltose, whereas addition of sucrose further enhances repression. The 
operon had previously been manipulated to allow titratable expression of GFP (Acebo 
et al., 2000b). 
malPM 4-, r+ ma1XCD , -º malAR 
1 
Mal 
R 
Figure 3.8 The Maltose operon in S. pneumoniae 
Two operons, involved in maltosaccharide uptake (ma1XCD) and catabolism (ma1MP), 
are divergently transcribed from neighbouring promoters. The third operon (malAR) is 
located downstream and its products are involved in the regulation. MaIR encodes for a 
transcriptional repressor that binds to each promoter. Binding activity is reduced and 
repression relieved with increasing concentrations of maltose. 
To determine if a this regulon could be used to regulate the expression of genes in our 
hands, pneumococcal strains were constructed with the IacZ gene inserted as a single 
copy between malM and malP on the pneumococcal chromosome as a pilot study. Two 
different strains were constructed, CH80 and CH79, one with a lacZ gene with the RBS 
of the rpoB gene and the other with a LacZ gene with the native RBS from pEVP3, the 
source plasmid for the lacZ gene. AC353, CH79 and CH80 were grown in THY broth 
alone or THY broth supplemented with sucrose or maltose. Expression of lacZ was 
assayed by measurement of ß-galactosidase activity in whole cells and reported in 
Miller units (Figure 3.9). Measurable ß-galactosidase activity in AC353 was negligible. 
CH79 and CH80 grown- in THY or THY sucrose gave increased 
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Figure 3.9 (3-galactosidase activity of ma1M:: lacZ fusion strains 
(A) f3-galactosidase activity measured in wild-type S. pneumoniae, 
maiM:: lacZ fusion strain (CH79) and ma1M:: 1acZ" " fusion strain 
(CH80) grown to mid-log phase in either THY, THY sucrose or THY 
0.8% maltose. 
(B) (3-galactosidase activity measured in CH80 was grown to mid 
exponential phase in different concentrations of THY 0.8% maltose. 
levels over the wild-type background and still greater levels when grown in THY 0.8% 
maltose. The construct containing the rpoB RBS, CH80, gave very much greater 
activity than CH79 in all conditions tested, consistent with there being a greater baseline 
amount of enzyme when translational efficiency is improved. The ß-galactosidase 
activity varied according to the maltose concentration in the medium (Figure 3.9). 
Given that the system appeared to allow some control over lacZ expression, a 
pneumococcal strain with the tnpRM allele inserted between malM and malP, CHI 02, on 
the chromosome and the antibiotic cassette present elsewhere on the chromosome was 
also constructed for use in assaying resolution. 
3.2.8 Determination of resolvase production and resolution with tnpRM 
Western blots with anti-resolvase antibody were performed on total protein extracted 
from cells grown to mid log phase in THY or THY 0.8% maltose (Figure 3.10). 
Resolvase was detectable in the pneumococcal strain harbouring the ply: tnpRM fusion, 
CH104, and in the strain with tnpRM inserted between malM and malP, CH102. 
Therefore alteration of the codon sequence of the tnpR gene had resulted in improved 
mRNA translation and detectable levels of enzyme. To see if these improvements 
resulted in functional resolvase enzyme, enabling resolution in S. pneumoniae, 
resolution was assayed for in cells grown to mid log phase in vitro in both the ply fusion 
strain and the maltose inducible strain and in vivo in the ply fusion only. CH49, the S. 
pneumoniae strain harbouring the antibiotic cassette alone, was used as a control to 
assess the background level of spontaneous resolution in all experiments (Figure 3.11). 
There was no detectable spontaneous resolution in CH49, but resolution was detectable 
in vitro in CH104, the ply reporter strain, and CH102, the maltose inducible strain. The 
level of resolution in each strain was -30%. There was no significant difference in the 
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Figure 3.10 Western blot for Resolvase protein in ply:: tnpRm reporter 
strain (CH104) and ma1M:: tnpR"'reporter strain (CH102). 
Western blot probing total protein extracted from cells grown to mid 
exponential phase with anti-resolvase antibody; Lane 1, purified resolvase 
enzyme, lane 2, (CH 104), S. pneumoniae strain harbouring nrf2:: resl -aad9- 
resland plv:: tnpR"'fusion, lane 3, (AC353) wild-type S. pneumnnioe, lanes 4 
and 5, (CH 104), S. pneumoniae strain harbouring orf2:: re. sl-aad9-resland 
ma/M:: tnpRMfusion grown in either THY or THY 0.8% maltose, lane 6, 
(AC66)V. cholerae strain harbouring the res-let-res cassette alone and lane7, 
(AC31 1) V. cholerae strain harbouring res-tet-res and vieS':: tnpR fusion. The 
same quantity of protein was loaded in each lane. 
level of resolution with increasing maltose concentrations in either maltose-inducible 
strain studied although there appeared to be a trend towards decreasing amounts of 
resolution with increasing maltose concentration. This is the opposite of what might be 
predicted (Figure 3.11) suggesting that there was a disconnection between increasing 
transcription of tnpRM and the concentration of functional enzyme in the cell. 
Resolution of the ply: tnpRM reporter strain was assessed in a murine model of 
pneumonia. Eight mice were inoculated with - 10' CFU of CH 102 intranasally. Pairs of 
mice were euthanased at 2,8,24 and 44 hours. The experiment was repeated in 
duplicate on a separate day. The percentage of Spcs pneumococci in the input inoculum 
and those recovered at each time point was determined (>400 colonies were tested for 
each mouse). The amount of resolution was similar between the two experiments but 
was at a level 3 fold less than that seen in vitro. Maximum resolution was seen at 24 
hours and was only in the order of 15%. 
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Figure 3.11 Assessment of resolution of reporter strains in vitro and in vivo 
(A) S. pneumoniae strains with either the resl-aad9-resl cassette alone 
(CH49), ply:: tnpR'1I" fusion and cassette (CH 104) or malM:: mpR'""'« fusion 
(CH 102) were grown to mid log phase in THY broth or THY 0.8% maltose. 
The percentage of Spc' CFU, shown on the Y axis, was determined for each 
strain. 
(B) Strain CH 102 was grown to mid log phase in varying concentrations of 
THY maltose. The percentage of Spc` CFU was determined for each media. 
(C) The kinetics of resolution as a marker for transcriptional induction of plv 
during S. pneumoniae infection. Eight Swiss-Webster mice were inoculated 
with Ix 101 CFU of CH 104. Pairs of mice were euthanased at 2,8,24 and 48 
hours post infection each and the percentage of Spe` CFU in the lung at each 
time point was determined. The experiment was repeated in duplicate. Results 
of one experiment are shown. 
3.3 SUMMARY 
This chapter outlines the attempts to apply RIVET, recombinase-based in vivo 
expression technology, to S. pneumoniae in order to use the technique to study 
pneumolysin gene expression in vivo in a murine model of infection. Initial attempts 
failed to give detectable resolution in vitro or in vivo. It was demonstrated that though 
the tnpR gene was transcribed under in vitro conditions there was no protein detectable 
by western blot. Replacement of the native resolvase RBS with one identical to that of 
the S. pneumoniae rpoB gene with a view to improving translational efficiency was 
ineffective and there was still no detectable resolvase enzyme produced. The nucleotide 
sequence of the tnpR gene and upstream 5' region was altered to include this preferable 
RBS upstream of the ATG start codon and replace any codons that were rarely used in 
S. pneumoniae with a more commonly used ones. In parallel a system to enable tighter 
control of specific gene expression with use of the maltose operon was developed. Use 
of the new altered tnpR" allele led to detectable resolvase protein production and 
resolution in vivo and in vitro. However the level of resolution was not robust enough 
nor responsive to increasing levels of transcription to be able to use the system as it was 
to answer the initial questions that it had been developed for. 
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CHAPTER 4 CHARACTERISATION OF VIRULENCE GENE 
REGULATORS IN S. PNEUMONIAE 
4.1 INTRODUCTION 
The work described in the previous chapter was performed with the aim of developing a 
method to study virulence gene regulation in S. pneumoniae in vivo. To this end 
attempts were made to implement RIVET in S. pneumoniae. When it became apparent 
that this methodology was not going to be robust or sensitive enough in S. pneumoniae 
to use in further experiments I proceeded to investigate other methods of studying 
virulence gene regulation in this organism. 
Three large scale STM screens in S. pneumoniae have been published (Hava and 
Camilli, 2002; Lau et al., 2001; Polissi et al., 1998). One study took 1786 insertion- 
duplication mutants to screen simultaneously for loss of virulence in both a murine 
model of pneumonia and one of bacteraemia (Lau et al., 2001). Of these, 186 mutants 
were initially identified as attenuated. Sixty were attenuated in, both models, 62 were 
attenuated solely in bacteraemia and the remaining 64 in pneumonia alone. Amongst 
the genes identified as being required for causing disease were some predicted to 
encode for transcriptional regulators or part of a signal transduction system. In a second 
study, 6149 mariner transposon insertion strains were screened. Of these, 387 mutants 
were attenuated for lung infection and 29 of these are thought to be involved in signal 
transduction or gene regulation, based on sequence similarity searches (Hava and 
Camilli, 2002). The phenotypes of a subset of the total 387 mutants were examined in 
two other murine models; bacteraemia and nasopharyngeal carriage. This identified 
four classes of mutants based on attenuation in animal infection models. Those 
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attenuated in causing (1) pneumonia, (2) pneumonia and bacteraemia, (3) pneumonia 
and nasopharyngeal carriage or (4) all three (Hava and Camilli, 2002). One 
interpretation of these data is that different virulence factors play specific roles in 
different tissues and/or at different times of the infective process. This would inevitably 
need the involvement of regulators that can orchestrate the overall changes in patterns 
of gene transcription, translation, protein activation, secretion etc. I hypothesized that 
genes identified in the STM screen that were predicted to encode proteins with a 
regulatory function might be involved in this virulence gene regulation. I planned to 
determine if this was the case by examining phenotypes of the mutants in different 
murine models of infection. I then intended to identify the genes in any `regulon' with 
the use of transcriptional profiling. 
4.2 RESULTS 
4.2.1 Differential attenuation of regulator mutants in different infection models 
On the basis of sequence similarity searches using the BLAST program 
(http: //www. ncbi. nlm. nih. gov/blast/) and knowledge of neighbouring genes on the S. 
pneumoniae chromosome five of the genes identified by an STM screen (Hava and 
Camilli, 2002) were selected for study (sp0156, sp0247, sp0461, sp0661 and sp1800). 
The magellan2 insertion mutations were backcrossed into AC353. In the cases of 
sp0661 and sp1800 further mutants were constructed as described below. 
The genes sp0156 and spO661 are predicted to encode response regulator components of 
a TCSTS and are adjacent to genes predicted to encode corresponding histidine kinase 
components (sp01 SS and sp0662 respectively). Although both genes were identified in 
the STM screen it was possible that the attenuated phenotype of these transposon 
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mutants was due to a polar effect on other genes in the operon. The open reading frame 
of sp0661 overlaps the open reading frame of sp0662 and sp0156 is only 5lbp away 
from the predicted start site of the next open reading frame/gene sp0157. For this reason 
I wished to construct two new mutants with in-frame deletions in sp0156 or sp0661. A 
S. pneumoniae strain, CHI 19, with an unmarked in-frame deletion of 529 bp following 
the ATG codon of sp0661 was constructed but a strain with an unmarked in-frame 
deletion in sp0156 could not be made despite multiple attempts and hence the 
magellan2 insertion mutation in sp0156 was backcrossed into AC353 and this strain 
was used in further competition assays. 
To determine if strains with mutations in the 5 chosen genes with predicted regulator 
function had global virulence defects or if they showed more selective attenuation in 
certain types of disease, competition assays in murine models of pneumonia, 
bacteraemia and nasopharyngeal carriage were performed. Mice were inoculated 
intraperitoneally with -Ix 106 bacteria for the bacteraemia model, with -1x 10' 
intranasally for the pneumonia model and with -1x 108 intranasally for the 
nasopharyngeal carriage model. Bacteria were recovered from the blood, lungs or 
nasopharyngeal washes respectively at 22 hours, 44 hours or 7 days post-inoculation. 
The in vivo competition index (CI) was calculated for each mouse by dividing the ratio 
of the mutant to wild-type bacteria, that were recovered from the mouse, by the ratio of 
the mutant to wild-type bacteria that were inoculated into each animal. The geometric 
mean of the Cis for each strain was determined and is listed in Table 4.1. A mean CI of 
less than 1 indicates a defect in virulence of the test strain as compared to the wild-type. 
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TABLE 4.1. Virulence in mice of regulator mutant strains in three murine models 
of infection assessed by competition assays 
Strain Relevant Genotype 
Geometric mean in vivo CI° 
Lung Carriage Bacteraemia 
infection 
CH108 AC353 sp0156:: magellan2 SmR <0.008 (6) 0.4 (8) 1.7 (4) 
CmR 
CH107 AC353 sp0247:: magellan2 SmR <0.08 (4) <0.09 (7) 0.25 (4) 
CmR 
STM901b AC353 sp0661:: magellan2 Sm' <0.017 (4) ND 0.55 (7) 
Cm' 
CHI 19 AC353 dspO661 Sm' 0.004 (6) 0.75 (6) <0.001(4) 
AC1213 AC353 rlrA:: magellan2 SmR <0.30 (7) <0.071 (10) 0.74 (4) 
Cm' 
STM206 AC353 <0.023 (4) 0.009 (6) 0.56 (3) 
mgrA 5' UTR:: magellan2 SmR 
CmR 
AC 1272 AC353 mgrA:: magellan2 SmR 0.47 (8) 0.58 (6) ND 
CmR 
AC1500 AC353 AmgrA SmR Spell 0.26 (12) 0.034 (6) 2.1 (8) 
Table 4.1 a The geometric mean of the in vivo competition index (CI) is shown. The 
number of animals infected in each experiment is indicated in parentheses. In the 
competitions in which no mutant bacteria were recovered from a particular animal the 
number 1 was substituted as the numerator when determining the in vivo ratio for that 
animal, thus the in vivo mean Cl is denoted as less than the calculated value. Geometric 
means shown in bold were considered significant (P-values < 0.05 by the student's two- 
tailed t-test). Open reading frames spO461 and sp1800 are renamed rlrA and mgrA. b The 
competition assays with STM90 were performed by D. Hava. (ND not done) 
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4.2.2 RlrA and MgrA have similarity to transcriptional regulators of group A 
streptococcus (GAS) 
What are these regulators regulating? I decided to focus more specifically on two 
regulators. Sp0247 was excluded on the basis of the mutant having a global virulence 
defect suggestive that this transcriptional regulator could be involved in regulating 
factors required for basic cellular processes important in cell survival in vivo and these 
may not be differentially regulated in vivo. Given the difficulty in constructing a 
deletion mutant, Sp0156 was also excluded. On the basis of sequence similarity 
searches using the BLAST program (http: //www. ncbi. nlm. nih. gov/blast/) sp0461 and 
sp1800 were selected for further study. 
The mutants with transposon insertions in genes sp1800 and sp0461 were attenuated in 
models of pneumonia and nasopharyngeal carriage suggesting that the products of these 
two genes are required for interactions with the mucosal surfaces of the respiratory 
tract. Both of these genes are predicted to encode proteins with similarity to 
transcriptional regulators in GAS (S. pyogenes). Sp0461 could encode a protein with 
49% similarity to RofA and Nra (Fogg et al., 1994; Podbielski et al., 1999) and sp1800 
could encode a protein that is 51% similar and 25% identical to the multiple gene 
regulator, Mga (McIver and Scott, 1997; McIver and Myles, 2002). These two gene 
products in S. pneumoniae were renamed RlrA (RofA-like regulator A) and MgrA 
(Mga-like repressor A). 
Mga and RofA/Nra of S. pyogenes regulate transcription of virulence genes encoding 
primarily surface-associated products. RofA and Nra have been shown to activate or 
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repress the transcription of genes encoding important adhesins such as fibronectin- 
binding protein (prtfl, collagen binding adhesin (cpa) and a second fibronectin-binding 
protein (prtF2). Mga activates the transcription of numerous virulence genes involved 
in S. pyogenes pathogenesis, including the genes encoding M family of proteins (emm, 
mrp, arp and enn), C5a peptidase (scpA), serum opacity factor (sof) and secreted 
inhibitor of complement (sic) (Caparon and Scott, 1987; Chen et al., 1993; Kihlberg et 
al., 1995; McLandsborough and Cleary, 1995). 
The rofA homologue rlrA lies in a 12 kb region of DNA that might constitute a 
pathogenicity islet and is divergently transcribed from six genes (sp0462 - sp0468). The 
islet is flanked by two IS 1167 insertion sequences. The gene organization is shown in 
Figure 4.1. Three of the islet genes encode proteins with similarity to microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMS) and three proteins 
similar to sortases (Figure 4.1). Sortases are enzymes that catalyse the covalent linkage 
of secreted proteins containing an LPXTG motif to the bacterial cell wall (Mazmanian 
et al., 1999; Mazmanian et al., 2001). Each of the putative MSCRAMMS, renamed 
RrgA, RrgB and RrgC have C-terminal sorting signals that are characteristic of 
LPXTG-containing proteins, except that the LPXTG sequence in each varies by two 
amino acids (Figure 4.1). One of the sortase genes, srtD, was also identified in the "same 
STM screen that had identified rlrA as being required for lung infection and subsequent 
work showed that an rrgA mutant strain was attenuated in a pneumonia and 
nasopharyngeal carriage model (Hava and Camilli, 2002). 
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A 
B 
Protein C-terminal sequence 
RrgA YPRTGGIGMLPFYLIGCMMMGGVLLYTRKHP 
RrgB IPQTGGIGTIIFAVAGAAIMGIAVYAYVKNNKDEDQLA 
RrgC VPDTGEETLYILMLVAILLFGSGYYLTKKPNN 
Figure 4.1 The rlrA locus 
(A) The r1rA gene is divergently transcribed from six genes. The entire locus is 
flanked by one frame-shifted and one intact IS 1 167 element. The sites of 
magellan2 insertions in r1rA and srtD, identified by STM, are shown with blue 
triangles. 
(B) The predicted C-terminal sorting signals of the three MSCRAMMS, RrgA, 
RrgB and RrgC, are listed. Each is characteristic of proteins anchored to the cell 
wall by sortases. The LPXTG motif (in bold) varies by the first amino acid. This 
is followed by a stretch of hydrophobic residues (underlined) and a charged tail. 
IS] 167 srtDCB rrgCBA rlrA IS 1167 
On the GAS chromosome mga lies directly upstream and reads in the same direction as 
some of the genes that it regulates including those encoding M protein and C5a 
peptidase (McIver and Myles, 2002; Pobielski et al., 1996; Rasmussen et al., 2000; 
Terao et al., 2001). In contrast, the arrangement around mgrA on the S. pneumoniae 
serotype 4 genome is different. It is approximately 450 bp upstream and divergently 
transcribed from a cluster of five small open-reading frames that appear to encode 
hypothetical proteins of unknown function and downstream of a gene encoding a 
putative Lad family transcriptional regulator (sp1799) (Figure 4.2). The mgrA gene 
itself has a predicted transcriptional terminator directly after the stop codon. The region 
encoding MgrA was actually identified twice in the serotype 4 S. pneumoniae STM 
screen (Hava and Camilli, 2002). One transposon insertion mapped to the middle of the 
1479 bp open-reading frame (AC 1272) and a second to a non-coding region 300 bp 
upstream of the predicted start site of mgrA (mgrA 5' UTR or STM206) (Figure 4.2). 
Encoding 
Encoding an hypothetical 
ABC proteins 
transporter I acI a mgrA 
(sp1801-1805) 
AA Figure 4.2 The mgrA locus 
The mgrA (sp1800) gene is upstream and divergently transcribed from a cluster of five 
small open-reading frames (yellow) encoding putative hypothetical proteins of 
unknown function and upstream of a gene encoding a putative LacI family 
transcriptional regulator (sp1799). The mgrA gene itself has a predicted transcriptional 
terminator directly after the stop codon. The sites of magellan2 insertions in or around 
mgrA identified by STM are shown with blue triangles. 
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These two STM mutants, AC 1272 and STM206, were attenuated to different degrees in 
competition assays (Table 4.1). Though both were attenuated for pneumonia and 
carriage, AC1272 showed a lower level of attenuation. This strain has a magellan2 
transposon inserted at approximately base pair 750 in the open reading frame. The DNA 
binding activity of the Mga of GAS has been mapped to two helix-turn-helix regions in 
the first 140 amino acids from the N-terminus. It is possible therefore that a truncated 
but partially functional protein is made in the S. pneumoniae strain, AC1272, which has 
some effect on the virulence phenotype. To avoid this problem a deletion insertion 
mutant was constructed as described below. 
4.2.3 Construction of an mgrA deletion strain and a strain over-expressing mgrA 
or rlrA. 
Three further mutants were constructed to use in experiments assessing whether 
transcription of specific genes were under the control of either R1rA or MgrA. These 
were one with a deletion-insertion of a Spc` gene, (aad9), in place of mgrA, (AC1500), 
and two merodiploid strains (AC 1278 and AC 1481) that had a second copy of either 
rlrA or mgrA inserted between malM and malP of the maltose operon. The latter strains 
place mgrA or rlrA under the control of the maltose promoter allowing over-expression 
of either gene product when grown in maltose (Figures 4.3 and 4.4). The phenotype of 
the new mgrA deletion mutant was also assessed in competition assays against the wild- 
type strain in the three murine models of infection. Similar to the transposon insertion 
mutants, the deletion strain was attenuated in both nasopharyngeal carriage and 
pneumonia but not in the bacteremia model (Table 4.1). 
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Figure 4.3 RPA for rlrA gene transcript 
RPA was used to confirm over-expression of rlrA gene under the control of 
the maltose inducible promoter. RNA was harvested from cells grown to 
OD6) 0.4 in either THY or THY 0.8% maltose and probed for r1rA. A rpoB 
probe was used as a loading control. The r1rA transcript level is 7-fold greater 
in AC1278 grown in maltose than in wild-type cells. 
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Figure 4.4 RPA for mgrA gene transcript 
RPA was used to confirm over expression of mgrA gene under the control of 
the maltose inducible promoter. RNA was harvested from cells grown to 
ODo(x) 0.4 in either THY or THY 0.8% maltose and probed for r/rA. A rpoB 
probe was used as a loading control. The fngrA transcript level is 12-fold 
greater in AC 1481 grown in maltose than in wild-type cells. Two mgrA- 
specific mRNA species were detected with the riboprobe. 
4.2.4 Each gene in the pathogenicity islet requires R1rA for expression 
On the basis of the organization of the islet and similarity to RofA it was hypothesized 
that rlrA acts as a transcriptional regulator that activates its own transcription and as 
well as that of the other six genes in the pathogenicity islet. The effect of an rlrA 
mutation on the steady-state levels of mRNA for each gene in the islet was determined 
by RPA. RPAs were performed using RNA isolated from wild-type AC353 or AC1213, 
the strain that harbors a transposon insertion in r1rA. Riboprobes specific to each islet 
gene, as well as to rpoB, were synthesized. The probe to rpoB gene was used to probe 
the same RNA and served as a loading control for each experiment. In the case of the 
seven genes within the islet, the riboprobes were designed to the immediate 5' end of 
each ORF, overlapping the putative translation initiation site, and such that a 200 to 400 
nucleotide fragment would be protected from digestion from the ribonuclease. The 
steady-state level of mRNA of each gene was decreased in AC 1213 compared to the 
wild-type strain (Figure 4.5). The level of decrease varied with each gene. The greatest 
decrease (10- and 11-fold) was observed for rrgB and rrgC, respectively. The rrgA 
message was only decreased by 2.5-fold and srtB, srtC and srtD messages by 6-, 7-, 
and 8-fold, respectively. The variability in detectable transcript level between these six 
genes is consistent with the presence of three promoters controlling their transcription: 
one for rrgA a second rrgB or rrgC and a third controlling srtB, srtC and srtD. The srtB 
probe protected three differently sized messages, suggesting the possibility that there 
are multiple transcriptional start sites within the sequence of the riboprobe. Each 
promoter appeared to be activated by R1rA. DNA binding studies and primer extension 
analysis, performed by Dave Hava, mapped the transcriptional start sites of promoters 
upstream of rlrA, rrgA, rrgB, and srtB and 
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Figure 4.5 RPAs of rlrA islet gene transcripts 
RPA to examine the expression of each of the rlrA islet genes in wild-type (wt) 
compared to rlrA:: magellan2 transposon insertion strain (rlrA). RNA was 
harvested from cells grown to OD6()() 0.4 in THY. A rpoB probe was used as a 
loading control. The results shown are from an experiment performed by Dave 
Hava. 
confirmed that R1rA bound to the predicted promoter sequences (Hava et al., 2003a). 
4.2.5 Unlike mga, mgrA does not appear to regulate neighbouring genes. 
As previously mentioned mgrA is approximately 450 bp upstream and divergently 
transcribed from a cluster of five small open-reading frames predicted to encode 
hypothetical proteins of unknown function (Figure 4.2). To test whether MgrA 
regulates transcription of this cluster RPAs were performed using probes against 2 orfs 
in the cluster, sp1803 and sp1804. In these experiments RNA was harvested from 
AC 1500 and AC 1481 grown in 0.8% maltose to mid exponential phase (OD6.0.4). A 
probe to rpoB gene served as a loading control for each experiment. Although both 
sp1803 and sp1804 were transcriptionally active, there was no detectable difference in 
the level of either transcript in the mgrA over-expressing versus the deletion mutant. 
Therefore mgrA does not appear to affect transcription of these genes in the growth 
conditions tested (Figure 4.6). 
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Figure 4.6 RPA to analyze the mRNA levels of sp1803 and sp1804 in wild- 
type (wt; AC353), mgrA deletion strain (0; AC1500) and mgrA over- 
expressing strain (+; AC1481). Riboprobes to . sp180.3, sp1804 and rpoB were 
generated and hybridized to 10µg of S. pneurnoniae RNA from the three strains. 
RNA was harvested from cells grown in 0.8% maltose to OD 0.4. Lanes U and 
D contain undigested riboprobes and riboprobes digested by Rnase in the 
absence of S. pneumoniae RNA. 
4.3 SUMMARY 
This chapter described the analysis of the virulence defect of 5 putative regulator 
mutants that were identified in an STM screen of TIGR4 assessed by using three murine 
models of infection. Two of these putative regulators, RIrA and MgrA were chosen for 
further examination. Both were similar to transcriptional activators of virulence genes in 
GAS, Given this similarity and the fact that they were identified as being required for 
nasopharyngeal carriage and for development of pneumonia in a murine model it was 
hypothesised that they would be involved in transcriptional regulation of virulence 
genes in S. pneumoniae. It was confirmed by RPA that RlrA acted as a transcriptional 
activator of six neighbouring genes. One of these, srtD, was a previously known 
virulence factor. MgrA, however, did not appear to effect transcription of neighbouring 
genes as assessed by RPA. 
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CHAPTER 5 INTERPLAY BETWEEN MGRA AND THE rdrA 
PATHOGENICITY ISLET 
5.1 INTRODUCTION 
MgrA has significant similarity to Mga, an important virulence gene regulator in GAS. 
Deleting mgrA in S. pneumoniae resulted in an attenuated phenotype showing that it is 
likely to be an important regulator of virulence genes in this pathogen. Preliminary 
experiments, described in the previous chapter, to identify some of the possible targets 
of this putative transcriptional regulator suggested that, at least in vitro, MgrA is not 
required for and does not regulate transcription of a neighbouring cluster of genes on 
the chromosome. 
The TIGR4 chromosome contains 2236 predicted coding regions of which 
approximately 65% have been assigned a biological role (Tettelin et al., 2001). 
Theoretically any of these 2236 genes could be a target for MgrA. At the time of 
conception of this project high-density DNA microarrays had been applied to a wide 
variety of systems for comparative genomic analysis (Behr et al., 1999), to monitor 
gene expression in whole genomes (deLisa et al., 2001) and more specifically for the 
identification of regulons within S. pneumoniae (de Saizieu et at., 2000). This chapter 
describes work performed to identify further targets of MgrA with the aid of microarray 
analysis. Since starting this work there have been a number of reports describing 
microarray technology to identify genome wide changes in expression of genes in S. 
pneumoniae strains with mutations in putative TCSTS or transcriptional regulators 
(Blue and Mitchell, 2003; Sebert et al., 2002). 
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5.2 RESULTS 
5.2.1 MgrA acts as a transcriptional repressor of the rlrA pathogenicity islet. 
The GAS homologue, Mga, shows variable transcription and activity at different stages 
in the growth phase (McIver and Scott, 1997). It is transcribed during exponential 
phase but transcription ceases as the bacteria enter stationary phase. To assess if the 
transcription of mgrA varied with growth RPAs were performed to analyse mRNA 
levels of the mgrA gene in AC353 at the four different time points during growth 
approximating to early, mid, late exponential and early stationary phase (Figure 5.1). 
Assessment of mRNA levels at late stages of stationary phase in S. pneumoniae is 
hindered by the fact that bacterial cells undergo autolysis and bulk mRNA degradation 
at this time (data not shown). Two mRNA species were detected with the mgrA 
riboprobe at all 4 time points. This is consistent with the gene having two 
transcriptional start sites as the riboprobe for mgrA was complementary to RNA 
overlapping the 5' untranslated mRNA and the coding sequence of the gene. MgrA 
transcript levels did not change over exponential phase to early stationary phase of 
growth. However post-transcriptional regulation and/or changes in the activity of the 
translated protein cannot be excluded. 
cDNA microarray analysis of gene expression patterns of the mgrA deletion and over- 
expressing strains (AC1500 and AC1481, respectively) was used in an attempt to 
identify genes regulated by MgrA. On the hypothesis that, similar to Mga, MgrA may 
not be active at all phases of growth, RNA for use on the microarrays was harvested 
from all 4 time points in the growth curve (as above). All three strains had similar 
growth kinetics in vitro (Figure 5.1). The vast majority of genes displayed comparable 
expression levels between the two strains (Figure 5.2). 
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Figure 5.1 RPAs of mgrA transcript and comparison of growth in vitro 
(A) RPAs were performed to analyse mRNA levels of the ingrA genes in 
AC353 at the four different time points. Riboprobes to ingrA and rpoB were 
generate and hybridised to 5 tg of total S. pnuemoniae RNA (AC353). Samples 
are loaded as follows; lane 1 undigested probe alone and lanes 2 to 5 probes 
hybridised to RNA harvested from cells grown to the OD6(x) indicated. 
(B) Growth curves for the wild-type (AC353 f), ingrA deletion mutant (") and 
ingrA over-expressing strain (0) cultured statically in Todd Hewitt broth plus 
5% yeast extract (THY) and supplemented with oxyrase (5µl ml-') and 0.8% 
maltose. Aliquots were removed for RNA extraction at 4 time points, indicated 
by the arrows, (equivalent ODo(x) values: early log - 0.2, mid log - 0.4, late log 
0.6 and stationary phase - 0.8) 
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Figure 5.2. Gene expression profiling 
of MgrA non-expressor (AC1500) 
and MgrA-overexpressor (AC1481) 
strains by spotted DNA microarray. 
Data are a measure of relative 
quantities of mRNA at the culture 
optical densities indicated, and 
represent the quotient of the 
hybridization of the fluorescent cDNA 
probe prepared from the AC 1500 or 
AC 1481 samples compared with a 
reference pool. Red represent high and 
green low experimental 
sample/reference ratios (see scale bar). 
Gray signifies technically inadequate or 
missing data. Columns represent arrays 
and rows represent genes. See 
materials and methods for experimental 
details. 
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A subset of genes that showed altered profiles between the two mutant strains (AC 1500 
and AC 1481) at only one time point was not considered further. One set of genes were 
notable in that their transcripts were more abundant in the AmgrA strain than mgrA 
over-expressing strain at all four time points assessed, suggesting that MgrA is involved 
in repressing these genes (Figure 5.2 and Table 5.1). These were the genes in the rlrA 
pathogenicity islet which was discussed in the previous chapter and shown to be 
virulence factors required for both lung infection and nasopharyngeal carriage (Hava et 
al., 2003a). 
Table 5.1. Average mRNA level of rlrA islet genes in AC1500 (mgrA deletion 
strain) relative to AC1481' (mgrA over-expressing strain) 
Fold difference in the mRNA level across the time course 
TIGR4 ORFb Gene OD 0.2 OD 0.4 OD 0.6 OD 0.8 
SP0461 rlrA 2.0 1.6 2.8 2.3 
SP0462 rrgA 2.4 2.1 3.0 3.6 
SP0463 rrgB 2.2 1.9 3.5 2.8 
SP0464 rrgC 1.8 1.7 3.1 2.5 
SP0466 srtB 2.0 2.8 2.7 2.8 
SP0467 srtC 1.7 2.7 4.4 2.4 
SP0468 srtD 2.4 1.7 2.3 1.5 
SP1800 mgrA 10.2 9.7 15.6 NA 
e The loge red/green ratio values from replicate arrays were averaged at each time point. 
For each OD sample, the averaged loge data from each AC 1481 sample was subtracted 
from the respective loge AC1500 data. The resulting data is expressed as the fold 
difference in levels between the two strains. Data from all arrays used in this study are 
also available (Gollub et al., 2003) (Hemsley et al., 2003). NA - not available. 
b Designations of the ORFs in the TIGR4 sequence which are on the microarray. 
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Confirmation of these results was obtained by RPAs performed with RNA isolated from 
three independent sets of cultures and assessing two time points in the growth curve for 
each (mid exponential phase, ODD 0.4, and late exponential phase ODwO0.6). The islet 
contains four promoters driving transcription of seven genes (Hava and Camilli, 2002; 
Hava et al., 2003a). Probes to a gene in each transcriptional unit, namely rlrA, rrgA, 
rrgB and srtD as well to rpoB were synthesized. As in previous RPAs, rpoB was used 
as a loading control for each experiment. All four of the tested islet genes showed 
increased mRNA levels in the mgrA deletion strain and decreased mRNA levels in the 
mgrA over-expressing strain at both time points and to a similar degree to that revealed 
by the microarray experiments (Figure 5.3). The level of each islet gene transcript was 
increased 2-3 fold in the mgrA deletion strain and decreased at least 2 fold in the mgrA 
over-expressing strain relative to wild-type at all time points tested. Together these data 
are consistent with MgrA acting as a transcriptional repressor of the islet genes. MgrA 
might bind directly to each promoter or alternatively could function indirectly by 
altering the expression of rlrA, a transcriptional activator, which subsequently effects 
the expression of the other six islet genes. 
5.2.2 RIrA does not regulate mgrA transcription 
R1rA is similar to RofA and Nra of GAS (Hava et al., 2003a). In GAS Nra acts as a 
transcriptional repressor of mga whilst in turn Mga activates nra transcription 
(Pobielski et al., 1999). To test the possible role of RlrA in regulation of mgrA in S. 
pneumoniae serotype 4 transcript levels of mgrA in wild-type and strains over- 
expressing rlrA or not expressing rlrA were assessed. RPAs were performed, probing 
for mgrA, using RNA harvested from wild type AC353, AC 1213 (a strain that habours a 
transposon insertion in rlrA) and AC 1278 (a strain that over-expresses rlrA from the 
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Figure 5.3 RPAs on rnrA islet genes 
RPAs were performed to analyze the mRNA levels of a gene in each 
transcriptional unit in the rlrA islet, in the wild-type (wt; AC353), mgrA 
deletion strain (A, AC 1500) and mgrA over-expressing strain (+, AC 1481). 
Riboprobes to each gene, as well as rpoB, were generated and hybridized 
to 10µg of S. pneumoniae RNA from the three strains. RNA was harvested 
from cells grown in 0.8% maltose to OD 0.4 or 0.6. Transcript levels were 
comparable at either time point. Results from an OD 0.4 are shown. 
Lanes U and D contain undigested riboprobes and riboprobes digested by 
Rnase in the absence of S. pneumonrae RNA. 
maltose inducible promoter). RpoB was used as a loading control. As shown in Figure 
5.4, there was no detectable difference in amount of mgrA message in the AC 1213 or 
AC1278 compared to wild-type (AC353). Neither of the two mgrA specific mRNA 
species were altered in the rlrA mutant strains providing no evidence of a role for R1rA 
in regulation of MgrA and suggesting a different regulatory circuit from that observed 
for the homologues in GAS. 
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Figure 5.4 RPA to analyze the mRNA levels of mgrA in wild-type (wt; AC353), rlrA 
transposon insertion strain (rnrA; AC1213) and rlrA over-expressing strain (+; 
AC1278). Riboprobes to mgrA and rpoB were generated and hybridized to 10 . tg of S. 
pneumoniae RNA from the three strains. RNA was harvested from cells grown in 0.8% 
maltose to OD 0.4. Lanes U and D contain undigested riboprobes and riboprobes 
digested by RNase in the absence of S. pneumoniae RNA. 
5.2.3 ZmpB operon 
Amongst the subset of genes that showed consistently altered profiles between the two 
mutant strains at only two time points in the arrays studies were sp0663 and sp0668. 
These are predicted to be part of a putative operon, containing amongst other genes, 
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sp0661, encoding the response regulator component of TCS09 (nomenclature of Lange 
et al, (Lange et al., 1999)), sp0663 (encoding a conserved hypothetical protein) and 
sp0664 (encoding a zinc metalloproteinase ZmpB), all of which had been identified by 
STM as being required for lung infection (Hava and Camilli, 2002). Sp0663 and sp0668 
showed a 1.5 and 4 fold increase in mRNA levels in the mgrA over-expressing strain as 
compared to the deletion strain at the two later time points in the growth curve. The 
other genes in the putative zmpB-operon did not show similar changes. Given that more 
than one gene in the region was identified as having altered mRNA levels on the 
microarray screen and that the region was suspected to contain at least one virulence 
factor, RPAs were performed to determine if this apparent up-regulation by MgrA could 
be confirmed. RNA was isolated from three independent sets of cultures. The last two 
time points in the growth curve for each (late exponential phase ODD 0.6 and early 
stationary phase ODD 0.8) were examined. Probes to sp0663 and sp0668 as well to 
rpoB were synthesized. In contrast to the results with the microarray there was no 
detectable difference in amount of sp0663 or sp0668 message in the AC1500 or 
AC1481 compared to wild-type (Figure 5.5). Since the array results could not be 
confirmed by an alternative method this was not pursued further. 
5.2.4 R1rA locus is not present in all strains that contain mgrA 
Comparative genomics between TIGR4 and D391R6, a serotype 2 S. pneumoniae strain, 
reveals that none of the rlrA islet genes are present in the latter strain but the mgrA gene 
is present, spr1622 (Tettelin et al., 2001). There is also a second gene (spr1404) in R6 
with sequence similarity to mga and mgrA. It is 40.5% identical and 61.1 % similar to 
the TIGR4 mgrA gene (Figure 5.6). 
146 
ow 
qw sp0668 ý, MIMr 
sp0663 
"b W 
Mo go 40 rpoB 40 40 40 
UD wt A+ wt A+UD 
Figure 5.5 RPAs on zmpB operon gene transcripts sp0663 and sp0668 
RPAs were performed to analyze the mRNA levels of . sp0663 and sp0668 
in 
the wild-type (wt; AC353), ingrA deletion strain (A, AC 1500) and mgrA over- 
expressing strain (+, AC 148 I ). Rihoprobes to each gene, as well as rpoB, 
were generated and hybridized to I Oµg of S. pneumoniae RNA from the three 
strains. RNA was harvested from cells grown in 0.8% maltose to OD 0.6 or 
0.8. Transcript levels were comparable at either time point. Results from an 
OD 0.6 are shown. Lanes U and D contain undigested riboprobes and 
riboprobes digested by Rnase in the absence of S. pnewnoniae RNA. 
SP1800 ------------------- MRDLLSKKSHRQLELLELLFEHKR--WFHRSELAELLNCTE 
Spr1622 MWYNCKRFNPIIYKERKIFMRDLLSKKSHRQLELLELLFEHKR--WFHRSELAELLNCTE 
Spr1404 ----------- MNYGGNTRMRNLLSTKVQRQLRLMETLIQNRN-- WMKLHELAEKLGCTE 
Mga -----------------MYVSKLFTSQQWRELKLISYVTENADAIGVKDKELSKALNISM 
SP1800 RAVKDDLSHVKSAFPDLIFHSSTNGIRIINTDDSDIEMVYHHFFKHSTHFSILEFIFFNE 
Spr1622 RAVKDDLSHVKSAFPDLIFHSSTNGIRIINTDDSDIEMVYHHFFKHSTHFSILEFIFFNE 
Spr1404 RILKSDLNELRIAFPSINIQSSVNGIMIDLEVNTSVEDIYQYFLANSQSFQLLEYMFFNE 
Mga LTLQTCLTNMQFMKEVGGITYKNGYITIWYHQHCGLQEVYQKALRHSQSFKLLETLFFRD 
SP1800 GCQAESICKEFYISSSSLYRIISQINKVIKRQFQFEVSLTPVQIIGNERDIRYFFAQYFS 
Spr1622 GCQAESICKEFYISSSSLYRIISQINKVIKRQFQFEVSLTPVQIIGNERDIRYFFAQYFS 
Spr1404 GLPIYRTIENLYFSSANLYRLGRNITKVLSSQFQIELSFTPSEIRGNEIDIRYFFAQYFS 
Mga FNSLEELAEELFVSLSTLKRLIKKTNAYLMHTFGITILTSPVQVSGDEHQIRLFYLKYFS 
SP1800 EKYYFLEWPF-ENFSSEPLSQLLELVYKETSFPMNLSTHRMLKLLLVTNLYRIKFGHFME 
Spr1622 EKYYFLEWPF-ENFSSEPLSQLLELVYKETSFPMNLSTHRMLKLLLVTNLYRIKFGHFME 
Spr1404 ERYYFLDWPF-PDLPEEDLTEFADFFYKITNYPMRFSIYRMYKLMIAISIHRVKNGHFID 
Mga EAYKISEWPFGEILNLKNCERLLSLMIKEVDVRVNFTLFQHLKILSSVNLIRYYKGHSAV 
SP1800 VDKDSFNDQSLDFLMQAEGIEGVAQSFESEYNISLDEEWCQLFVSYFQKMFFIDESLFM 
Spr1622 VDKDSFNDQSLDFLMQAEGIEGVAQSFESEYNISLDEEVVCQLFVSYFQKMFFIDESLFM 
Spr1404 LP-NHFYKEYYPLLKSIPNFQETLAYFSKHFGLEMTPDTIAQIFISFLQNDIFLDPQEFF 
Mga YDNKKTSHRFSQLIQSSLEIQDLSRLFYLKFGLYLDETTIAEMFSNHVNDQLEIG--YAF 
SP1800 KCVKKDS---- YVEKSYHLLS--- DFIDQISVKYQIEMENKDNLIWHLHNTAHLYRQELF 
Spr1622 KCVKKDS ---- YVEKSYHLLS --- DFIDQISVKYQIEIENKDNLIWHLHNTAHLYRQELF 
Spr1404 NSLEDNS---- QARYSYQLLS---QILEGLSKQYKITFTNHDELIWHLHNTAFFERQEIF 
Mga DSIKQDSPTGCRKVTNWVHLTNWVHLLDELEIRLNLSVTNKYEVAVILHNTTVLKEEDIT 
...... .... ...... 
SP1800 TEFILFDQKGNTIRNFQNIFPKFVSDIKKELSITYLETLEVCSSSMMVNHLSYTFITHTKH 
Spr1622 TEFILFDQKGNTIRNFQNIFPKFVSDVKKELSITYLETLEVCSSSMMVNHLSYTFITHTKH 
Spr1404 STPILFEQKALTIKKFEVYFPDFMGSARQELAQYRQAIGQHDHPEQLEHLMYTILTHAEN 
Mga ANYLFFDYKKSYLNFYKQEHPHLYKAFVAGVEKLMRSEKEPISTELTNQLIYAFFITWEN 
SP1800 LVINLLQNQPKLKVLVMS-NFDQYHAKFVAETLSYYCSNNF-ELEVWT-ELELSKESLED 
Spr1622 LVINLLQNQPKLKVLVMS-NFDQYHAKFVAETLSYYCSNNF-ELEVWT-ELELSKESLED 
Spr1404 LSTQLLENRPPIKVLIIS-NFDHAISLTFVDMLSYYCNNRF-TFDIWD-ELKTSPEILNQ 
Mga SFLEVNQKDEKIRLLVIERSFNSVGNFLKKYIGEFFSITNFNELDALTIDLEEIEKQYDV 
SP1800 SPYDIIISN---------- FIIPPIENKRLIYSNNINTVSLIYLLNAMM---FIRLDE-- 
Spr1622 SPYDIIISN---------- FIIPPIENKRLIYSNNINTVSLIYLLNAMM---FIRLDE-- 
Spr1404 TDYDIIVSN---------- FYIPGIT-KKFICRNHLSIMNLVNHLNTLSN--EIHLSNTL 
Mga IVTDVMVGKSDELEIFFFYKMIPEAIIDKLNAFLNISSADSLPLDKPIKNPLDFHRKEVI 
SP1800 --------------- 
Spr1622 --------------- 
Spr1404 --------------- 
Mga FPTPPNKLRAPPSTS 
Figure 5.6 Alignment of the amino acid sequences of Sp1800 (MgrA), 
Spr1622, Spr1404 and Mga 
The amino acid sequences of proteins MgrA from S. pneumoniae TIGR4 
and Spr1622 and Spr1404 from S. pneumoniae R6 were aligned with the 
sequence of Mga from S. pyogenes. An asterix (*) indicates identical 
residues in all four proteins, a semi colon (: ) identical or similar residues in 
three and a single dot (. ) identical or similar residues in two of the proteins. 
To look further for the presence of mgrA and rlrA across serotypes, dot-blot 
hybridizations were performed on chromosomal DNA from eight clinical isolates of 
different serotypes using a control probe to rpoB and probes to mgrA and rlrA. The 
rpoB probe was used as a control. The same strains were also tested by PCR for the 
presence of all three genes and two other islet genes, srtD and rrgA. The serotypes 
screened were chosen on the basis that they represent all 7 serotypes covered by the 
pneumococcal conjugate vaccine, Prevnar. D39, a serotype 2 strain, was included as a 
negative control. The PCR primers for mgrA (SP1800F/SPI880R) are predicted to be 
specific for the mgrA gene, Spr1622, in D39 and should not amplify a product from 
Spr1404. All strains were positive by dot-blot and PCR for the presence of mgrA and 
rpoB but the islet genes were only present in strains of serotype 4,9V and 6B (Figure 
5.7). 
MgrA or homolog is found in S. pneumoniae strains that do not possess the RlrA islet 
yet variation in expression of islet genes was the only consistent difference at all time 
points between the mgrA over-expressing and the mgrA deletion serotype 4 strains, as 
determined by the microarray experiments described above. It seems unlikely that the 
primary role of MgrA is to repress islet gene expression. It is more likely that MgrA has 
additional targets in vivo that were not detected by our microarray screen using RNA 
harvested from in vitro-grown bacteria and/or that it has alternative targets in non- 
serotype 4 S. pneumoniae strains. 
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Figure 5.7 Presence of mgrA and rlrA genes in clinical strains of serotypes 
present in the pneumococcal conjugate vaccine, Prevnar. 
DNA probes complementary to nrgrA and rlrA were used to probe dot blots of 
chromosomal DNA from clinical isolates of different serotypes. Each DNA was 
spotted in serial dilutions across the membrane. An rpoB probe was used as a 
positive control. All probes were complementary to the TIGR4 gene sequence. 
5.2.5 MgrA is a virulence factor in serotype 2 S. pneumoniae 
The results of three STM screens of S. pneumoniae have been published to date. One 
was performed in a serotype 19F strain (Polissi et al., 1998), a second in a serotype 3 
strain (Lau et al., 2001) and the most extensive in TIGR4 (Hava and Camilli, 2002). 
The mgrA gene is known to be present in all three serotypes but was only reported as 
being identified as a virulence factor in the TIGR4 STM screen. One possibility is that it 
is not required for disease in serotype 3 and 19F in the infection models used in the 
STM screens or that it was not identified in these screens as these were not 
comprehensive. To determine whether MgrA regulates any virulence factors in a non- 
serotype 4 S. pneumoniae strain a D39 strain (serotype 2) with an insertion deletion in 
spr1622/mgrA was constructed. This was assessed in competition assays against wild- 
type D39. Two models of infection were tested: lung infection and nasopharyngeal 
carriage. To construct serotype 2 strains with a deletion-insertion of a Spc' gene in place 
of mgrA PCR amplification of the mutated region in the serotype 4 strain, AC 1500, was 
performed using primer pairs 180AFI/I80SRX and the purified amplicon transformed 
into S. pneumoniae D39. The double recombination event was selected for by plating on 
Spe. Confirmation of disruption of spr1622 was confirmed by PCR and DNA 
sequencing. 
The serotype 2 mgrA mutant, CH207, was attenuated in the pneumonia model (Figure 
5.8) and the level of attenuation was greater than that caused by the corresponding 
mutation in TIGR4. It was not attenuated in a murine model of nasopharyngeal 
carriage. These data are consistent with MgrA being involved with regulation of factors 
in D39 that are important for invasive disease at a mucosal site but not for 
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nasopharyngeal carriage. As D39 does not contain the rlrA pathogenicity islet the MgrA 
regulator presumably is regulating other virulence factors in this strain. 
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Figure 5.8 Competition assays D39 versus D39AmgrA (CH207) 
Competition assays were performed using murine models of nasopharyngeal carriage 
and pneumonia. The in vivo competition index (CI) was calculated; each circle 
represents the Cl derived from a single mouse in each set of competitions and the 
number of mice infected in each experiment is shown in parentheses. A CI of less than 
1 indicates a virulence defect. Open circles indicate that no mutant bacteria were 
recovered from that animal and a value of 1 was substituted in the numerator when 
calculating the CI. The geometric mean of the Cis for all mice in a set of competitions is 
shown as a short solid line. The CI for pneumonia was statistically significant 
(*p<0.05). 
Whilst performing these experiments it was noted that the inoculum required to 
generate sufficient bacterial numbers to determine a CI in competition assays in the 
murine model of pneumonia with either the TIGR4 or D39 mgrA mutants was 100-200 
fold higher than is usually required for strains with mutations in other regulator- 
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encoding genes. This was repeatable over infections performed on a total of 6 separate 
occasions. To investigate this further 6 mice were infected with either 2x 10' wild-type 
D39 bacteria, a similar dose of CH207 (D39 mgrA deletion-insertion strain) or a mixed 
inoculum comprising of 2x 10' CFU of wild-type D39 and 2x 10' CFU of CH207 (ie a 
total inoculum of 4x 10' CFU). The input volume was adjusted to be the same for each 
mouse (40 µl). The infection was allowed to proceed for 44 hours in all but two mice, 
which were euthanised at 24 hours as they reached a sickness severity score requiring 
humane killing. Mice were scored for severity of illness, macroscopic lung abnormality 
at the time of lung dissection and the CFU/gram of tissue was recorded. 
The experiment was repeated in duplicate on a separate day. The results given are from 
one experiment but are representative of both experiments (Table 5.2 and Figure 5.9). 
As expected the mice infected with the attenuated CH207 strain alone showed no 
visible signs of infection and significantly less bacteria were recovered from the lungs 
compared to those infected with wild-type bacteria. Also, fewer mice, that were infected 
with the wild-type bacteria in combination with CH207, showed visible signs of 
infection, and significantly less bacteria were recovered from the lungs of these mice 
than the mice infected with wild-type alone (Table 5.2 and Figure 5.9). Therefore it 
appears that the mrgA mutant has the ability to restrict the growth of the wild-type 
bacteria in vivo and alter the course of the disease. Whether this is due to an alteration in 
host response to S. pneumoniae or due to an inherent change in the bacteria themselves 
is not clear. It is possible, for example, that they compete for sites needed to produce an 
infection such as a host cell-surface receptor. 
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Table 5.2 Affect of single and double infections: D39 and D39AmgrA (CH207) 
Infective strain State of health at Macroscopic CFU/gram 
and Mouse 44 hours' appearance of lung lung 
number 
D39 
1 Sick (euthanised at Red and friable 9.5 x 108 
24 hours) 
2 Sick (euthanised at Red and friable 1.18 x 10' 
24 hours) 
3 Sick Mottled/lobar changes 2.45 x 10' 
4 Sick Mottled/ lobar changes 2.59 x 103 
5 Sick Mottled/ lobar changes 7.83 x 103 
6 Sick Mottled/ lobar changes 1.03 x 104 
CH207 (AmgrA) 
1 Well Pink 0 
2 Well Pink 0 
3 Well Pink 0 
4 Well Pink 1.3 x 103 
5 Well Pink 1.76 x 103 
6 Well Pink 1.0 x 104 
Mixed infection (D39 and CH207) 
1 Well Pink 1 
2 Well Pink 4.5 x 102 
3 Well Pink 5.6 x 103 
4 Well Pink 7.4 x 103 
5 Sick +/- Mottled +/- 1.7 x 104 
6 Sick +/- Mottled +/- 4.6 x 104 
e State of health at 44 hours except for D39 1 and 2 that were euthansed at 24 hours 
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Figure 5.9 Murine infections using a pneumonia model: D39 and CH207 
(D39AmgrA) single and mixed infection 
Mice were inoculated intranasally with either D39 alone, CH207 (D39 
&ngrA) alone or both strains. The input doses were as indicated in 
parentheses. Six mice were infected in each group, euthanased at 44 hours 
and bacteria harvested from the lung. Each circle represents the CFU/gram 
of lung tissue for a single mouse. Open circles indicate that no bacteria were 
recovered from that animal. The geometric mean is shown as a short solid 
line. 
5.2.6 Are the genes of the rlrA pathogenicity islet the only targets of MrgA in 
serotype 4? 
The work described in this chapter confirms that MgrA is a virulence factor in TIGR4 
that represses the expression of genes within the rlrA pathogenicity islet. It is also a 
virulence factor in a second serotype, serotype 2. As the rlrA islet is not present on the 
genome in strains of this serotype, MgrA must be controlling the expression of factors 
other than the rlrA islet genes in serotype 2 strains. I wished to investigate whether 
MgrA is involved in controlling the expression of other factors in TIGR4 aside from the 
islet genes. It is quite possible that the in vitro growth conditions used to grow cells to 
harvest RNA for use on the microarrays were not appropriate for full activation of 
MgrA and hence not all targets were identified. The regulator may have a different 
state of activation in vivo and consequently regulate other factors in vivo. 
I decided to approach this from two different angles; Firstly, I wished to determine what 
environmental signals MgrA might be responding to in order to develop better in vitro 
conditions for MgrA activation with a view to repeating microarray studies. Secondly, I 
wished to compare single and double mgrA and rlrA mutants in competition assays with 
TIGR4 strains in mice to assess whether the effects of the two mutations were additive 
or not. 
5.2.7 Investigation of signals required for MgrA and RlrA activation 
Mga and RofA in GAS control the expression of virulence factors in response to 
changing environmental conditions. Mga is activated by growth in elevated carbon- 
dioxide (Caparon et al., 1992; McIver et al., 1995). RofA is affected by superoxide 
levels and oxygen partial pressure (Fogg and Caparon, 1997; Kreikemeyer et al., 2003). 
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Nra, however, does not appear to be regulated by similar conditions to RofA 
(Kreikemeyer et al., 2003). There is some evidence that the ambient oxygen 
concentration is an important factor in the ability of S. pneumoniae to regulate the 
characteristics of its cell surface. Oxygen levels affect the opaque and transparent phase 
variants differently. There is an increased production of capsular polysacharride (CPS) 
in opaque variants in conditions of reduced oxygen, whereas synthesis of CPS in 
transparent variants remains comparatively low under atmospheric or reduced oxygen 
conditions. To determine if oxygen and/or carbon dioxide levels are involved in the 
activation status of MgrA and R1rA in S. pneumoniae a lacZ reporter gene was used to 
examine the transcription of genes, rlrA and srtD in different environments. These 
genes were selected on the basis that they are known to encode virulence factors and are 
targets for MrgA and R1rA. There were no other known targets outside the islet for 
either regulator. Several strains were constructed: two with transcriptional fusions of 
the lacZ gene to rlrA or srtD (CH210 and CH214 respectively) and strains with single 
or double deletions in mgrA and rlrA in the lacZ fusion backgrounds (CH211, CH212 
and CH213) (Table 2.3). 
The affect of growth phase on transcription of rlrA and srtD was assessed. CH214, 
CH210 and wild-type, AC353, were grown in THY broth and aliquots taken at the same 
4 time points in the growth curve as had been used when harvesting RNA (early 
exponential, mid exponential, late exponential and early stationary phase). ß- 
galactosidase activity was measured from the lysed cell pellet (Figure 5.10). 
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Figure 5.10 ß-galactosidase activity of srtD:: lacZ and rlrA:: lacZ fusion strains 
CH210 (", srtD:: lacZ), CH214 (A, rlrA:: lacZ) and AC353 ( , wild-type) were grown 
in THY broth and aliquots taken at the ODD indicated. ß-galactosidase activity was 
measured from the lysed cell pellets. 
The level of activity seen in the srtD:: lacZ strain was greater than that seen in the 
rlrA:: lacZ strain and activity in both was constant over time. As there was no change in 
ß-galactosidase with growth all cells in subsequent experiments were grown to mid- 
exponential phase. Experiments were repeated in triplicate. 
The effect of altering the atmosphere was examined. ß-galactosidase activity was 
measured in cells grown to mid-exponential phase in normal atmospheric conditions 
(0.03% carbon dioxide, 20% oxygen), anaerobically (10% carbon dioxide, 0.03% 
oxygen) or in 10% carbon dioxide, 20% oxygen. In the srtD:: lacZ strain 0- 
galactosidase activity was highest in cells grown in 10% carbon dioxide and 20% 
oxygen. Activity was repressed by reducing either the oxygen level or the carbon 
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dioxide level (Figure 5.11) Deletion of mgrA in this background abolished the 
difference in activity seen in varying atmospheres indicating that MgrA was required 
for this effect. R1rA was absolutely required for srtD transcription as inactivation of 
rlrA in the srtD:: lacZ background reduced the ß-galactosidase activity to the 
background levels seen in wild-type cells (Figure 5.11). Additional deletion of mgrA in 
the srtD:: lacZ ArlrA strain had no effect on ß-galactosidase activity consistent with the 
idea that MgrA works to repress transcription of srtD by repressing rlrA transcription. 
In the rlrA:: lacZ strain ß-galactosidase activity was similar to that seen in wild-type 
cells (Figure 5.10). The level was increased in the mgrA deletion strain by 2-3 fold. 
There was no difference in the ß-galactosidase activity measured in different 
atmospheric conditions indicating that RlrA was not affected by changing carbon 
dioxide or oxygen levels (Figure 5.11). However the level of activity of the fusions was 
so low that it is possible that this is not an adequate method to test this hypothesis. The 
data is consistent with the activation status of MgrA being affected by oxygen and/or 
carbon dioxide levels. In vitro growth conditions that resulted in improved MgrA 
activation compared to those used for the microarray screen could not be determined. 
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Figure 5.11 ß-galactosidase activity of (A) srtD:: lacZ fusion strains (B) 
rlrA:: IacZ fusion strains in different atmospheres. 
(A) AC353 (wild-type), CH210 (srtD:: lacZ), CH211 (srtD:: lacZ AmgrA), 
CH212 (srtD:: lacZ rlrA:: magellan2) and CH213 (srtD:: lacZ 
rlrA:: magellan2 AmgrA) 
(B) AC353 (wild-type), CH214 (rlrA:: lacZ) and CH215 (rlrA:: lacZ EmgrA) 
All S. pneumoniae strains were grown in THY broth to mid exponential 
phase. ß-galactosidase activity was measured from the lysed cell pellets. 
Each strain was assessed in different growth atmospheres as indicated. Data 
for strains grown in 5%CO2,20% 02 is not shown but similar to results for 
growth in 10%C02,20% 02 . 
5.2.8 MgrA and R1rA act in the same pathway 
Whether two virulence genes interact as part of the same function or act independently 
can be investigated using a test referred to as a Qancelled Qut index or COI (Beuzon and 
Holden, 2001). The COI is calculated by competition of each single mutant against the 
double mutant. If the two genes contribute equally to the same function, the double 
mutant should not be more attenuated than the single mutant. Explained another way; 
the CI of wild-type versus the single mutant should be less than one, whereas the COIs 
should not be different from one. If the COI equals one it is possible that the action of 
one gene product is dependent on the gene product of the second gene i. e. they work in 
the same pathway. 
If the rlrA islet genes are the only targets for MgrA in TIGR4 then one would predict 
that the AmgrA rlrA:: magellan2 mutant (CH209) would have a similar in vivo 
phenotype to the rlrA:: magellan2 mutant strain (AC1213). To determine if this is the 
case a double regulator mutant was constructed. This strain, CH209 was tested in 
competition assays with AC 1213 for pneumonia and nasopharyngeal carriage (COI). 
The COI were not significantly different from I for either type of infection (Figure 
5.12). There was no additional attenuation over and above that seen in the rlrA mutant 
with the addition of a second mgrA mutation, consistent with the idea that both 
regulators act within the same pathway. These results are consistent with the hypothesis 
that MgrA does not regulate any other factors required for causing lung infection or 
nasopharyngeal carriage in a murine model in TIGR4 other than those in the rlrA islet. 
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Figure 5.12 COIs of rlrA:: magellan2 mutant versus &mgrA 
rlrA:: magellan2 double mutant 
Competition assays/COIs were performed using murine models of 
carriage and pneumonia. The COI was calculated; each circle 
represents the result derived from a single mouse in each set of 
competitions and the number of mice infected in each experiment is 
shown in parentheses. The geometric mean for all mice in a set of 
competitions is shown as a short solid line. No COI was statistically 
different from 1. 
5.3 SUMMARY 
In this chapter I have described work to identify potential targets for the transcriptional 
regulator MgrA. With the aid of cDNA microarrays the genes of the rlrA pathogenicity 
islet were identified as being repressed by MgrA at all time points across the growth 
curve. This was confirmed by RPAs probing separately prepared RNA for transcript of 
one gene from each of the four operons within the islet. Further RPAs determined that, 
unlike their counterparts in GAS, RlrA and MgrA did not appear to show reciprocal 
regulation. Genes in a second putative operon, the ZmpB operon, were identified by the 
microarray screen as possibly being transcriptionally activated by MgrA at late time 
points in the growth curve. This however was not confirmed by RPA. 
Published data on the S. pneumoniae genome in two serotypes (types 2 and 4) shows 
that the rlrA islet is not present in serotype 2 but mgrA is. Work described here extends 
this finding further with the use of dot blots probing for genes in total chromosomal 
DNA from 8 different clinical isolates representative of all the serotypes included in the 
pneumococcal conjugate vaccine. The mgrA gene was present in all strains but the islet 
was only detected in 3 serotypes, 4,9V and 6B. Competition assays showed MgrA to be 
a virulence factor in the serotype 2 D39 strain that does not possess the rlrA islet. This 
indicates that MgrA does control other factors involved in causing disease in at least 
one non-serotype 4 strain. In contrast there was no evidence that MgrA controls factors 
other than the islet genes in serotype 4 as a serotype 4 AmgrA rlrA:: magellan2 double 
mutant showed no greater attenuation than the rlrA:: magellan2 single mutant as 
assessed by competition assays in mice. 
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Studies using lacZ fusion strains showed that oxygen and carbon dioxide levels affected 
the level of transcription of the rlrA and SrtD genes of the rlrA islet. This required the 
presence of mgrA indicating that MgrA was involved, at least in part, in this regulation. 
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CHAPTER 6 FUNCTION AND DISTRIBUTION OF THE RLRA 
PATHOGENICITY ISLET 
6.1 INTRODUCTION 
In the previous two chapters I have shown that two transcriptional regulators R1rA and 
MgrA are required for virulence in a murine model of pneumonia and nasopharyngeal 
carriage. Both are involved in regulation of transcription of the genes on the rlrA 
pathogenicity islet. It has been demonstrated that islet-encoded transcriptional regulator, 
R1rA, is a positive regulator of each of the genes in the islet and that MgrA, encoded by 
a gene outside the islet acts as a repressor of islet gene transcription. No other targets 
have been identified for either regulator. Interestingly the rlrA islet is not present in the 
chromosome of all clinical isolates of S. pneumoniae and it is likely that the islet was 
acquired by a serotype 4 strain by horizontal transfer from another S. pneumoniae strain 
or another Gram-positive species. This idea is further supported by the fact that it is 
flanked by two IS 1167 insertion sequences allowing integration of the element into the 
genome to have occurred by homologous recombination or a transposition event. Gram- 
positive bacteria in general are known to contain mobile elements (Butaye et al., 2003; 
Gentry-Weeks et al., 2002; Lindsay et al., 2001). The S. pneumoniae genome itself is 
rich in insertion sequences (ISs) which make up -5% of the TIGR4 chromosome, 
corresponding to >3.5% (84 out of 2236) of the genes in this organism (Tettelin et al., 
2001). However the majority of these insertion sequence elements appear to be non- 
functional due to additional insertions, deletions and point mutations resulting in frames 
shifting or degenerate transposase genes. It conceivable that the DNA transformation 
system in S. pneumoniae may allow conversion of disrupted insertion sequence 
elements to functional ones by homologous recombination. The same system does allow 
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uptake of extra-cellular DNA and homologous recombination into or around IS sites on 
the chromosome. S. pneumoniae, therefore, could change its genetic make-up from 
either transposition events or by homologous recombination and in this way possibly 
gain new virulence factors. If the rlrA islet is transferable between strains of S. 
pneumoniae, its transfer would provide a means for the acquisition of new virulence 
factors. Data presented in chapter five shows that the element has not only inserted into 
the genome but that the genes have become integrated into at least one regulatory 
network within S. pneumoniae serotype 4. Based on the islet's organization, internal 
regulation and its presence in only a subset of strains, I hypothesised that the islet 
element contains the information necessary to function in any strain of S. pneumoniae 
that acquires it without the need for additional genetic alterations and that the surface 
adhesins would be expressed and functional. 
Work presented in this chapter assigns an in vitro phenotype associated with the rlrA 
islet, demonstrates that transfer of the rlrA element to a strain lacking the islet can result 
in a gain of function and investigates the occurrence of in vivo islet transfer in a murine 
model of nasopharyngeal carriage. The distribution of the islet in clinical strains was 
also investigated further to look for any correlation between virulence and islet 
presence. 
6.2 RESULTS 
6.2.1 The rlrA locus is involved in binding a human lung epithelial cell line in 
vitro 
Three genes on the islet, rlrA, rrgA and srtD, are required for lung infection and/or 
nasopharyngeal carriage in mice (Hava and Camilli, 2002; Hava et al., 2003a). The 
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rrgA gene is predicted to encode for an MSCRAMM suggesting that it has a role in 
binding to extracellular matrix molecules. However, it does not possess classical 
fibronectin- or collagen- binding regions as characterized in other Gram-positive 
organisms (Cue et al., 2001; Jaffe et al., 1996). It does, however, possess other domains 
found in MSCRAMMS such as a Cna protein B-type domain and von Willebrand factor 
(vWF) type A domain (Figure 6.1). The Cna domain is found in Staphylococcus aureus 
collagen-binding surface proteins and is thought to form a stalk in the protein that 
presents the actual ligand binding domain away from the bacterial cell surface 
(Snodgrass et al., 1999). The vWF domain is found in various proteins of which a 
common feature is the involvement in multi-protein complexes. Proteins that possess 
the vWF type A domain participate in events such as cell adhesion, migration and signal 
transduction (Doliana et al., 1993). The sortase encoded for by the srtD islet gene 
selectively recognizes and attaches RrgA to the cell wall (Hava and Camilli, personal 
communications). The other two sortases encoded by islet genes recognize the two 
other surface proteins, RrgB and RrgC, and do not act on RrgA (Hava and Camilli, 
personal communications). Given the requirement for SrtD on RrgA cell wall anchoring 
it follows that rrgA and srtD mutants have similar phenotypes. 
The human lung epithelial cell line, A549, has been used extensively as a model of the 
S. pneumoniae host mucosal cell interaction (Cundell et al., 1995a). These cells were 
therefore chosen for analysis of the involvement of R1rA, RrgA and SrtD in bacterial 
adhesion to host mucosal surfaces. The ability of wild-type AC353 and isogenic strains 
(AC 1213, AC 1215, AC 1214) possessing transposon-insertions in each of the three 
genes (rlrA, rrgA and srtD respectively) to adhere to A549 cells, was analysed. The 
transposon insertions were not believed to have polar effects on other genes in the islet 
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Figure 6.1 RrgA sequence 
Amino acid sequence of RrgA. CnaB domains are highlighted in red and the 
vWF type A domain in blue. The sortase recognition YPXTG motif is 
highlighted in bold and is followed by a stretch of hydrophobic residues (yellow) 
and a charged tail. 
as the transposon was either in a singly transcribed gene (rlrA and rrgA) or the last gene 
of an operon (srtBCD), (Figure 7.1). Adhesion assays were performed as described in 
section 2.5.1. A549 cells were grown to - 90-95% confluence. In vitro grown bacteria 
were added to the monolayer at an MOI of 10: 1. An average of 0.3% of the input wild- 
type cells adhered to A549 cells. Appropriate negative controls were included to 
determine if bacteria adhered to the plastic surface of the well or the glass coverslip 
incubated with serum alone. No bacteria were recovered from PBS-washed wells that 
had not been seeded with A549 cells, but had been pre-incubated with culture medium, 
confirming that S. pneumoniae did not adhere to the wells or coverslips alone. All 
experiments were performed in quadruplicate and each experiment was replicated 5 
times on different days. Transposon insertions in rlrA and rrgA reduced binding of S. 
pneumoniae to the epithelial cell layer by 5- to 10-fold (Figure 6.2), suggesting that 
rrgA is important for interactions between TIGR4 and lung epithelial cells. The strain 
with a transposon insertion in srtD did not produce consistent results. Unlike the other 
strains, there was a high degree of inter-experimental variability for this strain. On three 
occasions srtD mutant binding was at wild-type level and twice binding was reduced to 
20-50% of wild-type. 
To ascertain if the islet has a similar role in another S. pneumoniae serotype that 
possesses the element, the binding of a wild-type serotype 9V strain (AC 1365) was 
compared to isogenic rlrA and rrgA mutants (CH 185 and CH 184 respectively). An 
average of 0.1 % of the input wild-type serotype 9V cells adhered to A549 cells. The 
overall level of binding was decreased in the 9V strain compared to the serotype 4 
strain, binding was similarly dependent on the presence of the R1rA regulator and RrgA. 
169 
A 
B 
120 
ö 100 { 
80 
y 60 
40 
20 
0 
AC353 AC 1213 AC 1215 
(wt) (rlrA) (rrgA) 
Strain (serotype 4) 
140 
. ci 120 j 
100 l 
80 
0 
60 1 
40 
20 
ýI ý ___ 
AC 1365 CH 185 CH 184 
(wt) (rlrA) (rrgA) 
Strain (serotype 9V) 
Figure 6.2 Adherence of serotype 4 and 9V S. pneumoniae strains to A549 
lung epithelial cells 
A549 monolayers were inoculated with (A) Serotype 4 strains AC353 (wild- 
type), AC 1213 (rlrA:: magellan2) and AC 1215 (rrgA:: magellan5) or (B) 
Serotype 9V strains AC1365 (wild-type), CH185 (rlrA:: magellan2) and 
CH 184 (rrgA:: magellan5) S. pneumoniae strains. Mid-exponential growth 
phase bacterial cells (lx 106CFU) were added to A549 cells at a multiplicity of 
infection of 10: 1 and incubated for 40 minutes. The percentages of bacteria 
that adhered to the monolayers after three washes with PBS were determined. 
Triton/EDTA was added to each well to detach the cells and liberate bacteria, 
which were then enumerated by plating lysates on blood agar plates. The 
adherence of each strain is expressed relative to the adherence of the wild-type 
(serotype 4; AC353 or serotype 9V; AC 1365). Representative results from one 
of three independent experiments are shown. The assay was performed in 
quadruplicate in each experiment and the error bars represent the standard 
deviations. 
Transposon insertions into rlrA and rrgA reduced the binding of S. pneumoniae to the 
epithelial cell layer by 10 to 20-fold of the wild-type level (Figure 6.2). 
Immunofluorescence microscopy was used as an alternative method to assess adherence 
of wild-type, rrgA and rlrA mutant strains to the monolayer. A549 monolayers were 
grown on glass coverslips in 24-well tissue culture plates. In vitro grown serotype 4 
bacteria suspended in Ham's F12K tissue culture medium plus 10% fetal bovine serum 
were added to the monolayer at an MOI of 10: 1. The plates were spun at 1000 rpm for 2 
minutes, to increase initial contact between bacteria and cells, then incubated for 40 
minutes at 37°C and 6% CO2 after which time the culture fluid was removed from each 
well, the monolayers were washed 3 times with PBS (pH 7.4) to remove non-adherent 
bacteria and fixed in 3% PFA in PBS. Bacteria were labeled using an anti-capsular S. 
pneumoniae primary antibody and a Cyanine-2 (Cy2)-conjugated donkey anti-rabbit 
secondary antibody. Epithelial cells were permeabilised with 0.1 % saponin in PBS and 
labeled with Rhodamine-conjugated phalloidin to detect F-actin. 
A control experiment was carried out to confirm that the centrifugal sedimentation of 
bacteria affected all strains similarly. Coverslips were removed after the centrifugation 
step, prior to incubation and the cells present on the coverslips were directly fixed and 
labeled. The number of bacteria per epithelial cell was counted. Adjusted was made for 
actual input number. Over 200 epithelial cells were examined. There was no difference 
between the number of wild-type, rlrA and rrgA mutant strains associated with host 
cells after centrifugation and prior to the 40 minute incubation (data not shown). 
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Over 200 epithelial cells were examined for S. pneumoniae binding after the period of 
incubation and subsequent washes and fixing. Similar to the results seen by counting 
recovered CFU, binding was dramatically reduced by inactivation of either rlrA or rrgA. 
The level of reduction calculated by this method was greater than by counting recovered 
CFU. Binding of S. pneumoniae was reduced 20- to 40-fold in AC 1213 (rlrA mutant) 
and AC 1215 (rrgA mutant) respectively (Figure 6.3). 
6.2.2 Binding to A549 cells is affected by MgrA 
Deletion of mgrA increases the expression of all seven islet genes in vitro. However this 
in vitro regulatory effect is inconsistent with the in vivo phenotype displayed by the 
AmgrA mutant (Table 4.1). One might predict that an AmgrA mutant would have an 
opposite in vivo phenotype to an rlrA mutant. This is not the case. Both are less 
proficient at causing pneumonia or carriage than wild-type bacteria. To determine if the 
level of transcriptional de-repression of the islet genes seen in the mgrA deletion mutant 
corresponded to a measurable phenotypic effect on bacterial adherence, the ability of 
wild-type, rlrA mutants (AC 1213 and AC 1278) and mgrA mutants (AC 1500 and 
AC 1481) to adhere to A549 cells was analyzed. All strains were grown in THY 0.8% 
maltose prior to infection of the A549 monolayer as this media was required for 
maximal expression of mgrA or rlrA in the over-expressing mutants. The four mutant 
strains exhibited either increased or decreased adherence compared to wild-type 
depending on the nature of the mutation. The transposon insertion in rlrA reduced 
binding of S. pneumoniae to A549 cells to 10% of wild-type and conversely over- 
expression of rlrA increased binding to 160%. Over-expression of mgrA reduced 
binding to 30% and deletion of mgrA increased binding to 140% of wild-type (Figure 
6.4). 
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Figure 6.3 Immunofluoresence microscopy of serotype 4 S. pneumon: iae 
strains adhering to A549 lung epithelial cells 
A549 monolayers were inoculated with AC353, AC 1213 (rlrA:: magell(1n2) 
and AC 1214 (rrgA.: magel/aus) S. pneuunoniae strains. Mid-exponential 
growth phase bacterial cells (I x 106 CFU) were added to A549 cells at a 
multiplicity of infection of 10 and incubated for 40 minutes. (A) Coverslips 
were fixed after three washes with PBS. Bacteria were labeled with anti- 
capsular antibody (green) and F-actin of epithelial cells were visualised by 
staining with Rhodamine-conjugated phalloidin after permeabilisation with 
0.1% saponin (red). (B) The number of bacterial cells per epithelial cell of 
each strain is expressed. Representative results from one of three independent 
experiments are shown. The assay was performed in quadruplicate in each 
experiment and the error bars represent the standard deviations. 
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Figure 6.4 Role of MgrA in adherence of S. pneumoniae to A549 cells 
A549 monolayers were inoculated with AC353, AC 1213 (r/rA:: nlagellan12), 
AC1478 (r/rA++), AC1500 (AingrA) or AC1481 (ingrA++) S. prei nnoniae 
strains. Mid-exponential growth phase bacterial cells (1x 106 CFU) were added 
to A549 cells at a multiplicity of infection of' 10 and incubated for 40 minutes. 
The percentages of bacteria that adhered to the monolayers after three washes 
with PBS were determined. Triton/EDTA was added to each well to detach the 
cells and liberate bacteria, which were then enumerated by plating lysates on 
blood agar plates. The adherence of each strain is expressed relative to the 
adherence of the wild-type. Representative results from one of three 
independent experiments are shown. The assay was performed in 
quadruplicate in each experiment and the error bars represent the standard 
deviations. 
These data show that the alteration of the islet gene expression by MgrA seen in vitro is 
correlated with a change in adherence phenotype of the pneumococcal strain. However 
this in vitro phenotypic change does not appear to correlate with the in vivo phenotype 
of reduced virulence. 
6.2.3 Acquisition of the rlrA islet results in increased binding to A549 cells 
Serotype 2 strain D39 does not contain the rlrA islet. Its ability to bind to A549 cells 
using the same protocol as for serotype 4 strains was therefore examined. There was 
negligible binding as assessed by CFU count or immunofluorescence microscopy 
(Figure 6.6). 
The region surrounding rlrA islet on the TIGR4 chromosome was compared to the 
corresponding region in the R6 (a derivative of D39) genome sequence. Identical 
regions to those flanking the rlrA islet and neighbouring IS elements in TIGR4 were 
found in R6. Corresponding genes on the two chromosomes are greater than 99% 
identical at the nucleotide level. Interestingly though, the R6 sequence does not contain 
an IS element at the rlrA islet locus. Instead there is a 686 bp sequence in R6 that is not 
present in TIGR4 (Figure 6.5). To determine if acquisition of the islet by a strain that 
did not possess it resulted in a change of phenotype the rlrA islet was transferred into 
D39 by transformation of competent D39 cells with chromosomal DNA from a serotype 
4 strain that had a transposon insertion in the rlrA proximal IS element. The presence of 
the transposon allowed for antibiotic selection of transformants that gained the IS 
element. The presence of the islet in D39 was confirmed by PCR using chromosomal 
and islet-specific primers for each end of integration (Figure 6.5). PCR products could 
be detected only if integration of the whole islet had occurred at that specific site. 
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Figure 6.5 Islet integration site 
(A) The site of r/rA islet integration in TIGR4 is shown compared to the 
comparable site in the R6 genome. Genes, indicated as arrows, of the same 
colour are identical at the nucleotide level. The grey line in R6 after p/i 
indicates a 686 bp sequence that is not present in the TIGR4 genome sequence. 
(B) PCR confirmation of the site of integration using primer sets (PFL/OUTPFL 
and XYL/OUTXYL, indicated as red lines) corresponding to each end of the 
islet were used to amplify the junction regions. 
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Figure 6.6 Immunofluoresence microscopy of serotype 2 S. pneumoniae 
strains adhering to A549 lung epithelial cells 
A549 nlonolayers were inoculated with D39 (wild-type), a serotype 2 strain 
possessing the islet CH226 (IS1167. ". nragellan5), CH232 (IS1167. ": mggeIlcm5 
rlrA:: rrrugellan2) and CH246 (rrgA:: magellan2) S. pnermroniae strains. Mid- 
exponential growth phase bacterial cells (1 x1 O' CFU) were added to A549 cells 
at a multiplicity of' infection of 10: 1 and incubated for 40 minutes. (A) 
Coverslips were fixed after three washes with PBS. Bacteria were labeled with 
anti-capsular antibody (green) and F-actin in epithelial cells were visualised by 
staining with Rhodamine-conjugated phalloidin after pemicabilisation with 
0. I r/r saponin (red). Short chains of S. pneumcmiae bacteria can be seen in 
green. (B) The number of bacterial cells per epithelial cell of each strain was 
calculated. The fold increase compared to wild-type D39 is reported. 
Representative results from one of three independent experiments are shown. 
The assay was performed in quadruplicate in each experiment and the error bars 
represent the standard deviations. 
Confirmation of whole islet transfer was also obtained by ability to PCR amplify each 
of the seven genes from transformants. 20 transformants were screened by PCR and all 
showed successful integration of the entire islet. Two of these were assayed for binding 
to A549 cells. Results for only one (CH226) are shown but are representative of both 
strains. Acquisition of the islet resulted in measurable binding to A549 cells (Figure 
6.6). The binding was dependent on the islet presence as determined by subsequent 
inactivation of the rlrA or rrgA gene (Figure 6.6). This shows that binding required 
intact islet genes and specifically rlrA and rrgA. 
Together these results indicate that the rlrA islet can integrate into the chromosome of a 
S. pneumoniae strain that does not normally contain it by homologous recombination 
under appropriate conditions. It contains adequate information to allow acquisition of 
the element to result in a gain in function as assessed by in vitro binding to A549 cells. 
This implies that the surface adhesins and sortases are successfully translated, processed 
and expressed on the bacterial cell surface. That the gain in function was not due to the 
acquisition of other, unrelated genes was excluded by showing that subsequent 
inactivation of rlrA or rrgA results in loss of or reduction in binding. 
To determine whether integration of the islet into the D39 genome was sufficient to 
allow integration into endogenous regulatory networks strains were constructed that 
possessed the islet but that also either had a deletion in mgrA (CH207) or over- 
expressed mgrA (CH216). Binding of these two strains to A549 cells was compared to 
that of wild-type D39. There was no conclusive evidence in these assays that the 
endogenous MgrA regulator affected transcription of the newly acquired islet genes as, 
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unlike in AC353 (Figure 6.4), inactivation or over-expression of mgrA in the serotype 2 
background did not significantly affect binding to A549 cells (Figure 6.7). 
6.2.4 Acquisition of the rlrA islet results in increased virulence 
I wished to determine if islet acquisition also led to a change in virulence. Wild-type 
D39, a mutant with the whole islet integrated into the chromosome (CH226) and a 
strain isogenic to CH226 but with the rlrA gene inactivated (CH232) were used in 
competition assays. Three experiments were performed in each of two murine models 
(assessing pneumonia and nasopharyngeal carriage). D39 was competed against CH226 
or CH232 and CH226 was competed against CH232. 
CH226 out-competed D39 in both models of infection consistent with acquisition of the 
locus resulting in increased virulence in a pneumonia model and a more successful 
carriage phenotype (Figures 6.8 (A) and (B)). This gain in function appeared to be due 
to the presence of the islet as inactivation of the rlrA gene encoding the transcriptional 
regulator reversed the phenotype (Figures 6.8 (A) and (B)). 
6.2.5 In vivo transfer of the islet 
The nasopharynx contains many different bacterial species including pathogenic and 
non-pathogenic organisms (Kononen et al., 2002). There is likely to be inter-species 
and intra-species competition for colonization and growth. The nasopharynx potentially 
provides an environment conducive to inter- and intra-species transfer of genetic 
material. The rlrA islet may have been acquired from another Gram-positive species or 
another strain of S. pneumoniae resulting in increased fitness with respect to colonizing 
ability. The presence of the rlrA islet in only a small subset of S. pneumoniae suggests 
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Figure 6.7 Effect of MgrA on adherence of serotype 2 S. pneumoniae 
strains to A549 lung epithelial cells 
A549 monolayers were inoculated with D39 (wild-type), CH207 (AmgrA), 
CH216 (mgrA), a serotype 2 strain possessing the locus CH226 (IS1167:: 
magellan5) and mgrA mutant strains of CH226, CH244 (CH226 AmgrA) or 
CH254 (CH226 mgrA++) S. pneumoniae strains. Mid-exponential growth phase 
bacterial cells (lx106 CFU) were added to A549 cells at a multiplicity of 
infection of 10: 1 and incubated for 40 minutes. The percentages of bacteria 
that adhered to the monolayers after three washes with PBS were determined. 
Triton/EDTA was added to each well to detach the cells and liberate bacteria, 
which were then enumerated by plating lysates on blood agar plates. The 
adherence of each strain is expressed as a fold increase relative to binding of 
wild-type D39 cells. Representative results from one of three independent 
experiments are shown. The assay was performed in quadruplicate in each 
experiment and the error bars represent the standard deviations. 
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Figure 6.8 Competition assays for D39 strains - (A) pneumonia and (B) 
Nasopharyngeal carriage 
Competition assays were performed using a murine model of pneumonia. Wild- 
type D39, a mutant with the whole islet integrated into the chromosome (CH226) 
and a strain isogenic to CH226 but with the rlrA gene inactivated (CH232) were 
used. The in vivo competition index (CI) was calculated; each circle represents 
the CI for a single mouse in each set of competitions. A CI of less than 1 
indicates a virulence defect, a CI of greater than 1 indicates that the mutant out- 
competes the wild-type strain and a CI of 1 indicates that both strains are equal. 
The geometric mean of the CIs for all mice in a set of competitions is shown as a 
solid line. The CI marked with an asterix were statistically different to 1.0 
(*p<0.05). 
that it may have been acquired late in the evolutionary history of the organism or that it 
does not confer a selective advantage to all strains during interactions with the human 
host. To determine if inter-species transfer of the rlrA islet can occur in vivo, mixed 
infections in a murine model of carriage were performed. Mice were inoculated with a 
combination of two S. pneumoniae strains; one serotype 4 strain possessing an 
antibiotic-resistant marked islet (SpcR) and a second differently antibiotic resistant- 
marked serotype 2 strain (Sm'). This second strain does not possess the islet. Five mice 
were inoculated with -5x 107 CFU on day 0 with a 1: 1 ratio of the serotype 4 and 
serotype 2 strains. On day 7 they were euthanased and bacteria harvested from 
nasopharyngeal washes. Serial dilutions of these washes were plated onto blood agar 
plates supplemented with streptomycin (Sm). 10014g ml-' or spectinomycin (Spc) 200 
ssg ml` or both antibiotics. Acquisition of the islet by the serotype 2 strain or acquisition 
of SmR by the serotype 4 strain would be detected by a Spc Sm resistant phenotype, islet 
presence was confirmed by PCR and serotype of the Spc Sm resistant strain was 
determined by Quellung reaction. A competitive index for colonization was calculated 
as well as the proportion of any Sm Spc resistant bacteria. The serotype 2 strain was 
completely out-competed by the serotype 4 strain (CI < 0.001). No SmR Spc' colonies 
were obtained from three of the mice. 2 and 3 doubly resistant colonies were obtained 
from each of the other two mice, equating to -1 per every 104 - 103 bacteria in the total 
output. However each isolate was shown to be serotype 4 by Quellung reaction. This 
phenotype could result from spontaneous point mutation in the native rpsL gene 
resulting in streptomycin resistance, or from in vivo transfer of the mutated rpsL gene 
from serotype 2 to serotype 4 strains. 
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Given that the serotype 4 strain was more successful in colonizing than the serotype 2 
strain a second experiment with altered input ratio in favour of the serotype 2 strain was 
performed. Five mice were inoculated with -5x 10' CFU with an input ratio of 10: 1 
(serotype 2: serotype 4). No doubly resistant colonies were isolated on the output plates. 
Colonies from both serotypes were isolated but the serotype 2 was again out-competed 
150 fold by the serotype 4 strain (CI. = 0.0064). There was no evidence of inter-strain 
transfer of the islet in the experiments described above. 
6.2.6 Distribution of the islet amongst clinical isolates and correlation with 
invasion and carriage 
An initial screen has shown that the r1rA islet is present in only a proportion of clinical 
isolates of S. pneumoniae (Figure 5.6). Given that three of the islet genes are known to 
encode virulence factors and experiments described above indicate that transfer of the 
islet into a strain that does not normally harbour it leads to a gain in function as assessed 
by binding to A549 cells and murine models of pneumonia and carriage I wanted to 
examine the distribution of the islet in clinical isolates and to determine if there was any 
correlation between presence of the islet and virulence. 
A collection of 501 S. pneumoniae isolates from children <5 years old in Oxford has 
been built up over 8 years (1995-2003) (Brueggemann et al., 2003). One hundred and 
fifty isolates were obtained from children with invasive disease and 351 isolates are 
from three longitudinal studies of pneumococcal carriage. This collection has been 
previously characterised for sequence type by multilocus sequence typing (MLST) 
(Brueggemann et al., 2003; Enright and Spratt, 1998; Meats et al., 2003). Genomic 
DNA was obtained from a selection of isolates from this collection. These were 
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screened for the presence of islet by dot blot hybridization using a control probe to rpoB 
and a test probe to rlrA. The rpoB probe was used as a control to demonstrate the 
presence of non-significantly divergent DNA. The same strains were also tested by 
PCR for the presence of both these genes and two other islet genes, srtD and rrgA. The 
samples were allocated random numbers in Oxford to avoid any knowledge of serotype 
affecting interpretation of the dot blot and PCR results. These were un-blinded after 
completion of all the experiments. There was an excellent correlation between the dot 
blot and PCR results. There were no discrepant PCR results consistent with the presence 
of the primer sequences in each gene among different isolates. 
The data from the invasive strains, representative of the serotypes covered by the 
pneumococcal conjugate vaccine (Figure 5.6), indicated that the locus is only present in 
a proportion of serotypes. As only one strain in each serotype was examined it was not 
possible to say whether islet presence was serotype-specific or randomly distributed 
across strains of all serotypes. To test the hypothesis that islet presence was indeed 
serotype-specific clinical isolates of serotypes 4,9V and 9N were examined more 
closely. The Oxford collection contained six serotype 4 strains (5 isolated from children 
with invasive disease and 1 from nasopharyngeal carriage) and 15 serotype 9V strains 
(7 invasive and 8 carriage strains), 6 serotype 9N. These strains were selected for study. 
9N is genetically closely related to 9V, strains (1 invasive and 5 carriage) and were 
taken for comparison. Examination of these isolates would also help determine if islet 
presence was associated with invasion or not. All serotype 4 strains were positive for 
islet presence, no serotype 9N haboured the islet and 13 out of 15 9V isolates were 
positive for the islet. The two 9V strains that did not habour the islet had the same 
MLST sequence type (ST), which was different from the rest of the 9V isolates. 
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Table 6.1 Islet distribution amongst S. pneumoniae isolates: serotypes 4,9V and 
9N 
Serotype Sr Total" Invasive" Carriage" Islet presence 
4 205 4 3 1Y 
206 1 1 Y 
246 1 1 Y 
9V 162 96 3 Y 
163 21 1 Y 
406 2 2 N 
407 2 2 Y 
9N 66 615N 
405 11N 
' MLST sequence type 
b Data are number of isolates 
These data are consistent with the hypothesis that islet presence associates with ST. 
However from previous characterization of isolates in this collection it is known that 
isolates of closely related STs commonly have the same serotype and hence islet 
presence would also associate with serotype. 
Next a greater number of isolates were screened. Three isolates from each of the 13 
most commonly found serotypes (excluding serotypes 4,9V and 9N) were examined. 
Isolates were randomly selected for ST and invasive or carriage site collection. Only 
two further serotypes were found to possess the islet taking the total number of 
serotypes to five; 4,6B, 9V, 19F and 38 (Table 6.2). 
An empirical odds ratio (OR) was calculated to compare the probability of invasive 
disease due to strains possessing the islet to those without the islet to determine if there 
was a correlation between site of isolation of the strain (invasive or carriage) and islet 
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presence. Results from all isolates or only isolates from serotypes that harboured the 
islet were analysed. The OR was calculated using a method published elsewhere (Smith 
et al., 1993). An OR of 1 indicates that the islet was equally likely to be found in an 
invasive isolate or carriage isolate, an OR >1 indicates an increased probability for the 
islet to be found in invasive isolates, and an OR <I indicates a reduced probability for 
the islet to be found in invasive isolates. Islet presence was not significantly associated 
with invasive disease (Table 6.3). 
Table 6.2 Islet distribution amongst S. nneumoniae isolates 
Serotype STa Total" Invasive`' Carriage' Islet 
presence 
1 227 3 2I N 
3 180 2 2 N 
458 1 1 N 
6A 65 1 1 N 
395 1 1 N 
457 I I N 
6B 138 I I Y 
176 1 I Y 
273 1 I Y 
7F 191 3 2I N 
8 53 3 12 N 
14 9 2 I1 N 
124 I I N 
15B/C 411 2 II N 
412 I I N 
18C 113 2 2 N 
120 1 I N 
19A 172 1 I N 
193 1 1 N 
417 1 1 N 
19F 43 1 I N 
420 1 1 y 
426 1 1 Y 
23F 36 1 I N 
40 1 I N 
311 I I N 
33F 60 3 2I N 
38 310 2 11 Y 
393 1 1 Y 
e MLST sequence type, "Data are number of isolates. Serotypes that possess the islet are 
highlighted in grey 
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Table 6.3 Association of islet presence and invasive disease 
Invasive' Carriage' ORb CIC P value 
(%) (%) 
All strains 14 (47) 13 (33) 1.8 (0.6-5.4) 0.3d . 
(n=70) 
Strains with 14(93) 13 (87) 2.2 (0.1-68) 0.50 
islet (n=30) 
Data are numbers of isolates that possess islet. The percentage of the total carriage or 
invasive strains is reported in parentheses. " Odds ratio (OR). ` Cornfield 95% 
confidence interval. d Yates corrected test of significance used. ` Fisher exact test of 
significance used 
6.3 ' SUMMARY 
In this chapter several approaches were taken to investigate the physiological 
significance of rlrA islet presence. Presence of the islet in TIGR4 was associated with 
an ability to bind to A549 cells in vitro. This binding was dependent on expression of 
islet genes and more specifically on the presence of rrgA. The islet could be transferred 
to D39 in vitro and resulted in integration into the genome at the equivalent site to that 
which it is found in TIGR4. Integration into the genome was sufficient to result in a 
change in phenotype of the S. pneumoniae strain to one of increased binding to A549 
cells and also increased carriage ability and virulence in murine models of carriage and 
pneumonia. The hypothesis that integration into the genome was also sufficient to allow 
regulation of islet genes by endogenous chromosomal based transcriptional regulators in 
addition to the islet encoded regulator was tested by inactivation of mgrA in the islet 
transformed D39 background but results were inconclusive. In vivo transfer of the islet 
in a murine model of carriage could not be demonstrated. Finally the distribution of the 
islet amongst clinical isolates was examined. An empirical odds ratio (OR) was 
calculated to compare the probability of invasive disease due to strains possessing the 
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islet to those without the islet to determine if there was a correlation between site of 
isolation of the strain (invasive or carriage) and islet presence. The results did not reach 
statistical significance and hence I was unable to obtain convincing evidence for any 
association. 
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CHAPTER 7 DISCUSSION 
Analysis of virulence factors used by S. pneumoniae is essential for our understanding 
of the molecular mechanisms underlying the pathogenesis of disease. Identification and 
functional analysis of virulence genes and their protein products not only furthers our 
general understanding of mechanisms involved but can also provide us with specific 
knowledge that can be used in the development of antimicrobials or vaccines. An 
important goal would be to understand the timing and signals for expression and 
activation of every virulence factor and how virulence gene expression is co-ordinated 
in relation to other cellular processes. In this way it would become apparent which are 
the crucial steps to invasive disease and hopefully pin-point areas that are amenable to 
manipulation with a view to preventing and treating disease. With advances in 
molecular biological tools and techniques it is conceivable that this type of, goal is 
attainable. 
The first part of this study describes attempts to adapt a recombination- based in vivo 
expression technology (RIVET) for use in S. pneumoniae with the view of examining 
the timing of virulence gene expression. The latter parts of the study focus on the 
investigation of the roles of specific transcriptional regulators in virulence gene 
expression. The work provides further evidence that virulence determinants are not 
evenly distributed amongst strains of S. pneumoniae. It appears that different strains 
vary both in their quota of virulence factors and their regulation. 
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7.1 S. PNEUMONIAE AND RIVET 
At the time of initiation of this project our knowledge of expression of virulence factors 
and their regulation in S. pnemoniae was minimal. Studies in other pathogens such as V. 
cholerae and B. pertussis had given us some evidence that virulence factors show 
distinct patterns of expression in terms of timing and site of expression in vivo (Lee et 
al., 1999) and that the exact timing is important if not crucial to appropriate disease 
progression (Akerley et al., 1995). 1 hypothesized that this is similar in S. pneumoniae 
and with the goal of examining the expression of a known virulence factor, 
pneumolysin, I attempted to adapt the RIVET system for use in S. pneumoniae using a 
ply:: tnpR transcriptional fusion. This would have enabled me to determine the timing of 
ply gene induction in vitro initially and then during the course of a murine infection. 
Preliminary experiments showed that ply transcription was regulated over the course of 
in vitro growth, as determined by measurement of transcript levels (Figure 3.2). ply 
transcript was detectable even at early stages of growth and there was an increase in 
levels during exponential phase of growth. This was consistent with previous findings 
that cytoplasmic and extracellular Ply activity during growth in vitro is not normally 
detectable until late log phase (Benton et at., 1997). However this result could not be 
repeated by screening for resolution over the course of in vitro growth with RIVET 
constructs using a ply:: tnpR niot3S reporter in an S. pneumoniae strain that possessed the 
resolvase substrate cassette elsewhere on the chromosome. Resolution was not 
detectable in vivo during the course of a murine pneumonia infection either. 
Two possible reasons for failure of the initial RIVET constructs in S. pneumoniae, 
could have been due to a lack of a resolvable cassette or insufficient resolvase 
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production. The cassette was shown to be functional in an E. coli background (Figure 
3.4) and there was read-through transcription from the ply gene to tnpR mut135 as assessed 
by presence of a tnpR transcript in RNA extracts from the S. pneumoniae fusion strain 
(Figure 3.5). Attention was turned to assessment of production of the resolvase protein. 
One of the main drawbacks of IVET and RIVET as they were first described is that to 
detect induction of transcription in vivo any transcriptional fusion needs to be silent in 
vitro. Thus genes that are transcribed in vitro will be excluded from use even if they are 
further induced in vivo and play a pivotal role in infection. The beauty of the resolvase 
based version of IVET (or RIVET) is that it has shown that it can be adapted to 
overcome the problem of baseline transcription in vitro by alteration the translational 
efficiency of the tnpR mRNA (Lee et al., 1999; Lee et al., 2001). The RIVET system 
relies on production of sufficient resolvase, encoded by tnpR, to act on its substrate, an 
antibiotic resistance gene-containing substrate cassette, resulting in excision of a 
cassette from the genome (Figure 3.1). If a tnpR allele with a less efficient RBS is used 
in the fusion, less resolvase is produced for any level of transcription. There will be a 
threshold at which increased transcription will result in adequate enzyme production to 
give resolution, but below which there is insufficient enzyme to allow resolution. As- 
there was detectable ply transcription during in vitro growth the initial ply S. 
pneumoniae reporter strain was constructed with a tnpR allele (tnpR mu`l33) with reduced 
translational efficiency. It was possible that this reduced translation to such an extent 
that insufficient enzyme was produced to support resolution in the conditions tested. 
Supporting this hypothesis was the evidence that there was no detectable resolvase 
protein present in cell extracts from in vitro grown S. pneumoniae fusion strains (Figure 
3.5). This was not alleviated by replacement of the mutant tnpR m°"35 with a tnpR allele 
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that possessed an improved RBS (Figure 3.6) indicating that the lack of translation was 
not secondary to an inadequate ribosomal binding to initiate transcription. 
RIVET was initially demonstrated in a Gram negative bacterial background (Camilli et 
al., 1994; Camilli and Mekalanos, 1995). The resolvase gene was isolated from the 
Gram negative bacterial transposable element Tnyö, which is one of a family of 
transposons that are related to TO (Heffron, 1983). Although the majority of studies 
using the system had been in Gram-negative pathogens, it had been used successfully to 
identify in vivo induced genes in one Gram-positive organism, Staphylococcus aureus 
(Lowe et al., 1998). In this study the RBS site of the tnpR had to be replaced with a 
Gram-positive homologue to improve the translation of the resolvase in S. aureus. It 
was surprising therefore that this technique had not worked in S. pneumoniae. Codon 
usage has been shown to be important in determining translation rates in bacteria 
(Sorensen et al., 1989). Analysis of the codons in tnpR compared to usage within the 
pneumococcal genome identified 20 out of the total 184 codons of tnpR that were 
atypical and rarely used in S. pneumoniae (Figure 3.7). This number could be sufficient 
to abolish tnpR mRNA translation. In E. coli abolishment of rare codons and 
replacement with more common ones can alter mRNA translation to such a degree as to 
eliminate some post-transcriptional regulatory effects (Kuhar et al., 2001). Alteration of 
the nucleotide sequence of the tnpR gene to abolish rare codons throughout the gene and 
replace them with more frequently used ones resulted in detectable resolvase protein in 
whole protein extracts from in vitro grown strains of S. pneumoniae (Figure 3.10). This 
is consistent with the hypothesis that the codon usage in the native tnpR gene was not 
optimal for translation in S. pneumoniae. Yet despite the presence of resolvase in 
quantities comparable with those. seen in AC311 (Figure 3.10), a V. cholerae strain 
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harbouring vieS':: tnpR fusion and a res-tet-res cassette, that showed 100% resolution, 
resolution was only detectable in 30% of the S. pneumoniae tnpR fusion strains (Figure 
3.11). Levels of resolution in vivo were even less (Figure 3.11). 
Two forms of the protein were repeatably recognised by the anti-resolvase antibody in 
protein extracts from the tnpR fusion strains (Figure3.9) that were not clearly present in 
purified resolvase preparations or in AC311 (Figures 3.5,3.6 and 3.10). The reason for 
this is unclear. Resolvase is a 21 kDa protein that is composed of two structurally and 
functionally distinct domains. The C terminal domain has DNA binding activity and 
binds to sequences within the res sites. The N terminal domain mediates 
multimerisation of the enzyme. The active form of the enzyme usually consists of a 
dimer (Hatfull and Grindley, 1988). Both the monomer and dimer were apparent on 
SDS-PAGE gels of the purified protein (data not shown). The second protein 
recognized by anti-resolvase antibodies in the S. pneumoniae tnpR fusion strains was 
between 22 and 25 KDa in mass and as such did not represent a dimer. It is not known 
if this higher molecular weight protein represents an abnormal non-functional resolvase 
secondary to translation initiation at an alternative start codon, post-translational 
modification or purely an artifact of the gel production. If it is a non-functional 
resolvase-like protein that was able, to bind res sites and/or dimerise with functional 
resolvase, thus blocking the action of the usual form of the enzyme, it is conceivable 
that this dominant-negative activity could explain the lack of high levels of resolution 
seen in the S. pneumoniae fusion strains. Some credence is given to this hypothesis by 
the observation that increasing the amount of resolvase present, as determined by 
Western blots (Figure 3.10) resulted in a trend towards reduction in amount of 
resolution (Figures 3.1 IA). Though not statistically significant, there was also a trend 
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towards decreasing levels of resolution with increasing concentrations of maltose in the 
same strain (Figure 3.11) but it is not clear if this is secondary to increasing levels of 
TnpR expression or an independent affect of increasing maltose concentrations. 
Increasing TnpR could cause a reduction in resolution if the ratio of dominant negative 
to wild-type TnpR were to increase. It would be interesting to perform Western blots for 
resolvase enzyme on protein extracts from the MaIM:: tnpRM fusion strain (CH 102) 
grown in increasing concentrations of maltose and quantitate the dose-response. This 
would confirm whether a reduction in resolution is associated with more or less 
resolvase production. If the former were true then this would be further evidence for a 
dominant negative effect from a second form of the enzyme. 
The work presented in chapter one raises as many questions as it answers with respect 
to adaptation of RIVET for use in S. pneumoniae and reasons for failure. More 
experiments could be designed to investigate the problem further but from the 
perspective of the project and aim of investigating expression of virulence genes in this 
organism it was decided that this would not be beneficial to proceed with these 
experiments as there was no guarantee that a useful system could be developed, and 
hence work on RIVET was ceased. 
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7.2 CHARACTERISATION OF THE VIRULENCE DEFECT SEEN WITH 
INACTIVATION OF TRANSCRIPTIONAL REGULATORS 
IDENTIFIED BY STM 
The second part of this study focuses on transcriptional regulators identified by an STM 
screen and investigation of their role in virulence in murine models of S. pneumoniae 
disease. There is good evidence that regulation of gene transcription is important in 
virulence in S. pneumoniae. This is not surprising, as one would predict that the 
pathogen would have mechanisms to control virulence factor expression at the levels of 
gene transcription and translation, as well as regulating post-translation modifications to 
alter protein activation status. 
Evidence for the importance of transcriptional regulators in virulence in S. pneumoniae, 
that was available at the conception of this thesis project, came from STM screens and 
work following on from genomic searches to identify TCSTS in this pathogen. Three 
large scale STM screens in S. pneumoniae had been published (Hava and Camilli, 2002; 
Lau et al., 2001; Polissi et al., 1998). Two report the identification of factors involved 
in regulation of gene transcription that are required for virulence in murine- models 
(Hava and Camilli, 2001; Lau et al., 2001). Two separate genomic searches had 
identified the genes in the S. pneumoniae encoding 13 TCSTS genome, many of which 
were also highlighted in the STM screens, and assessed their role in virulence. None 
were required for virulence in serotype 3 or 22 S. pneumoniae (Lange et al., 1999) in a 
septicaemia model, but eight have been shown to be required for full virulence in 
serotype 3 S. pneumoniae in a murine model of pneumonia (Throup et al., 2000) and of 
these one is also required for efficient nasopharyngeal carriage in newborn rats in 
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serotype 3 S. pneumoniae (Sebert et al., 2002). 1 hypothesized that genes identified in 
the. STM screens that were predicted to encode proteins with a regulatory function, 
either isolated transcription regulators or TCSTS, controlled the transcription of known 
virulence genes and yet unidentified virulence genes. 
I confirmed that 5 genes encoding probable transcriptional regulators identified in one 
of the STM screens (Hava and Camilli, 2002) are indeed required for virulence as 
assessed by competition assays against wild-type bacteria (Table 4.1). Three genes, 
sp1800 or MgrA, sp0461 or rlrA, and sp0247, encode transcriptional regulators. Two, 
sp0661 and sp0156, encode components of TCSTS. Mutant strains with deletions or 
transposon insertions in each gene under study were tested in three different murine 
models; pneumonia, bacteraemia and nasopharyngeal carriage. The mutants show 
varying attenuation in the three models. CH 107 (sp0247:: magellan2) was attenuated to 
some degree in all 3 models, CH 119 (t spO661) is attenuated in lung and bacteraemia 
only, AC 1213 (rlrA:: magellan2) and AC 1500 (AmgrA) in lung and carriage only and 
CH108 (sp0156:: magellan2) in lung only. The requirement for virulence, therefore, is 
dependent on the type of infection and model used. This is consistent with the 
hypothesis that the regulators control the transcription of genes whose products are 
required in specific host environments and are important in adaptation to the different 
environments that the bacteria encounter during host infection or colonization. 
These data support the results from the STM screens and the studies on TCSTS, which 
also found varying attenuation in different disease models. The data for sp0661, 
however, is not fully consistent with the results from these published works. This gene 
encodes the response regulator TCS09 (nomenclature of Lange et al, (Lange et al., 
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1999)). In the thesis work presented here, the serotype 4 S. pneumoniae sp0661 
deletion-mutant was attenuated in both a pneumonia and a septicaemia model (Table 
4.1). The mutant was not impaired in in vitro growth (data not" shown). Lange and 
colleagues created knockout mutations in the genes encoding the same response 
regulator of TCS09 of serotype 3 and serotype 22 S. pneumoniae strains and found no 
difference in virulence between the mutant and wild-type strains in a similar murine 
septicaemia model. The infecting dose was similar in both studies but the strain of 
mouse, C57BL6/J (Lange et al., 1999) or Swiss Webster (this work), and the S. 
pneumoniae serotypes were different. The genetic background of the bacterial strain or 
the mice, or a combination of both may have resulted in the discrepancies observed 
(Gingles et al., 2001). The former certainly appears to be plausible. The contribution to 
the virulence of S. pneumoniae of the gene encoding the same response regulator (rrO9) 
was shown to be bacterial strain-dependent in a further study (Blue and Mitchell, 2003). 
Here rrO9 was found to be essential for virulence in D39 (serotype 2 strain) but not in a 
serotype 3 strain, when inoculated into MF 1 mice by the intra-peritoneal route. This 
strain difference suggests that the TCSTS, Rr09/HkO9, has different gene targets in 
genetic backgrounds. 
However there may be another explanation. The original serotype 4 sp0661 transposon- 
insertion mutant (STM90) was attenuated in a pneumonia model but did not show 
attenuation in a septicaemia model (Table 4.1 and (Hava and Camilli, 2002)). The 
transposon was not within the open reading frame of sp0661 but 21bp upstream of the 
predicted ATG start codon. It is possible that this transposon insertion disrupts spO661 
expression resulting in either expression at inappropriate times or in inappropriate 
quantities. Alternatively the transposon insertion may exert polar effects on other genes 
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in the operon, including sp0662, encoding the histidine kinase component of the 
TCSTS. The deletion mutant used in this thesis work had an unmarked, in-frame 
deletion resulting in fusion of the ATG start codon to the last 206 bp of the sp0661 open 
reading frame. This 206 bp contained the RBS and first 6 bp of the open reading frame 
for sp0662, Thus, the unmarked deletion mutant should result in preservation of sp0662 
transcription and translation. Although the genes encoding this response regulator (RR) 
and the histidine kinase (HK) lie adjacent to each other on the chromosome and are 
predicted to be part of the same TCSTS it is possible that their transcription is 
differentially regulated, with a promoter lying within the coding region of sp0661, or 
that the HK, once activated, could activate another RR aside from SP0661. Similarly 
SP0661 could be activated by a second HK. There are several examples of such cross 
talk between TCSTS (Li et al., 1995; Msadek, 1999). Disruption of both components 
may therefore have an overall different effect than disruption of one alone and could 
explain the variation in virulence phenotype between different mutants. 
The two strains with transposon insertions in or around mgrA from the STM screen 
(STM206 and AC 1272) and the mgrA deletion strain from this work (AC 1500) also had 
slightly different phenotypes in competition assays (Figure 4.2 and Table 4.1). A 
transposon insertion 300 bp upstream of the start site (STM206) had the greatest effect 
on virulence. RPA (data not shown) probing for mgrA transcript in the three mutants 
showed that there was no detectable mgrA transcript in either the deletion mutant or 
mutant with the transposon inserted into the coding sequence, but a transcript of a larger 
size than that seen in the wild-type strain was detectable in the mutant with the 
transposon insertion upstream of the mgrA start site. It is possible that in this latter 
strain the transposon insertion leads to disregulation of mgrA due to read-through 
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transcription from the transposon or effects on protein binding to the mgrA promoter 
region. This hypothesized inappropriate gene expression may be more detrimental than 
an actual gene knockout. Alternatively, I have not excluded the possibility that the 
upstream transposon insertion also has effects on the putative open reading frame in the 
opposite direction, sp1801-1805, and that these gene products are required for virulence 
(Figure 4.2). 
7.3 RLRA IS A TRANSCRIPTIONAL ACTIVATOR PRESENT ON A 
PATHOGENICITY ISLAND 
Having assessed the requirement for different transcriptional regulators in murine 
infection, experiments were performed to identify which virulence genes they were 
controlling. Transcriptional regulators often lie adjacent to their target genes on the 
chromosome but they may also regulate distant genes. The mutants with transposon 
insertions in genes spO461 and sp1800, renamed rlrA (encoding $ofA-like regulator 8) 
and mgrA (encoding frjga-like repressor Q), are attenuated in models of pneumonia and 
nasopharyngeal carriage. Neither appear to be essential for virulence in a septicaemia 
model, suggesting that the products of these two genes are required for regulation of 
factors that interact with the mucosal surfaces of the respiratory tract. 
Both of these genes are predicted to encode proteins with similarity to transcriptional 
regulators in GAS (S. pyogenes). Sp0461 encodes a protein similar to RofA and Nra 
(Fogg et al., 1994; Podbielski et al., 1999) and sp1800 encodes a protein that is similar 
to the multiple gene regulator, Mga (McIver and Scott, 1997; McIver and Myles, 2002). 
In GAS Mga and RofAINra regulate transcription of virulence genes encoding primarily 
199 
surface-associated products, many of which lie adjacent to the regulator on the 
chromosome. 
Analysis of the S. pneumoniae rlrA mutant using RPAs revealed that it is a 
transcriptional activator of itself and neighbouring genes on the chromosome (Figure 
4.5 and (Hava et al., 2003a)). The products of the target genes are predicted to be cell 
surface-associated and as such capable of affecting bacterial-host interactions at 
mucosal surfaces. RIrA is divergently transcribed from three genes encoding cell wall 
anchored proteins and three encoding sortases. The gene organization is shown in 
Figure 4.1. RPAs were used to measured steady state levels of each of these six adjacent 
genes in wild-type and rlrA mutant strain. The message was found to be decreased in 
the mutant strain as compared to the wild-type (Figure 4.5). The level of decrease varied 
for each gene in a pattern consistent with the hypothesis that RITA binds to and 
regulates three promoters, one controlling rrgA, a second rrgBC and a third srtBCD. 
This has subsequently been confirmed by primer extension analysis and DNAse I foot- 
printing (Hava et al., 2003a). 
The organization and functional analysis of this 12-kb region of DNA containing rlrA 
and its targets indicates that it represents a PAI in S. pneumoniae. A PAI is minimally 
defined as a multi-gene region of the genome, which is absent or sporadically 
distributed in non-pathogenic close relatives and that carries one or more virulence 
factors. The overall nucleotide composition of the island often differs from the core 
genome in G+C content and codon usage, reflecting the acquisition of PAIs by inter- 
species horizontal gene transfer. PAls are often flanked by sequences defining the 
edges, such as direct repeats that could arise from integration of a transposon or 
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bacteriophage (Hacker et al., 1997; Hacker and Kaper, 2000). The rlrA region fulfils 
some of these criteria. RIrA is divergently transcribed from the six genes that it 
regulates (sp0462 - sp0468). This whole region is flanked by two IS 1167 insertion 
sequences, which defines the islands edges. Three of the seven genes, sp0461, sp0462 
and sp0468, are required for virulence in serotype 4 S. pneumoniae (Hava and Camilli, 
2002; Hava et al., 2003a) and the island is absent in many S. pneumoniae strains 
[(Tettelin et al., 2001) and Figure 5.7). The G+C content of the island is not 
significantly different from the S. pneumoniae genome as a whole but a G+C difference 
between island and genome may not be observed if the DNAs of the donor of the PAI 
and the recipient have a similar G+C content. It is possible that the island was acquired 
by S. pneumoniae from another streptococcal species such as S. agalactiae. Sequence 
similarity searches using the BLAST program (http: //www. ncbi. nlm. nih. gov/blast/) 
identified a region in Streptococcus agalactiae that had a similar organization, namely a 
gene encoding transcriptional regulator divergently transcribed from three encoding cell 
wall anchored proteins and three encoding sortases. Many of these genes (SAG0644 - 
SAG0649) share small regions of sequence similarity to spO461 - sp0468 of S. 
pneumoniae. 
One other pathogenicity island, PPI1, has been formally described in S. pneumoniae 
(Brown et al., 2004; Brown et al., 2001). This 27-kb region contains piaABCD, 
encoding an iron transporter, and 28 other genes, some of which have been shown to 
encode virulence factors (Brown et al., 2004). The rlrA island will therefore be referred 
to as PPI2. There are undoubtably more PAIs to be identified and characterised in this 
pathogen. As different S. pneumoniae serotypes differ by as much as 10% in gene 
composition, PAIs may in fact compose a major fraction of the genome. 
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7.4 MGRA IS A TRANSCRIPTIONAL REPRESSOR OF GENES OF PPI2. 
Mga, of GAS, activates the transcription of several genes encoding cell surface- 
associated virulence factors involved in S. pyogenes pathogenesis, including the M 
family of proteins, C5a peptidase, serum opacity factor and secreted inhibitor of 
complement (Caparon and Scott, 1987; Chen et al., 1993; Kihlberg et al., 1995; 
McLandsborough and Cleary, 1995). The genes encoding M protein and C5a peptidase 
(McIver and Myles, 2002; Pobielski et al., 1996; Rasmussen et al., 2000; Terao et al., 
2001) lie adjacent to mgA on the GAS chromosome. RPAs were used to determine if S. 
pneumoniae MgrA affected the transcription of neighbouring chromosomal genes and 
microarray experiments were performed as part of a wider search for genes under MgrA 
control. 
Analysis of the S. pneumoniae mgrA deletion and over-expressing strains using RPAs 
revealed that MgrA did not effect transcription of neighbouring genes in the 
chromosome in vitro (Figure 4.6 and (Hemsley et al., 2003)). Microarray experiments 
comparing mRNA levels from in vitro grown wild-type S. pneumoniae to those from 
same mgrA mutants, however, identified that the level of transcript for each gene on 
PPI2 showed a consistent and statistically significant difference of 2-5 fold between 
strains at all growth time-points assayed. Transcripts were increased in the mgrA 
deletion strain compared to the mgrA over-expressing strain (Figure 5.2 and Table 5.1), 
consistent with the notion that MgrA acts as a repressor of transcription of genes within 
PPI2. This is perhaps not altogether surprising as it is known that the similar regulators 
in GAS show cross-regulation, with Nra acting as a transcriptional repressor of mga 
whilst in turn Mga activates nra transcription (Pobielski et al., 1999). There was no 
202 
reciprocal regulation of mgrA by R1rA detected in S. pneumoniae (Figure 5.4). 1 propose 
a model where MgrA binds to the promoter region of rlrA to repress rlrA transcription. 
This has the effect of also reducing transcription of other PPI2. genes, as they require 
R1rA for transcription (Figure 7.1). 
It cannot be excluded that MgrA acts at each of the 4 promoters of PPI2 but the fact that 
deletion of mgrA in a srtD:: lacZ rlrA:: magellan2 background does not result in an 
additional increase in ß-galactosidase activity over that seen in the srtD:: lacZ 
rlrA:: magellan2 strain argues against this (Figure 5.11). Further experiments could be 
performed to determine if MgrA does indeed bind to one or more of the promoter 
regions in the islet. These include: 
a) Gel mobility shift assays using a His6-tagged version of MgrA and DNA 
fragments representing each of the 4 promoter regions in PPI2 
b) DNase I foot-printing to precisely map the sites of His6-tagged MgrA binding 
What is surprising is that no other obvious candidate target genes for MgrA were 
identified in the array experiments. PPI2 is not present in all S. pneumoniae serotypes 
(Figure 5.7 and Tables 6.1 and 6.2). In contrast mgrA has been found in all of 8 
serotypes tested (Figure 5.7). One would expect MgrA to have a role in transcriptional 
regulation of other genes in strains that do not possess the PAI. I would have also 
predicted that there are additional genes under MgrA control even in strains that do 
possess PPI2, such as the TIGR 4 strain used in this study. 
What are the possible reasons for the failure to identify additional genes? Firstly, some 
genes may be regulated below the threshold for detection by microarray. Secondly, 
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MgrA may only regulate genes in a small fraction of cells within a population. Thirdly, 
it is possible that MgrA. does not regulate the expression of other genes in serotype 4 S. 
pneumoniae strains. If this is the case and the PPI2 genes are the only essential 
virulence genes controlled by MgrA in serotype 4 S. pneumoniae then one would expect 
that the AmgrA rlrA:: magellan2 mutant would have a similar in vivo phenotype in 
murine models of infection to the rlrA:: magellan2 mutant strain. Animal studies 
showed that the COIs were not significantly different from I for either pneumonia or 
nasopharyngeal carriage (Figure 5.12). In other words there was no additional 
attenuation in mice over and above that seen in the rlrA mutant with the addition of a 
second mutation in mgrA, consistent with the idea that both 'regulators act within the 
same pathway. Although this suggests that there are no other virulence factors under the 
control of MgrA in TIGR4 the murine COI experiments do not exclude the possibility 
that there are other genes, which do not have essential roles in virulence, under the 
transcriptional control of MgrA. There could be other virulence genes, but ones which 
act at different stages of infection not simulated in the murine models. 
In support of the hypothesis that the only targets for MgrA in TIGR4 are the islet genes 
is the fact that serotype 2 strains, R6/D39, have a further gene (Spr1404) encoding a 
protein similar to MgrA. This gene is divergently transcribed from a gene (Spr1403) 
predicted to encode for a membrane-associated protein, which has a sortase recognition 
sequence. Neither Spr1404 nor Spr1403 are present in the TIGR4 genome. It is possible 
therefore that other pneumococcal serotypes have other mgrA-like genes and each 
MgrA-like regulator has only one or a few genes whose transcription it effects, each set 
being unique to that strain. 
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Fourthly, MgrA is known to be functional in vivo as deletion of the gene results in a 
change in the virulence properties of the bacteria in murine models. The mRNA for the 
array experiments was harvested from bacteria grown in vitro. Many transcriptional 
regulators have two forms, one of which has functional activity to regulate gene 
expression (active form) and a second form, which has reduced or no activity (non- 
active form). The switch from one form to the other often requires a co-factor or partner 
protein or a modification such as phosphorylation or dephosphorylation. The in vitro 
conditions used in these studies are unlikely to mimic those seen in a murine infection. 
The signals required for full regulator activation may not have been present in vitro and 
MgrA may not have been fully active in these conditions. The in vivo data from mice 
(Table 4.1) and the results from the epithelial cell line adherence experiments (Figure 
6.4) are consistent with this hypothesis. Strains bearing a deletion of mgrA have a 
decreased ability to cause lung infection and nasopharyngeal colonization despite their 
increased ability to adhere to lung epithelial cells in vitro (Figure 6.4). It is possible that 
a different set of genes are regulated by MgrA in response to the in vivo environment 
experienced by the S. 'pneumoniae in the mouse than in the in vitro conditions in the 
binding assays. This could lead to expression of different surface factors and different 
phenotypes with respect to adhesion to host cells. 
Even if MgrA does not control genes outside PPI2 in serotype 4 S. pneumoniae strains, 
there appear to be additional genes under its control in other serotypes. There is good 
evidence that transcriptional regulators of S. pneumoniae have varying target genes in 
different strains. This is the case for the response regulator RR09/SP0661 (Blue and 
Mitchell, 2003; Lange et al., 1999), MicB (Kadioglu et al., 2003; Throup et al., 2000) 
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and RegR (Chapuy-Regaud et al., 2003) and data presented here also indicates that this 
is the case for MgrA. In addition to serotype 4 strains, MgrA is required for virulence of 
D39 in a murine model of pneumonia but not for nasopharyngeal carriage of the same 
strain (Figure 5.8). As D39, a serotype 2 S. pneumoniae strain, does not contain PPI2 
the MgrA regulator must be regulating other virulence factors in this strain. It would be 
interesting to perform similar microarray experiments to those performed with serotype 
4 with comparable D39 strains. Perhaps there are other loci exclusive to D39 that are 
under the control of MgrA. 
7.5 THE FUNCTION AND DISTRIBUTION OF PPI2 
PPI2 possesses 7 genes that encode for a transcriptional regulator (R1rA), three surface 
proteins (RrgABC) and three sortases (SrtBCD) that are required for the anchoring of 
these surface proteins to the cell wall (Hava et al., 2003a). In serotype 4 and 9V S. 
pneumoniae rlrA and rrgA are important for adhesion to lung epithelial cells (Figure 
6.2) and I propose that this adhesion is required for nasopharyngeal colonisation and 
production of pneumonia in the mouse. The rrgA gene is predicted to encode for an 
MSCRAMM suggestive that it has a role in binding to extracellular matri x molecules 
(ECM). Some other Gram-positive pathogens use binding of ECM molecules to 
facilitate adherence to and/or invasion of epithelial cells (Massey et al., 2001; Molinari 
et al., 1997). This is via interactions with integrins on host cells that can bind ECM 
components. If the ECM component is also bound by the pathogen, then ECM-integrin 
binding can facilitate bacterial adherence and, in some cases, uptake into the host cell. 
The actual ligand for RrgA is unknown. RrgA may bind to an ECM component or 
directly to an epithelial cell receptor. If it does bind an ECM component, such as 
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fibronectin or collagen, this could act as a bridging molecule between S. pneumoniae 
and epithelial cell integrins. 
S. pneumoniae has been notably infrequent in studies describing MSCRAMMs as 
receptors in Gram-positive pathogens. One such protein has been described in S. 
pneumoniae, PavA, a surface exposed protein that binds fibronectin (Holmes et al., 
2001). The pavA gene is present in S. pneumoniae strains of different serotypes. 
Determining the ligand for RrgA and defining the ligand-binding domains in the RrgA 
protein is therefore an interesting area for further work. This would firstly necessitate 
purification of recombinant RrgA and generation of anti-RrgA antibodies. The raising 
of antibodies would enable experiments to confirm that RrgA is surface exposed, as 
predicted. This could be achieved by a) Western immunoblot analysis of proteins 
present in cytoplasmic, membrane and cell wall fractions prepared from wild-type 
serotype 4 S. pneumoniae compared to D39 and serotype 4 rrgA mutants, b) 
immunoelectron microscopic visualization of RrgA on the bacterial cell surface and/or 
c) confocal immunofluorescence microscopy. Having confirmed that RrgA is cell 
surface-exposed, purified protein could also be used in experiments to identify its 
binding partner. Two broad approaches would need to be taken. Firstly, if RrgA does 
indeed bind an ECM component then the ligand might be identified successfully in 
RrgA binding assays to a panel of purified ECM components immobilized onto 
microtitre plate wells. Secondly, if RrgA binds epithelial cells directly, rather than an 
ECM component, it may be possible to identify the receptor with the aid of either 
affinity chromatography, using biotin labeled surface proteins from A549 cells over a 
RrgA affinity column (Isberg and Leong, 1990; Mengaud et al., 1996), or with the aid 
of a yeast two-hybrid system. 
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PPI2 is not present in all clinical isolates but has been acquired by some S. pneumoniae 
strains at some point in their evolutionary history. Are S. pneumoniae strains ready 
primed to accept additional virulence genes, allowing immediate functioning of these 
genes and integration into already present regulatory networks? Transferring PPI2 into 
D39, which does not normally possess it, results in increased adherence to A549 cells in 
vitro indicating that the surface adhesins and sortases are successfully expressed, 
processed and expressed on the bacterial cell surface (Figure 6.6). Acquisition of the 
element by D39 also results in increased virulence (Figure 6.8). It is apparent therefore 
that PP12 contains enough information to function without the apparent requirement for 
any additional genetic alterations in some S. pneumoniae strains that acquire PPI2. 
Although it could not be demonstrated that transfer of PPI2 occurs in vivo in a murine 
model, S. pneumoniae is naturally transformable and recombinational events, such as 
capsular locus swapping, do occur in the human host in vivo (Coffey et al., 1998; 
Coffey et al., 1999). Such events have played a significant role in the evolution of the S. 
pneumoniae genome (Feil et al., 2000). PPI2 is therefore likely to be transferred 
between strains in vivo. 
The fact that PPI2 is found at low frequency amongst clinical isolates (Tables 6.1 and 
6.2) indicates that it either does not undergo high frequency transmission between S. 
pneumoniae strains, its acquisition is relatively recent in the evolutionary history of S. 
pneumoniae or that it is not maintained in some strains that acquire it. There could be 
functional redundancy between PPI2 and other surface adhesins in S. pneumoniae 
strains. The acquisition of PPI2 by some strains may not affect the binding phenotype of 
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that strain if it already has other adhesins. If there is no selective advantage in having 
the element there will be no pressure to maintain PPI2 presence in the strain. 
Although acquisition of the island by D39 results in increased virulence in murine 
models of infection, there was no statistically significant correlation between islet 
presence and invasive disease seen in clinical isolates (Table 6.3). 
The genes of PPI2 are regulated by RITA, encoded by a gene on the island, but also by 
at least one regulator, MgrA, encoded by a gene present on the chromosome distant 
from PPI2. The phenomenon of regulators encoded outside a PAI regulating genes 
encoded on the PAI and vice versa (Kaper and Hacker, 2000). As yet there are no 
documented examples of chromosomal genes under transcriptional control of RlrA. 
However a 13-bp consensus sequence binding site for RIrA has been determined (Hava 
et al., 2003a) and this was used to query the TIGR4 genome sequence for other possible 
R1rA binding sites. The search identified 29 sequences which were present in putative 
promoters (Hava et al., 2003a). These include 2 known virulence genes (A. Camilli and 
D. Hava, personal communications) raising the possibility that R1rA does regulate genes 
outside PPI2. The hypothesis that R1rA does indeed regulate the transcription these 29 
genes could be tested by RPAs. It would also be interesting to perform microarray 
studies with rlrA mutant strains to identify any other genes under the transcriptional 
control of R1rA. 
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7.6 ENVIRONMENTAL SIGNALS REQUIRED FOR TRANSCRIPTIONAL 
REGULATOR ACTIVATION 
The gaseous composition experienced by S. pneumoniae varies with anatomical site 
within the human host (Table 7.1). The composition of air at the nasopharyngeal 
mucosa is higher in oxygen and lower in carbon dioxide than alveolar air or in the 
middle ear space. The availability of oxygen is also decreased in the common 
manifestations of disease caused by S. pneumoniae, such as pneumonia, empyema and 
otitis media as the exudative inflammatory response occludes air spaces limiting 
ventilation and gas -exchange 
(Harell et al., 1996; Hergilis and Magnuson, 1997; Sade et 
al., 1995). 
Table 7.1 Gaseous composition at mucosal surfaces within the human host 
Gaseous composition (%) 
N2 02 CO= 
Atmospheric/inhaled 74.09 20.84 0.04 
air 
Middle eae 83.66 6.86 9.47 
Alveolar Air' 74.9 13.6 5.3 
Expired air 74.5 15.7 3.6 
The figures given are in a non-disease state. The actual composition in compartments, 
such as the alveolar compartment or middle ear, will also vary with the normal 
ventilatory cycle and in the presence of pathology (Harell et al., 1996; Hergilis and 
Magnuson, 1997; Sade et al., 1995). 
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S. pneumoniae might be able to sense these changes and as a result induce changes in 
the expression of surface structures affecting interactions with the host epithelial cells 
and bacterial adhesion. There is some evidence that the ambient oxygen concentration is 
an important factor in the ability of S. pneumoniae to regulate the characteristics of its 
cell surface (Figure 7.2). The S. pneumoniae colony morphology is dramatically 
different with growth on solid media anerobically as compared to growth non- 
anaerobically with a shift to a larger and more mucoid colony under anaerobic growth 
(Weiser et al., 2001). This reflects, amongst other things, a difference in capsular 
polysaccharide production. Oxygen levels affect the opaque and transparent phase 
variants differently, with greatest effect is on the opaque (0) variant. There is an 
increased production of capsular polysacharride (CPS) in 0 variants in conditions of 
reduced oxygen, whereas synthesis of CPS in transparent variants remains 
comparatively low under atmospheric or reduced oxygen conditions (Weiser et al., 
2001). The expression of capsule is necessary for S. pneumoniae to evade 
opsonophagocytosic clearance during infection but may be detrimental to adhesion and 
carriage. 
Little is known about the role of carbon dioxide in regulating S. pneumoniae cellular 
processes and surface and other virulence factors although the pathogen requires carbon 
dioxide for growth (Flanagan and Paull, 1998). In the study by Weiser and colleagues 
cited above alteration of carbon dioxide levels had no further effect on CPS production 
over and above that seen with reduction of oxygen levels, consistent with oxygen rather 
than carbon dioxide being the major determinant in the levels of CPS (Weiser et al., 
2001). 
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4. Competence 
T ComDE 
T 
CiaRH 
MicAB ? 
102 Level 
CspD MgrA 
TCapsule production Alteration in surface adhesins 
Figure 7.2 Model of the regulation of cellular processes by oxygen levels 
Change in environmental oxygen levels regulates at least three different 
cellular processes in serotype 4 S. pneumoniae. Reduction in oxygen results 
in repression of competence, increase in capsule production and probable 
alteration in cell-surface adhesins. Repression of competence is mediated by 
three TCSTS, MicAB, CiaRH and ComDE. Whether they function in the 
same or parallel pathways is unclear. Alteration in capsule production by 
oxygen levels may involve CspD and surface adhesins, MgrA. 
GAS and other streptococci regulate the expression of virulence factors in response to 
changes in oxygen and carbon dioxide levels (Nakamura et al., 2004). Mga and RofA 
are known to be involved in this pathway in GAS. MgA is activated by growth in 
elevated carbon-dioxide (Caparon et al., 1992; McIver et al., 1995). RofA is affected by 
superoxide levels and oxygen partial pressure (Fogg and Caparon, 1997; Kreikemeyer 
et al., 2003). In contrast Nra does not appear to be regulated by similar conditions to 
RofA (Kreikemeyer et al., 2003). 
Expression of the PPI2 gene srtD in S. pneumoniae is responsive to changes in oxygen 
and carbon dioxide levels and this requires the presence of MgrA (Figure 5.11). 
Decreases in both oxygen and carbon dioxide levels result in reduced srtD transcription, 
as measured by ß-galactosidase activity in a srtD: lacZ fusion strain. However the 
galactosidase remains constant in all three atmospheres tested if the mgrA gene is 
inactivated in this strain background. This is consistent with either increased repression 
of transcription of srtD by MgrA with reduction in oxygen or carbon dioxide levels or 
lifting of transcriptional repression of srtD by MgrA with increased oxygen or carbon 
dioxide levels. It is not clear, however, whether a change in oxygen or a change in 
carbon dioxide levels exerts the strongest effect or at what level the response is 
achieved and therefore one can only speculate as to the physiological relevance of this 
effect in the host. It has not been formally demonstrated here that the other PPI2 genes, 
such as rrgABC, also show increased transcription in conditions of reduced oxygen and 
carbon dioxide levels or that increased srtD transcription results in altered surface 
protein expression but I hypothesise that this is the case. The data could be consistent 
with the model that adhesin production is greatest and CPS production least in the 
nasopharynx thereby favouring adherence to epithelial cells. As oxygen levels decrease 
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in the lower respiratory tract and in areas of pathology, CPS production increases and 
production some surface adhesins decreases resulting in a bacterial phenotype that 
favours avoidance of opsonophagocytosis and clearance by the host immune cells. 
It is not known what, if any, factors are involved in signaling between gas concentration 
sensing and alteration of the activation status of MgrA. MgrA does not possess a PAS 
domain and hence is unlikely to sense changes in oxygen levels directly. No 
conclusions can be drawn about the involvement of RlrA in the response to alterations 
in gaseous compositions of the environment as the level of activity of the rlrA: lacZ 
fusions in experiments performed in order to examine this, was very low. It is possible 
that this is not an adequate method to assess rlrA transcription. RofA activity has been 
shown to be affected by oxygen levels in GAS, but neither it nor RlrA possess PAS 
domains. MicB, the HK component of a TCSTS in S. pneumoniae, is the only PAS 
domain-containing protein in S. pneumoniae (TIGR4 genome) (Echenique and Trombe, 
2001 a) and has been implicated in oxygen sensing in this pathogen. Competence is 
normally repressed under oxygen limitation (Echenique et al., 2000; Echenique and 
Trombe, 2001 a, b). Mutation of the PAS domain in MicB abolishes the kinase activity 
of the recombinant protein and allows the expression of competence under conditions of 
reduced oxygen. The oxygen-responsive alteration in S. pneumoniae surface structures 
could also require MicB. 
7.7 CONCLUSION 
The factors that determine the virulence of S. pneumoniae are very complex. The 
requirement for certain virulence factors varies according to the environment that the 
pathogen encounters. The distribution of some virulence genes and their regulation also 
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varies between S. pneumoniae strains. This -is illustrated by the work described in 
chapters 4,5 and 6 investigating the function, regulation, and distribution of the 
transcriptional regulators MgrA and R1rA, both of which are required for 
nasopharyngeal carriage and production of pneumonia in mice by serotype 4 S. 
pneumoniae. Both regulators control the transcription of genes of a newly described 
PAI, PPI2, yet the distribution of the two regulators varies among S. pneumoniae 
strains. The gene encoding R1rA is present in PPI2, which is carried by relatively few 
S. pneumoniae serotypes and the gene encoding MgrA is located on the chromosome 
outside PPI2 and appears to be present among most serotypes. It is likely that MgrA 
controls the transcription of additional virulence genes in serotypes that do not harbour 
PPI2 and thereby emphasizes the likelihood of a different repertoire of virulence genes 
among different serotypes and strains of this important human pathogen. 
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the thesis. 
a. C Hemsiey, E Joyce, DL Hava, A Kawale and A Camilli. 2003. MgrA, a 
homologue of Mga, acts as a transcriptional repressor of the r1rA 
pathogenicity islet in Streptococcus pneumoniae. J Bacteriol 185: 6640- 
47. 
b. DL Hava, C Hemsley and A Camilli. 2003. Transcriptional regulation in 
the Streptococcus pneumoniae rlrA pathogenicity islet by RITA. J 
Bacteriol 185: 413-21. 
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